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Summary 
 
Applicant: Ms Sally Rachel Jennings  
Thesis title: Using EEG to investigate premature aging and cognitive decline 
in adults with Down’s Syndrome  
  
Down’s Syndrome (DS) is a genetic disorder associated with intellectual 
disability, accelerated aging and a propensity for early-onset Alzheimer’s 
disease (AD). Beta-amyloid plaques are one of the pathological hallmarks of 
AD, and also a common characteristic of the older DS brain. AD treatment 
trials are now moving towards administration of the intervention at preclinical 
stages, with the goal of preventing cognitive decline in the first place, rather 
than trying to halt or reverse existing pathology. Consequently, it has become 
essential to develop biomarkers of AD, which can: 1. Predict clinical changes 
and 2. Track the effectiveness of putative preventative treatments. The strong 
association between DS and AD means that this research is particularly 
important for people with DS and it presents a high-risk group for exploring 
predictive biomarkers.   
 
Electroencephalography (EEG) is a non-invasive and inexpensive measure of 
cortical activity, which is being evaluated with the typically developing (TD) 
population as a potential biomarker of AD. This thesis aims to evaluate EEG 
as a potential predictor of cognitive decline associated with DS-AD. There are 
several potential EEG measures that could be explored. Following a review of 
the literature, the predictive potential of the following event-related potentials 
(ERPs): mismatch negativity (MMN) and P300 (P3a and P3b), were chosen 
for exploration with cross-sectional and longitudinal investigations.  
 
The thesis begins by exploring how the ERPs differ for a cross-section of 36 
adults with DS and 39 age- and gender-matched TD controls. As expected, 
the MMN waveform was smaller for adults with DS than TD controls. 
However, the P3b waveform was predominantly absent for adults with DS, 
whilst the P3a response was significantly enlarged. The P3a response was 
also enlarged for the adults with DS who scored lower on a 
	 4 
neuropsychological measure. The neuropsychological measure indexes 
frontal functions, which are compromised early in DS-AD.  
 
This experiment also provided evidence that MMN was related to age in DS, 
with increasing latencies and decreasing amplitudes for older participants. 
The differences in MMN amplitude between the groups (DS, TD) were 
isolated to the older adults. These findings lend support to the premature 
aging hypothesis of DS.  
 
The thesis also included a longitudinal follow-up in which 34 adults with DS 
underwent a repeated cognitive examination one year after their EEG and 
initial cognitive assessment. The analyses found that adults with DS who had 
lower MMN amplitudes at the initial assessment were more likely to decline at 
the cognitive follow-up. This finding suggests that MMN may be a potentially 
useful clinical tool for predicting the cognitive decline associated with DS-AD.  
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1 Chapter 1. General introduction 	
1.1 Study purpose 	
One of the most striking observations in Down’s Syndrome (DS) is the 
remarkably high rates of Alzheimer’s disease (AD), which presents a 
significant burden beyond the associated intellectual disability (ID). We are 
beginning to consider the biochemistry behind AD and develop aligned 
treatments. However, the treatments will only be of use if we can determine 
who will benefit, in time to benefit. This thesis aims to explore an inexpensive 
and non-invasive technology called electroencephalography (EEG). The 
technology has been used previously with the general population to compare 
typically developing adults to those who have AD or DS. In light of the high 
risk, early onset and homogenous acquisition of AD in DS this thesis now 
aims to evaluate EEG as a predictor of the associated cognitive decline.  	
1.2 Chapter overview  	
The chapter begins by describing the DS brain, from synapses to cortical 
structure. Then the aetiology and pathology of AD are discussed, with a view 
to exploring the interaction between the two disorders (DS-AD). Synaptic 
dysfunction is a theme throughout the chapter because: 1. Synaptic function 
forms the basis of neurocognitive function, 2. Synaptic abnormalities are one 
of the earliest indicators of AD development, and 3. Widespread pathology at 
a synaptic level will likely generate abnormal EEG signals. This thesis is 
primarily concerned with evaluating the extent to which EEG can predict the 
associated features of AD (aging, cognitive decline). More specifically, the 
EEG products to be explored are event-related potentials (ERPs): mismatch 
negativity (MMN) and P300 (P3a, P3b). The introduction concludes by 
describing how: 1. Potential predictors (biomarkers) of DS-AD can be 
evaluated, and 2. The ERPs have been previously related to DS, typical and 
pathological (AD) aging. The overall aim of this thesis is to evaluate the ERPs 
(MMN, P3a, P3b) as potential predictors of the cognitive decline associated 
with DS-AD.  
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1.3 Down’s syndrome  
 
1.3.1 Trisomy 21  
 
John Langdon Down first described the phenotypic features of Down’s 
Syndrome (DS) 150 years ago (1866). The phenotypical features of DS 
include a flat nasal bridge and short stature (Roizen & Patterson, 2003). From 
a cognitive perspective, people with DS typically present with deficits in 
memory and language (Lott & Dierssen, 2010). Indeed, DS is the commonest 
identified cause of intellectual disability with a prevalence of 1 in every 650 to 
1000 live births (Bittles, Bower, Hussain, & Glasson, 2007). DS is a genetic 
disorder attributed to the triplication of chromosome 21 (Lamb et al., 1996), 
which was first demonstrated by LeJeune et al. (1959). DS results from the 
full trisomy in 95% of cases, with Robertsonian translocations and mosaicism 
accounting for the remaining 5% (Hunter, 2010).	 
 
1.3.2 Head and brain morphometry   
 
One of the marked phenotypic features of DS is the head morphology, which 
is brachycephalic (Roizen & Patterson, 2003). Furthermore, the DS profile, 
specifically the nasal bridge, is stereotypically flatter than that of TD controls 
(Roizen & Patterson, 2003). The DS brain is typically 20% smaller than 
typically developing (TD) population brains (Roizen & Patterson, 2003), and 
becomes comparatively smaller still for older adults (50+ years) (Mann, 
Royston, & Ravindra, 1990). Specific regions of the brain that are notably 
smaller in DS include the: cerebellum, brainstem and frontal lobes (Ross, 
Galaburda, & Kemper, 1984; Schmidt-Sidor, Wisniewski, Shepard, & Sersen, 
1990). In contrast, the ventricles are disproportionately enlarged in DS 
(Pearlson et al., 1998); whilst the cerebral sulci have less depth and the gyri 
are less complex than is the case in TD individuals (Aylward et al., 1997; 
Pinter, Eliez, Schmitt, Capone, & Reiss, 2001; Teipel et al., 2004; Teipel et al., 
2003). The developmental, neural abnormalities in DS are further exacerbated 
by the brain atrophy of aging (Teipel & Hampel, 2006). This thesis is an EEG 
study of adults with DS, which acknowledges the atypical head and brain 
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morphometry by: 1. Overcoming the flat profile, and maximising comfort, by 
elevating the facial adjustments of the EEG kit with a paper bridge at the 
nasal bridge; 2. Allowing for atypical electrode positions to be maximal for the 
event-related potentials (ERPs) of interest by employing an across-scalp, 
rather than single canonical electrode, approach to the analyses. This 
approach is detailed in chapter 2, section 2.13.  
 
1.3.3 Neurons 
 
The reduced brain size in DS is potentially explained by the reduced number 
of cortical neurons in this group (Larsen et al., 2008).  A stereology study by 
Larsen et al. (2008) compared the brains of four DS foetuses with controls to 
show that, at 19 weeks of gestation, the DS foetuses had an average of 6.85 
billion neocortical cells (neurons and microglia), which is a 34% reduction 
compared to controls. Indeed, a morphometry study of children with DS (birth 
– 12 years) found reduced neuronal density at between 20 and 50% 
(Wisniewski, Laure-Kamionowska, & Wisniewski, 1984). This reduction in 
neuronal density has been most consistently reported in the granular layers 
(Ross et al., 1984; Schmidt-Sidor et al., 1990). Although the DS brain is 
smaller and has fewer neurons than average, the radial columns are wider but 
less numerous. This is evident in the abnormal cortical stratification seen in 
DS foetuses (22 weeks) (Schmidt-Sidor et al., 1990). Furthermore, the 
columns are wider and more widely dispersed for children with DS than TD 
children (Buxhoeveden & Casanova, 2002). 
 
1.3.4 Dendrites  
 
Beyond arguments about neuronal density, dendritic structure and number 
are altered in the cortex and hippocampus in DS (for a review see Fiala, 
Spacek, and Harris (2002)). Dendrites are the primary receptive vehicle for 
neurons (Kasai, Matsuzaki, Noguchi, Yasumatsu, & Nakahara, 2003; Sorra & 
Harris, 2000). Furthermore, synapses are formed at dendritic spines 
(DeFelipe & Fariñas, 1992) therefore an abnormal dendritic structure would 
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predict abnormal synaptic function (Belichenko et al., 2004). The nature of the 
dendritic abnormalities have been grouped in three types of spines: long, thin 
and irregularly distributed; short; or, very large and sparsely distributed 
(Marin-Padilla, 1976). Dendritic abnormalities are progressive throughout the 
life-course. Up to the age of 2.5 months, the dendritic branching in layer III 
pyramidal cells of the prefrontal cortex is comparable between DS and TD 
(Vukšić, Petanjek, Rašin, & Kostović, 2002). However, in DS, by the age of 
two years the dendritic branching and length (apical, basal) has been reported 
to fall below normal levels (Becker, Armstrong, & Chan, 1986). For older 
adults with DS (no AD), the number of dendritic spines in the pyramidal 
neurons (apical, basilar areas) is reduced further still (Suetsugu & Mehraein, 
1980). Typically, the number of dendritic branches and spines increase 
between birth and 15 years, after which time the number gradually declines 
(Sachio Takashima, Ieshima, Nakamura, & Becker, 1989). However, in DS 
the dendritic increase during childhood is minimal whereas the decline during 
adulthood is maximal (Takashima, Lida, Mito, & Arima, 1994). Dendrites play 
a range of essential roles: from the functioning of synapses to connectivity in 
the whole brain (Diaz, Sanchez, Duchen, Nakano, & Perez, 2016; Kasai et al., 
2003; Sorra & Harris, 2000). Therefore, the abnormal dendritic structure in DS 
could be mechanistic for the impaired cognitive functioning reported for this 
group (Contestabile, Benfenati, & Gasparini, 2010).  
 
1.3.5 Synaptic and functional deficits  
 
Cognitive functions such as learning and memory are underpinned by 
communication at a synaptic level (Benfenati, 2007). Therefore the cognitive 
impairment associated with DS may be the result of abnormal dendritric 
structure, and the inevitable compromise of synaptic function (Contestabile et 
al., 2010). Cognitive functions that are served by the hippocampus, such as 
learning and memory, are frequently impaired in DS (Pennington, Moon, 
Edgin, Stedron, & Nadel, 2003). DS mouse models have found that 
hippocampal dendritic spines are abnormal, which leads to altered synaptic 
function and plasticity (Contestabile et al., 2010).  In Ts62Dn mice, slices 
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have been tested from the hippocampal region: CA1, to find a reduction in 
long-term potentiation (LTP) due to induction failures (Siarey, Stoll, Rapoport, 
& Galdzicki, 1997; Siarey et al., 1999). The increased inhibition of N-methyl-d-
aspartate (NMDA) receptors (NMDARs) has been postulated as the 
physiological basis for the induction failure because the administration of a 
GABAA receptor antagonist (picrotoxin) has been shown to restore LTP 
(Belichenko, Kleschevnikov, Salehi, Epstein, & Mobley, 2007; Costa & 
Grybko, 2005; Kleschevnikov et al., 2004). As demonstrated in DS-mouse 
models focused on the hippocampus, an imbalance between inhibitory and 
excitatory neurotransmission compromises synaptic plasticity (Belichenko et 
al., 2004; Keck, Hübener, & Bonhoeffer, 2017; Kleschevnikov et al., 2004).  
 
The hippocampus uses synaptic plasticity to support memory function 
(Contestabile et al., 2010). Memory can be characterized as implicit or 
explicit. Implicit memory formation is an automatic process, which requires 
limited attentive effort (Graf & Schacter, 1985). In contrast, explicit memories 
are formed from an attentive and intentional learning process (Graf & 
Schacter, 1985). The relative strengths and deficits in DS memory processing 
demonstrate this dichotomy. In a study by Vicari, Bellucci, and Carlesimo 
(2000), 14 children with DS performed comparably to mental-age matched TD 
children on tasks which required implicit memory, but were significantly 
impaired on explicit memory tasks. In experimental environments, adults with 
DS have demonstrated insufficient attention (Krinsky-McHale, Devenny, 
Kittler, & Silverman, 2008), poor information coding and unsuccessful retrieval 
strategies (Carlesimo, Marotta, & Vicari, 1997), which inevitably leads to 
impaired explicit memory. For older adults with DS, the common association 
of memory deficits with the disorder poses a challenge for disentangling the 
intellectual disability from a dementia diagnosis.   
 
1.3.6 Accelerated aging in Down’s Syndrome  
 
In the literature, the terms ‘premature’ and ‘accelerated’ are used 
interchangeably to describe aging in DS (Oliver & Holland, 1986; Zigman, 
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2013). The average life expectancy of people with DS has significantly 
increased in recent years from 12 years old in the 1940s to an average of 
57.8 years old for women and 61.1 years old for men, in developed countries 
(Bittles et al., 2007; Glasson et al., 2003). However, average life expectancy 
for adults with DS is still much lower than the general population in the UK 
(81.2 years) and USA (79.3 years) (WHO, 2016). This comparatively reduced 
life expectancy has leant support to the argument that aging is accelerated in 
DS. Indeed, accelerated aging in DS is evident across several physiological 
systems: from earlier menopause to premature skin wrinkling (see Zigman, 
2013 for a review).  
 
The calcification of the basal ganglia in DS, which can begin as early as 5 
years old, has been postulated as a neurological indicator of accelerated 
aging in DS (Ieshima, Kisa, Yoshino, Takashima, & Takeshita, 1984; Mann, 
1988). Furthermore, a machine learning exploration of structural MRI scans 
found that the average, predicted brain age for 46 adults with DS was 2.49 
years older than 30 typically developing (TD) controls (Cole et al., 2017).  
However, predicted brain age was highly variable within the DS group 
because of individual differences in Aβ deposition and cognitive impairment 
(Cole et al., 2017). Indeed, accelerated aging to the neurological system is 
largely characterised by early-onset Alzheimer’s disease (AD) in DS (Zigman, 
2013).  
 
Adults with DS not only develop AD at earlier ages than the general 
population, but at a much higher rate (Holland, Hon, Huppert, Stevens, & 
Watson, 1998). Indeed, by the age of 50 everybody with DS has the 
neuropathological hallmarks of AD: Aβ plaques(Mann, 2006), and almost half 
(40%) display clinical symptoms (Holland, Hon, Huppert, Stevens, & Watson, 
1998).  The strongest predictor of AD is chronological age. However, there is 
contention as to whether the risk for AD development is related to a specific 
“age” range, or is an inevitable part of the “aging” process if one were to live 
long enough (Ritchie & Kildea, 1995).  
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1.4 Alzheimer’s disease 
1.4.1 Introduction to Alzheimer’s disease  
 
Alois Alzheimer first described the pathological features of AD in 1907. The 
description was based on the post-mortem examination of a 51 year old 
woman who had exhibited memory loss and unusual behaviours in the later 
stages of her life (Alzheimer, Stelzmann, Norman Schnitzlein, & Reed 
Murtagh, 1995). The dysfunction and loss of synapses is a significant feature 
of AD (Selkoe, 2002). However, the disease pathology is typically 
characterised by severe cortical atrophy, neurofibrillary tangles (NFTs) 
containing hyperphosphorylated tau and beta-amyloid (Aβ) plaques (Korczyn, 
2008). The first symptom of AD is typically anterograde memory decline, 
which is later followed by language impairment and executive dysfunction 
(Feldman & Woodward, 2005; Small et al., 1997). Beyond, the cognitive 
dysfunction associated with AD, a clinical diagnosis also includes a deficit in 
everyday skills (Richards et al., 1999).  
 
1.4.2 The amyloid cascade hypothesis  
 
The ‘amyloid cascase hypothesis’ proposes that the deposition of the 
insoluble, neurotoxic, Aβ protein is the primary determinant of AD (Hardy & 
Higgins, 1992). The hypothesis offers that excessive quantities of Aβ, either 
from over-production or ineffective clearance, leads to the formation of Aβ 
plaques, then neurofibrillary tangles (NFT) and neurodegneration (Hardy & 
Higgins, 1992; Hardy & Allsop, 1991; Hardy & Selkoe, 2002; Selkoe, 1991). 
Aβ results from the amyloidogenic cleavage of APP by β-secretase (BACE-1), 
and then γ-secretase (Selkoe, 1990).  The cleavage process is displayed in 
figure 1.1, which includes the non-amyloidogenic pathway that produces 
harmless peptides. β–amyloid, the end product of the amyloidogeneic 
pathway, can aggregate into soluble monomers and dimers, which do not, in 
of themselves, pose a neurotoxic problem (Haass & Selkoe, 2007). 
Alternatively, insoluble fibrillar formations can occur which, in a sheet 
structure, results in β–amyloid deposits (De Strooper, Vassar, & Golde, 2010). 
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β–amyloid deposits are at the core of senile plaques – a hallmark of AD. In 
conclusion, this process of cleaving and aggregating β–amyloid is 
hypothesised to set off the pathological cascade towards clinical AD.  
 
Of course, there is resistance to the amyloid cascade hypothesis, including a 
recent call from Herrup (2015) to reject the hypothesis all together. Herrup 
(2015) primarily discredits that there is a linear relationship between Aβ and 
dementia. Herrup (2015) goes on to promote alternative mechanisms of AD 
development, such as tauopathy, autophagy failure, neuroinflammation and 
mitochondrial dysfunction. A recent reflection on the amyloid cascade 
hypothesis, which is co-authored by one of the model's originators (Hardy), 
concurs that "a linear relationship between amyloid-β and dementia is not 
teneable" (Hardy & De Strooper, 2017, pg. 854). However, this is framed 
within the context that AD drug development should acknowledge the input 
and interactions between multiple mechanisms of AD development, rather 
than view the hypotheses competitively (Selkoe et al., 2016). This thesis 
acknowledges the other mechanisms of AD development but has only 
described the amyloid cascade hypothesis because of the strong genetic 
connection to DS-AD (section 1.5.2).  
 
 
Figure 1.1. The intracellular processing of the amyloid precursor protein from 
Querfurth and LaFerla (2010).  		
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1.5 Alzheimer’s disease in Down’s Syndrome  
 
1.5.1 High risk of AD in DS  
 
Adults with DS are at very high risk of developing the pathological features of 
AD. Indeed, Aβ deposits are seen in the brains of people with DS by the 
second or third decade of life (Mann, 1988) and Aβ plaques by the fifth 
decade of life (Mann, 2006). Furthermore, 40% of people with DS over the 
age of 50 are living with AD ( Holland et al., 1998), which rises to 75% over 
the age of 60 (Ball et al., 2006). The proposed reason behind this risk is 
associated with the genetic aetiology of DS, as described below in section 
1.5.2.  
 
1.5.2 The genetic basis of DS-AD  
 
DS is the caused by the triplication of chromosome 21 (Wiseman et al., 2015), 
where the APP gene is located. Therefore, due to a gene dosage effect, 
adults with DS have a life-long overproduction of the peptide product cleaved 
from APP: Aβ (Wiseman et al., 2015). Inline with the amyloid cascade 
hypothesis, this gene dosage effect is postulated to be the primary causative 
factor for high rates of AD in DS (Hardy & Higgins, 1992). Chromosome 21 
also codes for the superoxide dismutase 1 (SOD1) gene (Zana, Janka, & 
Kálmán, 2007), which may explain why AD is not only more prevelant in DS, 
but has a much earlier onset (Cenini et al., 2012). SOD1 creates hydrogen 
peroxide product from superoxide (Sea et al., 2014), the overproduction of 
which causes oxidative stress (Levanon et al., 1985; Sinet, 1982). Oxidative 
stress is linked with aging, which supports an accelerated aging model of DS 
(Finkel & Holbrook, 2000; Sohal, Mockett, & Orr, 2002). Furthermore, DS-AD 
may be earlier onset (40+ years) than sporadic AD (60+ years) because the 
overexpression of SOD1 accelerates the formation of superoxide radicals, 
which act on pre-amyloid to increase Aβ deposition (Harman, 2002).   
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1.5.3 The intersection between DS and AD  
The ‘amyloid cascade hypothesis’ (Hardy & Higgins, 1992) is the prevailing 
theory as to why people with DS have a higher incidence and earlier onset of 
AD compared to the typically developing population (Ball et al., 2006). The 
‘reserve capacity hypothesis’ (Mortimer, 1988) provides a complimentary 
account to the ‘amyloid cascade hypothesis’. The two main tenets of the 
‘reserve capacity hypothesis’ are: 1. Reserve capacity – remaining functional 
brain tissue; 2. Threshold – amount of brain tissue required to sustain ‘normal’ 
cognitive functioning (Mortimer, 1988).  The morphology of the DS brain is 
characterised by, amongst other features: reduced overall cortical volume 
(Lott, 2010); disproportionately diminished frontal lobes (Aylward et al., 1999); 
and reduced neuronal density (Lott, 2010). Thus, people with DS are 
proposed to have a limited ‘reserve capacity’ from birth, which lowers their 
‘dementia threshold’. Furthermore, Holland et al. (1998) suggested that the 
abnormal brain morphology in DS interacts with AD to influence the clinical 
presentation of the disease. The focus of the differing clinical presentation is 
compromised frontal lobe functioning in DS (Ball et al., 2006; Ball, Holland, 
Treppner, Watson, & Huppert, 2008). Indeed, cross-sectional studies of 
amyloid deposition in DS have found that the striatum is the first effected 
region, closely followed by the prefrontal cortex (Annus et al., 2015; Handen 
et al., 2012; Hartley et al., 2014).  
 
The frontal lobes mediate functions in three broad domains, which can 
become compromised with the onset of AD: 1. Cognition – working memory, 
attention span, executive function; 2. Emotion – apathy, depression; 3. 
Behaviour – personality changes, inhibitory control. In a prospective, 
population based study conducted by Ball et al. (2006) it was suggested that 
early clinical indicators of AD, for participants with DS, were better defined by 
changes in personality, behaviour and executive dysfunction than decline in 
episodic memory. In a study of adults with ID, adults with AD-DS presented 
with comparatively more maladaptive behaviours, such as being excessively 
uncooperative (Cooper & Prasher, 2002). A longitudinal study of 30 adults 
with DS, over 16 months, found that adults in the early stages of cognitive 
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deterioration (10) also showed declines in executive function and changes in 
behaviour (Adams & Oliver, 2010).  Together, these findings suggest that 
frontally mediated processes, such as executive functions, should be focused 
on when investigating early indicators of AD in DS.  
 
1.5.4 Executive dysfunction in DS-AD   
 
Executive functions (EF) are a family of abilities that make it possible to 
instigate and maintain purposeful actions. There are three-core executive 
functions (Diamond, 2013; Lehto, Juujärvi, Kooistra, & Pulkkinen, 2003; 
Miyake et al., 2000): 1. Inhibition: behavioral (self-control) and cognitive 
(selective attention), 2. Working memory, and 3. Cognitive flexibility: set 
shifting for example. Higher-order abilities such as reasoning, planning, and 
problem solving are built on these core EFs (Collins et al., 2012; Lunt et al., 
2012). The cognitive deficits typically associated with DS can make it difficult 
to parse the ID from the development of dementia. Indeed, there is some 
contention as to whether executive dysfunction in this group is developmental, 
age-related or dementia-related (Ball, Holland, Treppner, Watson, & Huppert, 
2008). For example, a comparison between younger adults (<40 years old) 
with DS and individuals with generalized ID, who were matched for verbal 
ability, found that the adults with DS were significantly impaired on the EF 
tasks (Rowe, Lavender, & Turk, 2006). In order to tease out the 
developmental abnormalities from the clinical progression of DS-AD, Ball and 
colleagues developed, and/or modified, a battery of neuropsychological tests: 
the Cambridge Examination for Mental Disorders of Older People with Down's 
Syndrome and Others with Intellectual Disabilities (CAMDEX-DS) (Ball et al., 
2006) and, the Executive Function test battery for people with DS (EFDS), 
which is also known as the Cambridge Executive Functioning Assessment 
(CEFA) for People with Intellectual Disabilities (Ball et al., 2008).   
 
The CEFA and the Behavioural Assessment of the Dysexecutive Syndrome 
(BADS-C) were compared to assess their validity as measures of EF in ID, by 
Willner, Bailey, Parry, and Dymond (2010). The tests (CEFA, BADS-C) were 
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administered to 40 adults with mild to moderate ID, who attended day centres, 
to find that both had weak relationships with IQ (Willner et al., 2010). 
However, whilst the BADS-C suffered with floor effects, the CEFA was less 
affected (Willner et al., 2010). The authors concluded that the CEFA was a 
suitable measure of EF for adults with mild to moderate ID, whereas the 
BADS-C had limited utility with this group (Willner et al., 2010). The CEFA, 
referred to as EFDS for the remainder of the thesis, was chosen as the 
measure of EF in DS because: 1. Executive dysfunction is one of the earliest 
indicators of AD in DS (Ball et al., 2006); 2. The EFDS has been 
independently verified as an appropriate measure of EF for this group (Willner 
et al., 2010); 3. The EFDS is consistently used by the Dementia in Down’s 
Syndrome research stream at Cambridge, so the continued use in this thesis 
provides coherence and a platform for between-study comparisons. The 
EFDS will be discussed in greater details in the general methods section 
(chapter 2).  
 
Ball, Holland, Watson, and Huppert (2010) conducted a study with 72 adults 
who had a diagnosis of DS, but not AD. The researchers administered the 
EFDS, and conducted interviews with the participants’ parent or carer. The 
study found that the majority (95.7%) of participants who were reported to 
have one (or more) behavioural change(s), also exhibited disinhibited 
behaviours (Ball et al., 2010). Furthermore, participants’ disinhibition score 
negatively correlated with their performance on three of the EFDS tasks: cats 
and dogs, Tower of London (ToL), and scrambled boxes (Ball et al., 2010). Of 
these tasks, performance on ToL and scrambled boxes was related to the 
number of informant reported changes in personality and behaviour (Ball et 
al., 2008). The tasks were designed to assess: planning, response inhibition, 
and working memory functions (Ball et al., 2008). The findings suggest that 
disinhibition, and executive dysfunction, are early behavioural indicators of the 
functional decline associated with the development of AD in DS. Furthermore, 
the prominence of disinhibition in the DS-AD profile supports the hypothesis 
that the early clinical presentation of the disease is more indicative of frontal-
type dementia than typical AD (Ball et al., 2010). Ball et al. (2010) went on to 
speculate that the behavioural vulnerability to disinhibition suggests that the 
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serotonergically mediated orbito-frontal circuit may be particularly vulnerable 
to the initial pathology of DS-AD. 
 
Further support for early frontal compromise in DS-AD comes from Adams 
and Oliver (2010). The authors conducted the Neuropsychological 
Assessment of Dementia in Individuals with Intellectual Disability (NAID) three 
times over 16 months. The authors compared the adults with DS who had 
declined (10), to those who had not (20), to find that adults with cognitive 
deterioration showed deficits in executive function (Adams & Oliver, 2010). 
Furthermore, executive dysfunction was: 1. Limited to the decline group, 2. 
Related to behavioural changes, and 3. Independent of memory decline 
(Adams & Oliver, 2010). Together, these results suggest that frontal 
compromise, as indexed by executive dysfunction and behavioural changes, 
occur early in DS-AD and prior to memory problems.  
 
Nevertheless, there is some resistance to the hypothesis that frontal 
compromise is the earliest indicator of DS-AD (Blok, Scheirs, & Thijm, 2016; 
Deb, Hare, & Prior, 2007). This resistance is primarily centred on difficulties in 
diagnosing AD in DS. Parsing deficits associated with AD, from ID related 
impairment, is universally agreed as a challenging process (Deb et al., 2007; 
Nieuwenhuis-Mark, 2009; Sheehan et al., 2015; Strydom et al., 2010; 
Zeilinger, Stiehl, & Weber, 2013). Deb et al. (2007) uses this difficulty to 
suggest that DS-AD diagnoses are typically delayed; by which time frontal 
compromise is detectable, rather than being an ‘early’ symptom. Blok et al. 
(2016) also argued that adults with DS showed an early compromise of 
immediate memory, which is comparable to AD development for TD adults. 
These differing opinions on how AD presents in DS is a result of the 
difficulties in making a diagnosis and different tools being used, across 
studies, to do so (Nieuwenhuis-Mark, 2009). This presents a potential 
confound to be mindful of in the present thesis. Nevertheless, the weight of 
evidence does suggest that AD presents differently for adults with DS (Ball et 
al., 2008; Lott & Head, 2001; Nieuwenhuis-Mark, 2009; Strydom et al., 2010), 
most commonly with frontal dysfunction.  
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1.6 Synaptic dysfunction   
 
It has been suggest that: “Alzheimer’s disease is a synaptic failure”  (Selkoe, 
2002). Indeed, the earliest symptoms of AD correlate best with cholinergic 
and glutamatergic synaptic dysfunction (Davies, Mann, Sumpter, & Yates, 
1987; DeKosky & Scheff, 1990; Maurice & Goguadze, 2017; Parsons, 
Danysz, Dekundy, & Pulte, 2013; Selkoe, 2002; Terry et al., 1991). 
Furthermore, synaptic dysfunction speaks to early functional, rather than later 
structural, challenges to the AD affected brain, which is potentially more 
valuable when identifying therapeutic targets (Selkoe, 2002). The build up of 
Aβ is linked to synaptic dysfunction, and memory deficits, in that Aβ binds to 
α-7 nicotinic acetylcholine receptors, which reduces acetylcholine release and 
consequently the maintenance of long-term potentiation (LTP) (Wang et al., 
2000). Figure 1.2 outlines a hypothetical model of how Aβ and synaptic 
dysfunction interact in AD pathogenesis (Selkoe, 2002).  		
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Figure 1.2. “A hypothetical sequence of the pathogenetic steps of AD” from 
Selkoe (2002).  
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1.7 Excitability 
 
1.7.1 Hypo- and hyper-excitability in older adults 
 
Even with typical aging, older adults may perform comparatively worse on 
tasks of episodic memory (Balota, Dolan, & Duchek, 2000) and working 
memory (Foos & Wright, 1992) than younger adults. This comparatively 
poorer behavioural performance has been complimented by functional 
magnetic resonance imaging (fMRI) studies. Some imaging (fMRI) studies 
with older adults have found that activity is reduced in the left prefrontal cortex 
(PFC) at the memory encoding stage (Logan, Sanders, Snyder, Morris, & 
Buckner, 2002) and the medial temporal lobes at the retrieval stage (Cabeza 
et al., 2004). This “under-recruitment” model has been a popular explanation 
for the cognitive deficits associated with TD older adults. However, there is 
also an argument for the effects of “over-recruitment” (Grady, 2008).  
 
“Over-recruitment”, the heightened activity of brain regions, has typically been 
associated with better task performance. For example, in an fMRI study of a 
source memory recall task the PFC was engaged bilaterally for higher 
performing, older adults, whereas younger adults and lower performing older 
adults showed a right PFC dominance (Cabeza, Anderson, Locantore, & 
McIntosh, 2002). The suggestion was that lower performing older adults were 
inefficiently using the same circuitry as they always had, whereas higher 
performing older adults compensated for their age-related decline by 
recruiting alternative neural networks (Cabeza et al., 2002). An alternative 
suggestion is that “over-recruitment” refers to non-selective activity rather than 
the recruitment of focused alternatives (Logan et al., 2002). Furthermore, 
older adults may display atypical, increased activity in the PFC because they 
find the task more taxing than younger adults (Grady, 2008). Consequently, 
for older adults to succeed at the challenging task they may require greater 
use of frontally mediated executive functions, which would result in increased 
PFC activity (Grady, 2008). Furthermore, an fMRI study found that older 
adults over-recruited fronto-parietal regions when the task was difficult, and 
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performance was low (Spaniol & Grady, 2012). The authors alluded to the 
over-recruitment being a result of an increased demand, or ineffective use, of 
cognitive resources, rather than compensatory mechanisms (Spaniol & 
Grady, 2012). However, it was not possible to qualify this suggestion with the 
available data (Spaniol & Grady, 2012).  
 
1.7.2 Hyperexcitability and excitotoxicty in AD  
 
Hyper-excitability in pathological aging has been investigated with mouse 
models of AD. AD is typically associated with the break-down of synapses 
leading to a decrease in neuronal activity (Busche et al., 2008). An AD mouse 
model study by Busche et al. (2008), using two-photon Ca2+ imaging 
confirmed that there was decreased neuronal activity in layers II and III of the 
cortex. However, the authors went on to demonstrate that neurons near the β-
amyloid plaques showed increased and spontaneous Ca2+ transients (Busche 
et al., 2008). This excitotoxic response was attributed to a decrease in 
synaptic inhibition (Busche et al., 2008). At a cortical circuits level, β-amyloid 
can induce aberrant, excitatory discharge (Palop & Mucke, 2010). In a study 
of human amyloid precursor protein (hAPP) transgenic mice, Palop et al. 
(2007) reported that the mice exhibited spontaneous activity in the cortical 
and hippocampal networks because of excitotoxin challenge. The authors 
suggested that β-amyloid triggered the aberrant excitation in these regions, 
resulting in compensatory effects from the inhibitory mechanisms (Palop et 
al., 2007). In an attempt to reduce over-excitation, the inhibitory circuitry 
exerted increased restraint over the granule cells and detrimentally 
constrained the functionality of the excitatory circuits (Palop et al., 2007). In a 
DS mouse model, the increased inhibition of granule cells resulted in LTP 
deficits (Kleschevnikov et al., 2004). This finding further supports the 
hypothesis that the constant limitation of excitotoxic injury with compensatory 
inhibitory mechanisms can detrimentally impact on neural functionality, 
including those which serve learning and memory processes (Palop et al., 
2007; Palop & Mucke, 2016).  
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1.7.3 High rates of epilepsy in Alzheimer’s disease  
 
Epilepsy is a neurological disorder characterised by excessive, synchronous 
neuronal activity which manifests as seizures (Fisher et al., 2005). Between 
10 and 22% of individuals with AD have at least one unprovoked seizure 
during the course of their illness (Mendez & Lim, 2003). Furthermore, late-
onset epilepsy has been reported in 80% of cases where individuals have DS 
and AD (Evenhuis et al., 1990; Lai et al., 1989). There are suggestions that 
the severity of AD is a significant predictor of seizure onset (Amatniek et al., 
2006). However, Palop et al. (2009) suggested that the incidence of seizures 
is independent of disease stage. Therefore, it is unclear as to whether there is 
a shared or separate aetiology between Alzheimer’s and late-onset epilepsy 
(Noebels, 2011). Individuals who develop AD at a younger age of onset 
appear to be more susceptible to epileptic seizures than those with late-onset 
of the disease (Amatniek et al., 2006; Mendez, Catanzaro, Doss, Arguello, & 
Frey, 1994). Considering that adults with DS have a high prevalence of early 
onset AD (Evenhuis et al., 1990), epilepsy is an important consideration when 
working with this group.  
 
1.8 The rising cost of Alzheimer’s disease  
 
With rising life expectancy, AD has become a pandemic. Worldwide, over 46 
million people are currently living with AD, and this number is expected to 
double every 20 years (Prince et al., 2015). The global cost of caring for 
adults with AD will reach $1 trillion US dollars by 2018 (Prince et al., 2015). 
Despite the staggering economic and emotional strain that the disease poses, 
only two classes of drugs have been approved for treating the disease: 
cholinesterase inhibitors (4 from 1993-2001) and NMDA receptor antagonists 
(1 in 2003). Since 2003, 400 clinical trials have been performed in an attempt 
to generate more effective treatments, but none have been successful 
(Cummings et al., 2013). The treatments have primarily targeted Aβ plaques 
and NFTs of hyperphosphorylated tau peptides; therefore, the drugs are 
designed to remove these neurotoxic components rather than the regenerate 
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the associated cortical atrophy. As the drugs are primarily tested on adults at 
the latter stages of the disease, this target imbalance has been suggested as 
a potential explanation for the wide-spread, trial failures in AD. Consequently, 
there is now great interest in developing markers for the preclinical stages of 
AD so that therapeutic interventions, including those for neurotoxic 
components, can be administered when there is still functionality to be 
preserved rather than the more challenging task of restoring lost functions 
(Jackson & Snyder, 2008). Indeed, even modifying the disease progression 
with a one-year reduction could reduce the number of adults with AD by 9.2 
million in 2050 (Brookmeyer, Johnson, Ziegler-Graham, & Arrighi, 2007).  
 
1.9 Biomarkers of Alzheimer’s disease  
1.9.1 Definition  
 
The term ‘biological marker’, commonly referred to as ‘biomarker’, pertains to 
“a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or biological responses to 
a therapeutic intervention” (Biomarkers Definitions Working Group., 2001). 
This thesis is primarily concerned with evaluating electroencephalography 
(EEG) as measure of the typical biological process of aging, and as a 
potential indicator for the pathological development of AD in DS.  
 
1.9.2 Biomarker investigations in DS-AD 
 
The Down Syndrome Biomarker Initiative (DSBI) is a pilot, proof of concept 
study for deep and frequent phenotyping of adults with DS, with a view to 
using this model to identify potential markers of AD in DS (Rafii et al., 2015). 
In that pilot work, the 12 adults with DS (no AD) under went: cognitive testing 
(including CAMCOG-DS); volumetric magnetic resonance imaging (MRI); 
amyloid imaging with: position emission tomography (PET) and retinal scans. 
The participants tolerated the testing regime well, which suggested that the 
model could be expanded to multi-site testing, in the search for biomarkers of 
AD (Rafii et al., 2015).  
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A recent systematic review by Castro, Zaman, and Holland (2016) considered 
the role of biomarkers in potential prospective preventative treatment trials in 
DS-AD. The review discussed six classes of potential biomarkers: plasma, 
cerebrospinal fluid (CSF), positron emission tomography (PET), magnetic 
resonance imaging (MRI), optical coherence tomography (OCT) and EEG. All 
of the biomarkers are still at a fledgling stage of research and development 
but the blood based biomarkers (plasma, CSF), have been most extensively 
researched in the general population.  
 
In the search for biomarkers of AD, blood plasma studies typically focus on 
Aβ42/ Aβ40 ratios. Aβ42 is considered a neurotoxic product of APP (Selkoe, 
1994). A study of blood plasma samples from 506 adults with DS found that 
adults with the highest concentrations of Aβ40 and Aβ42 were at highest risk 
of developing AD (Coppus et al., 2012). Blood plasma samples are typically 
taken from the arm of participants, by venepucture. Consequently, the Aβ 
levels apply to the tissues of the body rather than specifically the brain. In 
comparison, CSF bathes the spine and brain, providing a more targeted 
reading of Aβ levels in the brain. However, the acquisition of CSF is a much 
more invasive procedure, which requires a lumbar puncture. A longitudinal 
assessment of CSF as a biomarker of AD found that adults with mild cognitive 
impairments (MCI) and the lowest CSF Aβ42 levels (at baseline) were the 
most likely to transition to AD, within 5 years (Buchhave et al., 2012). Lower 
CSF Aβ42 levels are believed to reflect an increased retention of Aβ in the 
brain, which can be imaged by PET as the hallmarks of AD: Aβ plaques (Jack 
et al., 2010).  
 
Imaging techniques such as PET and MRI are typically used, within an AD 
biomarker framework, to map the progression of the disease rather than to 
indicate prodromal stages (Sabbagh et al., 2015). This is because the 
measures are most informative at the latter stages of the disease: 
demonstrating the cortical amyloid burden (PET), and the associated cortical 
atrophy (MRI) (Castro et al., 2016). Recent studies have moved to imaging 
amyloid in the retina, as an easily accessible extension of the central nervous 
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system, but have yet to correlate the amyloid burden with cognitive decline 
(Rafii et al., 2015).  
 
EEG has received extremely little attention as a biomarker of DS-AD (Castro 
et al., 2016). Nevertheless, as early as 1993 it was suggested that cortical 
slowing in DS adult aging, as measured by quantitative EEG (qEEG), could 
be used as a model of AD development (Soininen et al., 1993). More 
specifically, slowing and diminished frequency of the dominant occipital 
rhythm signals the onset of cognitive deterioration indicative of DS-AD 
(Menéndez, 2005). Furthermore, qEEG has been tested as a potential 
diagnostic medium for DS-AD, with a decrease in centroid frequency being a 
distinguishing factor (from DS no AD) (Salem et al., 2015).  
 
From evaluating dementia research with the typically developing population, 
Jelic and Kowalski (2009) remain unconvinced about the diagnostic utility of 
qEEG. Jelic and Kowalski (2009) came to this conclusion by evaluating 46 
articles on the subject. The authors conceded that individual studies showed 
high diagnostic accuracy for dementia and MCI (using qEEG) but the 
evidence was not sufficient to incorporate this tool into routine clinical practice 
(Jelic & Kowalski, 2009).  In contrast, Jackson and Snyder (2008) were 
positive about the prognostic potential of electoencephalographical measures: 
qEEG and event related potentials (ERPs). Jackson and Snyder (2008) came 
to this conclusion by reviewing articles that had been published on the topic 
over the previous six years. P300 was highlighted as an ERP with prognostic 
potential for the transition from MCI to AD (Gironell, García-Sánchez, 
Estévez-González, Boltes, & Kulisevsky, 2005; Jackson & Snyder, 2008).  
P600 was highlighted as a potentially useful ERP for indicating the MCI stage, 
and N400 for mild AD (Jackson & Snyder, 2008). However, unlike P300, both 
these ERPs (P600, N400) have a strong language component, which could 
be conflated with ID rather than AD related cognitive impairment. 
Nevertheless, all of these electroencephalographic measures require more 
evaluative research to see whether their prognostic potential can be reached.  
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1.9.3 Evaluation of EEG against biomarker criteria 
 
‘Criteria for establishing a good biomarker for the diagnosis of dementia’ have 
been set out previously by Humpel (2011, p. 27, box 1). However, the criteria 
set out by Humpel (2011) were focused on evaluating blood and cerebral 
spinal fluid biomarkers. Therefore, the present project used a refined and 
categorised version of the criteria so potential electroencephalographic 
markers of AD can be evaluated. Please see table 1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1. Criteria for evaluating EEG as a marker of AD for the present 
project and future investigations. Adapted from ‘criteria for establishing a good 
biomarker for the diagnosis of dementia’ by Humpel (2011, p. 27, box 1) 
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1.9.4 The potential for EEG as a biomarker 
 
From a mechanistic perspective, one of the earliest processes in the 
development of AD is synaptic dysfunction (Busche et al., 2008). This 
synaptic dysfunction leads to aberrant, excitatory neuronal activity (Palop et 
al., 2007). The constant, compensatory inhibition of aberrant excitation can 
reduce neural functionality, including those which serve learning and memory 
processes (Palop et al., 2007). EEG is a technology which measures, with 
high temporal resolution, changes in voltage over the scalp resulting from 
summed postsynaptic potentials in cortical neurons (Teplan, 2002). Therefore, 
as a coarse measure of neural activity (Luck, 2005), EEG could be an 
informative biomarker of AD.  
 
Over the past 10 years there have been substantial improvements in the 
quality of EEG equipment and computing power (Jackson & Snyder, 2008). 
Consequently, EEG has recently been proposed as a technology with the 
potential to both delineate preclinical stages of AD and assess the 
effectiveness of therapeutic interventions, in real-time (Jackson & Snyder, 
2008). EEG is a promising candidate for screening preclinical and at risk 
populations because it is relatively inexpensive, non-invasive and widely 
available (Poil et al., 2013). EEG also has a widely inclusive clinical utility as 
some paradigms are passive and thus require limited active participation. 
Consequently, EEG could be informative about the cognitive impairment of 
individuals whose neuropsychological tests succumb to “floor effects” or who 
cannot comply with test demands. Furthermore, EEG as a measure of current 
cortical activity could potentially contribute to understanding AD progression 
within the mild, moderate and severe disease categories.  
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1.10 Electroencephalography  
1.10.1 Introduction to EEG  
 
An electroencephalogram (EEG) give a continuous, coarse measure of neural 
activity (Luck, 2005). From such a continuous recording, neural responses 
time-locked to specific stimuli can be extracted, and averaged as waveforms 
(Luck, 2005). These responses are referred to as event related potentials 
(ERPs). Two features are used to measure ERPs 1. Latency (ms): which is 
considered an index of processing speed, and 2. Amplitude (µV): which is 
associated with cognitive resource allocation (Duncan et al., 2009). ERPs can 
also be characterised by the locus and distribution of the activity at the scalp 
(Duncan et al., 2009). ERPs can be further characterised by polarity: the 
voltage difference between the recording and reference electrodes. The 
predictable generation of ERPs, in response to specific stimuli, provides a 
non-invasive time-course of cognitive processing in TD adults (Duncan et al., 
2009). Consequently, ERPs could be, and have been, informative about 
cognitive compromise in pathological states (Duncan et al., 2009). The current 
section will described previous explorations with typical (aging) and abnormal 
(AD, DS) states with a view to identifying future avenues of research into the 
nature of AD in people with DS. The general methods chapter (chapter 2) 
provides more detail on the physiology of EEG recordings, and ERP 
generation.   
1.10.2 Criteria for ERP selection 
 
The criteria for ERP selection in this thesis were: 1. The ERPs have been 
suggested in previous research to index brain regions and postulated 
cognitive processes of interest in AD, and 2. The means of recording the 
ERPs are acceptable and feasible for aging adults with DS. As a result, the 
ERPs selected for study were mismatch negativity (MMN) and P300 (P3a and 
P3b components). The rationale for the choices will now be discussed in 
terms of the ERPs’ physiological underpinnings (section 1.10), and previous 
research that has used the ERPs to investigate typical and pathological aging 
(section 1.11), and DS (section 1.12).     
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1.11 ERPs: background 	
MMN and P3 are well-defined, well-established components which have the 
operational basis to be applied to clinical disorders (Duncan et al., 2009).  
N400 and P600 have a similar sound basis, but also contain a language 
component (Duncan, 2009), which would conflate with the ID in a DS-AD 
investigation.  
1.11.1 MMN 	
Mismatch negativity (MMN) is an ERP that presents as a fronto-central 
negativity. MMN is sometimes referred to as N2, N200 or N2a (Duncan et al., 
2009). MMN is elicited when an incoming stimulus deviates (is mismatched) 
from the standard stimuli sequence, within a passive paradigm (Gene-Cos, 
Pottinger, Barrett, Trimble, & Ring, 2005). MMN is generated bilaterally at the 
auditory cortices, with some recruitment from the frontal cortex (Giard, Perrin, 
Pernier, & Bouchet, 1990). The auditory cortex activity reflects the automatic, 
pre-perceptual component to the potential whereas the frontal recruitment 
refers to the involuntary shift in attention to the ‘mismatched’ stimuli (Escera, 
Alho, Winkler, & Näätänen, 1998; Escera, Yago, & Alho, 2001; Giard et al., 
1990; Rinne, Alho, Ilmoniemi, Virtanen, & Näätänen, 2000). MMN is 
calculated as a difference waveform, by subtracting the average ERP 
response to standard stimuli from that to deviant stimuli, within 100-250 ms of 
stimulus presentation (Duncan et al., 2009). MMN reflects the automatic 
detection of a new, deviant stimulus compared to the sensory memory trace 
of previous, repetitive stimuli (Duncan et al., 2009).  
 
From a physiological perspective, MMN generation in the auditory cortex is 
likely the result of repetitive stimulation (standard tones) leading to tonic 
response inhibition, which is counteracted by deviant (mismatched) 
stimulation, via glutaminergic mechanisms (Javitt, Steinschneider, Schroeder, 
& Arezzo, 1996). However, this inhibition hypothesis is limited to simple 
auditory MMN, and does not explain the MMN response to complex auditory 
relations or stimuli (words) (Korpilahti, Krause, Holopainen, & Lang, 2001; 
Obleser et al., 2006; Pulvermüller et al., 2001; Shtyrov & Pulvermüller, 2002). 
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A predictive coding model would be more explanatory (Strelnikov, 2007), and 
is expanded on in section 1.14.  
1.11.2 P300: P3a and P3b  	
P300 was first described by Sutton, Braren, Zubin, and John (1965) and is 
perhaps the most studied ERP. P300 is a scalp positivity which can peak 
anywhere between 250ms and 1000ms but typically peaks at 300ms, as the 
name suggests (Olichney, Yang, Taylor, & Kutas, 2011). P300 is sometimes 
referred to as P3 and comprises two potentials: ‘P3a’ and ‘P3b’ (Polich, 2007). 
P3a is the earlier component, which peaks within 200-300 ms of the stimulus, 
with a fronto-central locus (Squires, Squires, & Hillyard, 1975). P3a is the 
much lesser studied component. Indeed, in the literature, the term P300 
usually just refers to the P3b component, which is maximal over parietal areas 
(Polich & Kok, 1995). The scalp-wide presence of P300 (Soltani & Knight, 
2000) has lead to the suggestion that the potential either has several 
independent generators, or reflects the central integration of wide-ranging 
connections (Duncan, Kosmidis, & Mirsky, 2003; Nieuwenhuis, Aston-Jones, 
& Cohen, 2005; Pineda, Foote, & Neville, 1989). Nevertheless, the foci of 
P300 generation have been suggested as the: hippocampus, superior 
temporal sulcus, ventrolateral prefrontal cortex, and potentially the 
intraparietal sulcus (Halgren et al., 1995; Halgren, Marinkovic, & Chauvel, 
1998; Kiss, Dashieff, & Lordeon, 1989; Smith et al., 1990).  
 
P300 is the electrophysiological response to detecting an ‘oddball’, target tone 
which breaks a sequence of repeated, ‘standard’ tones. P3a is seen in 
response to rare or novel events, whereas P3b requires attentive, evaluative 
and categorical processes to be elicited in response to a deviant tone 
(Duncan et al., 2009; Johnson & Donchin, 1978). The amplitude of P300 is 
enhanced by salience (Yeung & Sanfey, 2004), and diminished by excessive 
repetition (Squires, Wickens, Squires, & Donchin, 1976). The P3a component 
is considered to be the evaluative response to novelty (Friedman, Cycowicz, 
& Gaeta, 2001). The P3b is generally considered to be an index of cognitive 
processes required in the maintenance of working memory and the allocation 
of attentional resources (Polich & Kok, 1995). 
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From a physiological perspective, several neurotransmitter systems are 
involved in the generation and modulation of P300 (Hansenne, 2000). P300 
amplitude is increased by noradrenergic agonists (Pineda & Swick, 1992) 
and/or, in a biphasic relationship, decreased by dopaminergic agonists 
(Stanzione et al., 1991). Conversely, P300 amplitude is decreased by 
cholinergic antagonists (Hammond, Meador, Aung-Din, & Wilder, 1987) and 
gabaergic agonists, which also increases P300 latency (Meador, 1995).  
 
1.12 ERPs: typical and pathological aging 
1.12.1 MMN 	
MMN can be viewed as a means of indexing auditory sensory memory traces 
(Pekkonen et al., 1996). The relationship between MMN and aging is 
elucidated as declines in sensory memory and perceptual accuracy relate to 
both factors (MMN, older adults) (Demiral, Malcolm, & Henderson, 2012; 
Fakhri, Sikaroodi, Maleki, Ali Oghabian, & Ghanaati, 2012; Lauzière, Dubois, 
Brière, & Nadeau, 2012; Stewart & Wingfield, 2009). Studies have suggested 
that the age effect on MMN is isolated to an amplitude decrease (Pekkonen et 
al., 1996; Pekkonen, 2000; Schiff et al., 2008). Indeed, MMN seems to 
succumb less to aging effects than later, more cognitive components, like P3b 
(Schiff et al., 2008).  
 
MMN amplitudes decrease with age (Alain, McDonald, Ostroff, & Schneider, 
2004; Alain & Woods, 1999; Bertoli, Smurzynski, & Probst, 2002, 2005; 
Cooper, Todd, McGill, & Michie, 2006; Czigler, Csibra, & Csontos, 1992; 
Horváth, Czigler, Birkás, Winkler, & Gervai, 2009; Horváth, Czigler, Winkler, & 
Teder-Sälejärvi, 2007; Karayanidis et al., 1995; Kisley, Davalos, Engleman, 
Guinther, & Davis, 2005; Pekkonen et al., 1996; Pekkonen, 2000; Rimmele, 
Sussman, Keitel, Jacobsen, & Schröger, 2012; Schiff et al., 2008; Tsolaki, 
Kosmidou, Hadjileontiadis, Kompatsiaris, & Tsolaki, 2015; Woods, 1992), but 
are significantly smaller still for adults with AD compared to age-matched 
controls (Kazmerski, Friedman, & Ritter, 1997; Pekkonen, 2000). However, 
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the strongest responses to deviant auditory stimuli are elicited fronto-centrally 
and as such MMN has been suggested as a valuable indicator of front-
temporal dementia (Hughes & Rowe, 2013). The early behavioural 
presentation of AD in DS appears to be weighted towards changes in 
cognitive functions underpinned by the frontal lobes (Ball et al., 2006; Ball, 
Holland, Treppner, Watson, & Huppert, 2008). As such, the initial presentation 
of DS-AD is more akin with fronto-temporal dementia than typical AD (Ball et 
al., 2006). Therefore, it would be relevant to investigate age and AD related 
changes in DS by using paradigms which elicit fronto-centrally distributed 
ERPs.	 
1.12.2 P300: P3a and P3b  
 
With typical, adult aging, P300 has been shown to decrease in amplitude and 
increase in latency (Duncan et al., 2009; Kerr, van Albada, Rennie, & 
Robinson, 2010; Polich, 2007; Rossini, Rossi, Babiloni, & Polich, 2007; Schiff 
et al., 2008; Walhovd, Rosquist, & Fjell, 2008). The physiology behind this 
relationship has been linked with: 1. The volumetric changes to brain regions 
(fronto-temporal, hippocampus), which support P300 generation, with typical 
aging (Fjell, McEvoy, Holland, Dale, & Walhovd, 2013), and 2. The typical 
decline in functions indexed by P300: attention and memory (Quigley, 
Andersen, Schulze, Grunwald, & Müller, 2010; Quigley & Müller, 2014). 
Again, the literature is generally referring to the P3b component when the 
term P300 is used. However, frontal lobe functioning is potentially less 
efficient for older adults (Fabiani, Friedman, & Cheng, 1998). Furthermore, a 
topographical study of P300 distribution found that, with age, sources move to 
have a frontal distribution, and the maximum intensities gain a temporal locus 
(Tsolaki et al., 2015). These topographical findings present an argument for 
whole brain, rather than single canonical electrode, analyses when exploring 
the relationship between the ERPs and typical aging.  
 
The ERP P300 (P3) has been used frequently and successfully to 
disambiguate AD from typical aging in the general population and as such has 
been selected for this project. P300 elicited under a standard, auditory oddball 
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paradigm is one of the most commonly used ERPs to investigate AD (Ally, 
Jones, Cole, & Budson, 2006). The studies have generally suggested that 
cognitive decline in AD is reflected in longer P300 latency times (Gungor et 
al., 2005; Jiménez-escrig et al., 2002; Lai, Lin, Liou, & Liu, 2010), and 
reduced P300 amplitudes, compared to age-matched controls (Ally et al., 
2006; Caravaglios, Costanzo, Palermo, & Muscoso, 2008; Gungor et al., 
2005; Lee et al., 2013). Again, references to P300 in the literature are typically 
referring to the P3b component.  
 
A meta-analysis of 48 studies which compared auditory P300 latency between 
TD adults, and adults with MCI (8/48) or AD (40/48), was conducted by Howe, 
Bani-Fatemi and De Luca, (2014) with a view to evaluating the preclinical 
diagnostic value of P300 latency for MCI and AD. The meta-analysis was 
launched because although previous studies have been predominantly 
positive about the utility of P300 latency in AD research, some studies have 
failed to find a significant relationship between the two (Ashford, Coburn, 
Rose, & Bayley, 2011; Lee et al., 2013). The meta-analysis concluded that 
P300 latency was a useful tool in clinical, AD research but more studies were 
required to confirm the usefulness at the MCI stage (Howe et al., 2014). 
 
Using typical EEG recording and analysis methods, the sensitivity and 
specificity of P300 to AD have been reported in the literature, with high 
variation, at between 50% (Gironell et al., 2005) and 80% (Karim Bennys, 
Rondouin, Benattar, Gabelle, & Touchon, 2011). The conventional methods 
referred to are ERP waveform averaging from single electrode sites (Pz for 
example). However, recent studies which have employed more sophisticated 
methods, such as dipole source analysis and topographical scalp maps, have 
improved sensitivity and specificity to >80% (Bonanni et al., 2010; Frodl et al., 
2002; Juckel et al., 2008). Indeed, sensitivity has been reported at as high as 
90% (Frodl et al., 2002), and specificity at 97% (Bonanni et al., 2010). 
Sensitivity and specificity to the dementia-type (AD) is essential from a 
biomarker perspective (Humpel, 2011).			The meta-analysis also highlighted 
how P300 research in AD has predominantly focused on the P3b component, 
and the contributions of P3a have been overlooked (Howe et al., 2014) and 
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are little understood (Polich, 2007). These assertions have informed the 
methodological and research focus (P3a) choices in this thesis.  
 
1.13 ERPs: a systematic review of previous DS studies  
1.13.1 Literature search  	
A systematic review was conducted to explore mismatch negativity (MMN) 
and P3 (P3a, P3b), in relation to DS. The review used the search terms and 
inclusion pathway outlines in figure 1.3 (1.12.2. The article identification 
process). The PubMed, Scopus and Web of Science databases were 
searched in order to identify all published articles about the ERPs (MMN, P3) 
and DS. In an attempt to be fully inclusive, all of the synonyms for mismatch 
negativity (MMN, N2, N200, N2a) and P3 (P300, P3a, P3b) were searched. 
Nevertheless, the literature on the ERPs (MMN, P3) and DS is scarce, as only 
30 unique results were found. Of the search results, the review only included 
original ERP (MMN, P3) studies, which were written in English, and recruited 
children or adults with DS. Studies were predominantly excluded when DS 
was referred to but not tested as a participant group. Consequently, only 16 
articles were appropriate for full review. The full list and summary of the 
articles can be found in table 1.2 (1.13.3. The articles identified), and the 
review in section 1.13.4. Summation and review of the identified articles.  
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1.13.2 The article identification process 
Figure 1.3. The article identification process for a systematic review of event 
related potentials (ERPs): MMN and P3, in Down’s Syndrome (DS). The 
literature search was carried out on 6th February 2017. TD = typically 
developing, ID = intellectual disability, AD = Alzheimer’s disease.  
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1.13.3 The articles identified  
Author  Sample ERP Measures 
 
Key Findings  1/3 
Arisi et al. 
(2012) 
15 adults with DS (16-38 yrs, 7 males) 
16 age-matched TD controls (7 males)  
 
N1, N2 (MMN),  
P1, P2  
Adults with DS, and normal hearing thresholds, showed 
longer latencies than controls, across the measures. N2 was 
only present in 14 DS and 14 TD.  
 
Blackwood et al. 
(1988) 
89 adults with DS (16-66 yrs), including  
16 with DS-AD 
29 adults with fragile X syndrome 
83 TD adults 
(Abstract only)  
 
P300 P300 latency increased at (approximately) 37 years old for 
adults, and at 54 years old for control participants. The 16 
adults with DS-AD drove the premature latency increase.  
César, et al. 
(2010) 
17 adults with DS (18-39 yrs, 10 males)  
34 TD controls (18-39 yrs, 20 males)  
 
N1, P2,  
N2, P3 
Adults with DS showed longer latencies on all the measures 
and smaller amplitudes for N2-P3.   
Díaz & Zurron 
(1995) 
12 children with DS (mean 14.16 yrs) 
12 TD controls (mean 14.58 yrs)  
 
 
 
SAEP,  
MAEP,  
LAEP: N1,  
P2, N2, P3 
Relative to control participants, the N2 and P3 latencies were 
longer in DS. The N2-P3 amplitude decreased with 
successive blocks for controls. However, the N2-P3 
amplitude was constant in DS, until the fourth block where the 
amplitude rose.  
 
Kakigi, et al. 
(1994) 
47 adults with DS (18-48 yrs,  
M = 30.8 yrs, 26 males) 
37 adults with AD (60-82 yrs,  
M = 68.5 yrs, 15 males) 
43 younger TD controls (22-53 yrs,  
M = 30.8yrs, 17 males) 
20 older TD adults (60-78yrs,  
M = 69.1yrs, 10 males) 
P300 Only 24 adults with DS showed consistent ERPs, of which 
there was a delayed and frontal shift to the P300. This frontal 
shift was not present in the AD or TD (younger, older) 
participants.  
Kaneko, et al. 
(1996) 
 
18 children with FAS  
18 children with DS  
18 TD children  
Total of 54 children (4-15 yrs, M = 9.1 yrs) 
 
  
 
 
P300 The children with FAS and DS showed significantly longer 
parietal P300 (P3b) latencies than TD children. Furthermore, 
the amplitude of the frontal P300 (P3a) was significantly 
larger for DS than FAS or TD children.   
	 53 
Author  Sample ERP Measures 
 
Key Findings  2/3 
Kazan et al. 
(2016) 
17 children with DS (7-15 yrs, M = 10.9 yrs, 
8 males) 
21 TD (7-15 yrs, M = 9.8 yrs, 5 males)  
 
BAEP, P300 With a quantitative analysis, there were no statistically 
significant differences in P300 latencies between the groups. 
With a qualitative analysis, 33% of DS children showed 
increased P300 latency.  
 
Lalo, et al. 
(2005) 
20 adults with DS (18-31 yrs, M = 24 yrs,  
10 males) 
20 TD adults (19-31 yrs, M = 25 yrs,  
10 males)  
 
 
N1, P2, N2a 
(MMN), N2b, 
P3a, P3b  
P3b was present in 55-65% of adults with DS, compared to 
75-85% of controls, and was longer in latency. For control 
participants, MMN was present for most and P3a for half. In 
contrast, the presence of all three ERPs (P3a, P3b and MMN) 
in DS was as low as 10-25% of participants.   
Medaglini et al. 
(1997) 
45 adults with DS (M = 30.6 yrs, 16 males) 
TD controls  
(Abstract only)  
 
 
 
N1, P2, N2,  
P3, qEEG  
Adults with DS showed longer latencies and smaller 
amplitudes of P300 than controls. Within group (DS), P300 
latency and amplitude differences did not distinguish young 
from old, and AD from no AD. P300 latencies were abnormal 
(>2.5 SD) in 47% of cases.  
Miezejeski et al. 
(1994) 
80 males: 13 with DS, 23 with generalised 
ID, 44 TD controls 
(Abstract only)  
 
P3, P5 Adults with DS and control participants had comparable P3 
latencies, but shorter latencies than adults with generalised 
ID.  
Muir et al. 
(1988) 
65 adults DS 
20 adults fragile X  
(Abstract only)  
 
 
P300  Over the course of two years, 14% of the adults with DS 
developed AD. Of those who developed AD at follow-up, 78% 
showed an increase in P3 latency of 3 standard deviations 
above the group mean.   
Niwa, et al. 
(1983) 
4 children with DS (11-17 yrs,  
M = 15yrs, 1 male) 
4 children with autism (12-17 yrs,  
M = 14.1yrs, 4 males) 
5 TD children (11-22yrs, M = 17 yrs)   
 
 
 
 
 
P300 Participants with autism showed significantly lower P300 
amplitudes than the other groups (DS, TD). The DS and TD 
groups showed similar P300 amplitudes. The latencies did 
not significantly differ between groups.  
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Author  Sample ERP Measures 
 
Key Findings  3/3 
Seidl et al. 
(1997) 
10 children with DS (11-20 yrs,  
M = 15 yrs, 6 males) 
10 age- and gender-matched TD  
controls (M = 15.1 yrs) 
 
Antihistaminergic treatment group:  
12 TD adults (20=28 yrs, 6 males)  
 
 
 
N1, P2,  
N2, P3  
Participants with DS showed longer latencies for N1, P2, N2 
and P3. The mean P3 amplitude at Cz was smaller in DS 
than TD, but not significantly.  Between testing blocks the P3 
amplitude decreased for TD participants but remained 
constant for DS participants. For the antihistaminergic 
treatment group, pheniramine administration increased P3 
latency and maintained P3 amplitude during repeated 
stimulation. These findings implicate the histaminergic system 
in the modulation of P3.  
 
St. Clair & 
Blackwood 
(2013)  
101 adults with DS (16-66 yrs) 
88 TD controls (18-75 yrs)  
N100, P200, 
P300 
P300 waveforms were obtained from 90 adults with DS and 
85 TD controls. For adults with DS, P300 latencies were 
significantly longer, and P300 amplitudes significantly 
smaller, than TD controls. P300 latencies increased with age 
for both groups, however the intercept for age-related change 
was 37yrs for DS and 53 yrs for TD.  
 
Vieregge, et al. 
(1992) 
14 adults with DS (22-42 yrs,  
M = 32 yrs, 5 males)  
18 younger TD controls (22-26 yrs, 
M = 24 yrs, 5 males) 
20 older TD controls (55-87 yrs,  
M = 67 yrs, 8 males)  
 
N1, P2,  
N2b, P3  
P3 latencies were longer for adults with DS than the younger 
and older TD controls. The P3 amplitude was similar in DS 
and younger controls, but larger than older controls. 
However, for adults with DS, there was an amplitude shift 
towards positivity, across the measures, and with a fronto-
central focus. For adults with DS, P3 did not correlate with 
age or cognitive test performance.  
 
Wetter & 
Murphy (1999) 
20 adults with DS (M = 26 yrs, SD = 10) 
20 age-matched TD controls  
N1, P2,  
N2, P3  
Adults with DS showed longer P3 latencies than controls. 
Adults with DS and cognitive decline showed longer latencies 
than adults with DS but no AD components.  
 
Table 1.2. Studies on the ERPs (MMN, P3) in DS. Abbreviations: ERP = event related potential, M = mean, SD = standard 
deviation, DS = Down’s Syndrome, TD = typically developing, ID = intellectual disability, FAS = foetal alcohol syndrome, yrs = 
years, BAEP = brainstem auditory evoked potentials, SAEP = short latency auditory evoked potentials, MAEP = middle latency 
auditory evoked potentials, LAEP = late latency auditory evoked potentials. The potentials in bold are those which were analysed in 
the article and were of interest (MMN, P3) for the review. The key findings pertain to the measures of interest (MMN, P3). The 
potentials are listed as they were written in the text. MMN can also mean N2a, and sometimes N2 (depending on the time period 
used in the text). P3 can also mean P300, and be referring to the P3a or P3b component. 
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1.13.4 Summation and review of the identified articles  
 
Across the studies, P3 was predominantly presented to have longer latencies 
for adults and children with DS, than TD control participants (Blackwood et al., 
1988; César, Caovilla, Munhoz, & Ganança, 2010; Kakigi, Neshige, Matsuda, 
& Kuroda, 1994; Lalo, Vercueil, Bougerol, Jouk, & Debû, 2005; Medaglini et 
al., 1997; Seidl et al., 1997; St. Clair & Blackwood, 2013; Vieregge, Verleger, 
Schulze-Rava, & Kömpf, 1992; Wetter & Murphy, 1999). However, DS P3 
latencies were shorter when compared to children with foetal alcohol 
syndrome (FAS) (Kaneko, Ehlers, Philips, & Riley, 1996), and adults with 
generalised intellectual disability (ID) (Miezejeski, Heaney, Belser, & Sersen, 
1994). In three cases, the P3 latencies in DS were presented as comparable 
to TD children and adults (Hellen Medeiros Kazan et al., 2016; Miezejeski et 
al., 1994b; Niwa, Ohta, & Yamazaki, 1983), and children with autism (Niwa et 
al., 1983). However, Kazan et al. (2016) presented a discrepancy between 
quantitative and qualitative analyses of P3 latencies. In a quantitative 
analysis, 17 children with DS presented with similar P3 latencies to 21 TD 
children. In contrast, a qualitative analysis revealed that a third of the children 
with DS showed increased P3 latencies (Kazan et al., 2016). This discrepancy 
ties into a larger research issue of considering a heterogeneous disorder 
(DS), which encompasses a wide range of intellectual ability and disability, as 
a homogenous group.  
 
P3 latency was linked with the hypothesis of premature aging in DS for two 
studies: Blackwood et al. (1988) and St. Clair & Blackwood (2013). The 
studies found that the intercept for age-related increase to P3 latency was 37 
years for adults with DS and 53 years for TD controls (Blackwood et al., 1988; 
St. Clair & Blackwood, 2013). However, Blackwood et al. (1988) went on to 
suggest that the 16 adults with DS-AD might have driven the premature 
latency increase.  A link between increased P3 latency, aging and DS-AD was 
presented in a 2-year, longitudinal study of adults with DS that suggested of 
those (14%) who transitioned to AD, 78% showed a significant increase in P3 
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latency (Muir et al., 1988). A comparison of DS and AD, as individual 
disorders, indicated that the locus of P3 was shifted frontally for adults with 
DS but not for TD adults, with and without AD (Kakigi et al., 1994).  
 
There were discrepancies between the studies that compared P3 amplitudes 
between participants with DS and TD controls. Two adult studies suggested 
that P3 amplitude was significantly smaller for participants with DS than TD 
controls (César et al., 2010; St. Clair & Blackwood, 2013), whereas a study of 
children suggested that the amplitudes were similar between groups (Niwa et 
al., 1983). Further studies of children with DS presented that P3 amplitudes 
did not habituate and diminish (remained constant) across trials (Díaz & 
Zurron, 1995; Seidl et al., 1997), and would even increase on the final round 
(Díaz & Zurron, 1995), or be generally larger than they were in TD and FAS 
children (Kaneko et al., 1996). Kaneko et al. (1996) suggested that the larger 
P3 amplitude was specifically a frontal P3 (P3a), which ties into other 
observations of a frontal shift in the P3 locus for adults with DS (Kakigi et al., 
1994; Vieregge et al., 1992). The rationale for an enlarged frontal P3 (P3a) 
was presented as 1. A disturbance in generating a P3b response (Kakigi et 
al., 1994), 2. A failure to habituate, and inhibit, at an electrophysiological level 
(Díaz & Zurron, 1995), and 3. A potential product of accelerated aging in DS 
(Kakigi et al., 1994). This finding is predominantly driven by child studies 
using 10-year-old EEG acquisition and analysis techniques. The research 
should be developed, beyond single electrode analyses, to a group (adults) 
that can speak to the relationship between P3, premature aging and AD 
development.  
 
Similar to the AD literature, the ERP studies in DS studies have been 
predominantly focused on the P3 potential. Indeed, only one study (Arisi et al., 
2012) discussed MMN in the absence of P3 findings. The few studies which 
referenced MMN spoke of increased latencies and reduced amplitudes (Arisi 
et al., 2012; César et al., 2010; Lalo et al., 2005). The paucity of research on 
this potential presents a need for more investigations, using up-dated 
techniques.  
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1.14 Predictive coding 	
Predictive coding utilises the economical assumption that the majority of 
sensory cues from the environment are repetitive and therefore redundant 
(Jack & Hacker, 2014). This top-down assumption: ‘prediction’, is used to 
constrain processing of bottom-up, sensory inputs (Friston, 2005). The 
processing is constrained to only those which defy the assumption: ‘prediction 
errors’ (Friston, 2005). This economical, hierarchical framework can be used 
to contextualise ERPs (MMN, P3a, P3b) as ‘prediction errors’ (Garrido, Kilner, 
Kiebel, & Friston, 2007; Lieder et al., 2013; Wacongne et al., 2011). In the 
absence of attention, the processing of prediction errors occurs at a low-level, 
producing MMN and P3a waveforms (Bekinschtein et al., 2009). A pattern is 
extracted when these low-level, ‘local’ violations are processed at higher-
levels (Chennu, Noreika, et al., 2013). This pattern extraction uses 
environmental cues to improve the quality of the top-down predictions 
(Chennu, Noreika, et al., 2013). This is an iterative process: low-level, ‘local’, 
environmental cues inform higher-level, ‘global’ predictions; these predictions 
are then used to constrain processing from the lower levels (Chennu, Noreika, 
et al., 2013). When attention is engaged and violations occur at this higher 
‘global’ level of processing then a P3b waveform is generated (Bekinschtein et 
al., 2009). This distinction in prediction error processing can be used to 
delineate ‘local’ (MMN, P3a) and ‘global’ (P3b) components, within the same 
odd-ball paradigm: the global-local paradigm (Bekinschtein et al., 2009). The 
global-local paradigm was developed by Bekinschtein et al. (2009) and forms 
the basis of this thesis. The paradigm is described in detail in the general 
methods (chapter 2, 2.15).  
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1.15 Rationale 	
The predictable high risk of AD in DS presents a considerable burden for this 
aging population. The highest risk for AD development is age, rendering age 
as an unavoidable consideration in any investigation of AD. The reactive 
rather than preventative administration of AD treatments has thus far gleaned 
poor results; so treatment development is now moving towards testing at 
prodromal stages. Consequently, identifying individuals who will develop AD, 
and when they will develop it, has never been more important. Furthermore, 
the efficacy of preventative treatments needs to be tested in real time, rather 
than waiting 20 years to see if someone develops the disease. With these 
observations, the development of appropriate biomarkers of ‘who’ and ‘when’ 
AD will develop, has gained significant interest. Older adults with DS develop 
the pathology of AD with inevitability. Having identified the ‘who’, it is now 
important to predict ‘when’. In order for a biomarker to be usable as a 
widespread tool, it must be easy to administer, relatively inexpensive and non-
invasive. As such, EEG has garnered some attention as a marker of AD in the 
TD population. The ultimate aim of this thesis is to evaluate ERPs as potential 
predictors of the cognitive decline associated with DS-AD. The thesis will build 
on each chapter in an attempt to achieve this aim: Firstly, as DS is associated 
with atypical brain morphology, the extent to which the ERPs differ from age-
matched TD controls will be established. Secondly, the ERPs will be 
considered in terms of the highest AD-risk factor: age, with a view to exploring 
the premature aging hypothesis of DS. Thirdly, the ERPs’ relationship with 
neuropsychological measures, associated with early DS-AD development, will 
be explored. Finally, a preliminary exploration of whether the ERPs can 
predict cognitive decline, a year later.  										
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1.16 Thesis aims  	
The overall aims of the study are as follows, and are explored in the four 
findings chapters:  
 
1. To use electroencephalographic measures (MMN, P3a, Pb) to 
compare adults with Down’s Syndrome and typically developing 
controls, within a predictive coding framework (chapter 3).  
 
2. To use electroencephalographic measures as a means of testing the 
accelerated brain aging hypothesis in Down’s Syndrome (chapter 4).  
 
3. To explore whether electroencephalographic measures relate to a 
range of neuropsychological measures, that have been reported to be 
sensitive to the functional decline associated with the early stages of 
Alzheimer’s disease in Down’s Syndrome (chapter 5). 
 
4. To investigate the potential value of electroencephalographic measures 
as predictors of cognitive decline in adults with Down’s syndrome 
(chapter 6).   
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2 Chapter 2. General methodology  
 
2.1 Introduction 	
The methodologies used in data collection and analyses for the study are 
described in this chapter. The subsequent data chapters (chapter 3,4,5) all 
share methodologies relating to participant recruitment and assessments. The 
data chapters (3,4,5,6) also share methodologies for data collection and pre-
processing of the electrophysiological data. Therefore, the subsequent data 
chapters will only describe deviations to the general methodology that are 
relevant to the specific subject matter of the chapter.  
 
2.2 Approvals from Regulatory Authorities  	
Ethical approval to conduct the study (reference 14/LO/1411) was provided by 
the Queen Square National Research Ethics Service (NRES) on 08.09.14. 
The committee had the expertise to assess studies aiming to include 
individuals who may lack the capacity to consent to participation. Following 
favourable ethical opinion, the Cambridgeshire and Peterborough NHS 
Foundation Trust (CPFT) Research and Development office (R&D) approved 
the study on 10.10.14. The study was enacted within the ethically approved 
protocol and the CPFT R&D governance framework. Confirmation of the 
study’s ethical approval can be found in appendix A.  
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2.3  Design 
 
A schematic of the testing schedule is provided in figure 2.1 and expanded 
upon below.   
 
Figure 2.1. A schematic of the study design: left to right is the chronological 
order of the study, the blue sections are cross-sectional, and the green are 
longitudinal. The numbered arrows denote the number of participants who 
transitioned from one phase of the project to the next. The numbered arrows 
from ‘Home Visit 2’ to ‘Cambridge Visit’ indicate that 36 participants 
completed the EEG assessment, of whom 15 successfully had blood samples 
taken and 11 had PET (and MRI) scans. 35 of these participants transitioned 
to the ‘Longitudinal Phase’.  
 
The study was composed of two phases:  
 
Cross-sectional phase: men and women with Down’s Syndrome (DS) aged 
20+ years old (aiming for approximately 10 participants per decade), and age- 
and gender-matched controls from the typically developing (TD) population, 
were recruited for neuropsychological and electrophysiological assessments. 
The work comprising the cross-sectional phase of the research is described in 
three chapters. In chapter 3, the electrophysiological measures were 
compared between adults with DS and TD controls. In chapter 4, the effect of 
Home Visit 1 
  
Cross-sectional Phase Longitudinal Phase 
Home Visit 2  Home Visit 3 Cambridge Visit 
Discussion 
  
Consent 
  
Hearing test 
  
Cognitive 
assessments 
Cognitive 
assessments 
(continued) 
Interview with 
parent/carer 
  
  
Completed the  
EEG assessment  
  
Blood sample taken 
  
PET (and MRI) scan 
completed  
Discussion 
  
Consent 
  
Repeat cognitive 
assessment - CAMDEX 
only: interview with parent, 
CAMCOG with participant  
43  
15  
36  35  
11  
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age on the electrophysiological measures was explored both within and 
between groups (DS, controls). In chapter 5, the relationship between the 
neuropsychological and electrophysiological assessments was explored.  
 
Longitudinal phase: at the first assessment period there were 
neuropsychological and electrophysiological testing components, as 
described in sections 2.8 and 2.14, respectively. Between 9 and 14 months 
after the first assessment period all the participants with DS were invited for a 
repeat neuropsychological assessment. The purpose of the repeated 
neuropsychological assessment was to explore whether the initial 
electrophysiological assessment had predictive value for any cognitive decline 
observed between the first and the second assessments (chapter 6).  
 
2.4 Collaborations  	
This study is part of a larger ‘Defeat Dementia in Down’s Syndrome’ research 
stream in the Cambridge Intellectual and Developmental Disabilities Research 
Group (CIDDRG), which is composed of several studies. The amyloid imaging 
study (11/EE/0348) and the mitochondrial function study (12/EE/0249), were 
the primary source of participant recruitment for the present study. The PET 
data was collected and processed at the Wolfson Brain Imaging Centre 
(WBIC) by researchers on the amyloid imaging study: Dr Tiina Annus and Mr 
Liam Wilson, University of Cambridge. Dr Young Hong and Dr Tim Fryer 
performed the kinetic modelling and reconstruction of the PET data at the 
WBIC, University of Cambridge. An eye imaging study (14/EE/118) ran 
concurrently with the present study so some cross-sectional 
neuropsychological testing was shared with Miss Madeleine Walpert. Some 
longitudinal neuropsychological testing was shared with Miss Paula Castro, a 
research intern. The electroencephalographic assessments and analyses 
methods were developed in collaboration with Dr Srivas Chennu, Dr Tristan 
Bekinschtein and Dr Valdas Noreika, at the University of Cambridge.  
 
	 63 
2.5  Participants  	
2.5.1  Identification  	
The participants with DS were predominantly identified from their previous 
participation in studies run by the ‘Defeat Dementia in Down’s Syndrome’ 
research stream in CIDDRG. Only participants with DS who consented to 
being approached for future studies were identified for the present study. The 
subset of participants with DS who had not taken part in previous CIDDRG 
studies were identified through charities, predominantly the Down Syndrome 
Association (DSA).  The DSA, and a local support charity for people with 
intellectual disability (ID) called Eddies, were also encouraged to advertise the 
research group’s open days. The primary reason for the open days was to 
involve previous participants and interested members of the public in our 
research findings and plans. People with DS who expressed interest in taking 
part in research at the open days left their contact details and were later 
contacted with study specific information and the opportunity for a home visit, 
to further explain what participation involves. Participants with DS were 
identified for the longitudinal phase by virtue of having been involved in the 
cross-sectional phase of the project, and having agreed to be contacted about 
future studies. Ethical approval was gained to recruit through: NHS services, 
predominantly local learning disability community teams; Cambridgeshire and 
Peterborough Foundation Trust (CPFT) clinicians and Participant 
Identification Centres (PICs). However, no participants were recruited through 
this avenue. 
 
The age- and gender-matched typically developing controls were initially 
recruited through advertisements in: public libraries; job centres; University of 
Cambridge buildings, predominantly the Department of Psychiatry, 
Department of Experimental Psychology and Addenbrooke’s Hospital. To 
attract a wider range of control participants, ‘Join Dementia Research’ (JDR) 
was also used. JDR has a database of individuals who are interested in taking 
part in research. A JDR administrator contacted individuals, by email, who 
lived within a 50-mile radius of Cambridge and matched the inclusion criteria 
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for the study. People who were potentially interested in participating made 
contact with the researcher by phone or email, using the contact details on the 
advertisement, to express an interest in taking part.  
 
2.5.2 Approach  	
Potential participants with DS who agreed, or whose carers and consultees 
agreed, to be contacted by the research team were sent an information pack 
about the study which included: a covering letter that introduced the study, 
information sheets for the participant and carer, and a reply slip.  
 
Potential participants for the age-matched, typically developing control group 
contacted the research team directly to discuss the study. The potential 
participants were then presented with an information sheet, which explained 
the study in more detail and were encouraged to ask the researcher 
questions.  
 
2.5.3 Recruitment and informed consent  
 
Adults with DS are a potentially vulnerable group, especially when any 
intellectual disability is compounded by a dementia diagnosis. Consequently 
the informed consent process and capacity to consent concerns were 
thoroughly and carefully addressed. The informed consent process was 
delivered in line with the provisions of the Mental Capacity Act 2005 where 
participants demonstrated understanding, retaining, weighing and 
communicating their decision to take part in the study. The informed consent 
process for the study is fully described in the following paragraph.  
 
Potential participants with DS who agreed to receive information about the 
study found enclosed within that information pack a reply slip. The potential 
participant, or their carer, to indicate their interest in participating and to 
provide the name and telephone number of the ‘person that knows them best’, 
filled out the reply slip. The research team then called the ‘person that knows 
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them best’ to organise when a researcher could visit them at their home, or 
another convenient location. During this visit the researcher further discussed 
the study with the potential participant and the ‘person that knows them best’. 
The researcher explained the study using materials that were composed of 
pictures, made in Widgit, and simple language to maximise understanding 
and thus capacity to consent to the study. Participants were asked questions 
about the study information to assure the researcher of their understanding.  
Previous experience from research at CIDDRG has suggested that many 
people with DS have the capacity to consent to participating in studies, 
provided that the study information is made accessible. However, provision 
was made for those potential participants who lacked the capacity to consent 
to participating in the study. In such cases a person able to act on behalf of 
the potential participant, most likely the ‘person that knows them best’ with 
whom we would have already been liaising, was approached as their personal 
or nominated consultee. The consultee was asked to form an opinion as to 
whether or not the potential participant would have objected to participating in 
the study. The assent of the participant was always required. So if at any point 
the participant indicated, either verbally or with aversive body language that 
they wished to be withdrawn from the study then they were. The process was 
repeated for the longitudinal phase. Only one participant was recruited 
through the consultee process. 
 
The potential age- and gender-matched typically developing controls used the 
research team’s contact details listed on the advertisement to express an 
interest in participating. The potential participants were then provided with 
more information about the study and the opportunity to discuss the study with 
a researcher. These measures were considered adequate for the controls to 
give informed consent.  
 
All of the information materials and consent forms can be viewed in the 
appendices B-P.  
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2.5.4 Inclusion and exclusion criteria  	
Inclusion Criteria  
• At least 20 years of age  
• Clinically diagnosed Down's Syndrome (for the DS group) 
• Typically developing and age-and gender-matched to the Down's 
Syndrome group (for the controls) 
Exclusion Criteria  
• Unable to indicate hearing tones delivered at 1000Hz and 3000Hz at 
55dB by the Siemens HearCheck Screener, which is a portable system 
• Have active, or history of, schizophrenia themselves or in first-degree 
relatives  
• Evidence on cognitive screening of mild cognitive impairment (MCI) or 
dementia (for the controls) 
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2.5.5  Sample size calculation  	
To our knowledge, having explored the relevant literature, there is no clear 
consensus about the minimal clinically relevant effect size for such a study. 
However, we have found five similar studies (all the studies compare 
participants with DS to typically developing (TD) controls; 4 studies use age 
matching; 1 study uses age- and gender-matching) – details are shown in 
table 2.1, which focused on the P3b latency measure to compare people with 
DS to typically developing populations. These studies were selected based on 
how they: 1. Compare P3b latency between participants with DS and TD 
controls, and 2. Made the means and standard deviations of the P3b 
latencies, for both groups (DS, TD), available.  The P3b measure has been 
selected as it has been most extensively studied in the AD and DS 
populations. From these five studies we found that the mean difference in P3b 
latency between groups across studies was 72ms and that the pooled 
standard deviation was 45ms, giving an “average” effect size of 1.6. The 
project also aims to investigate early markers of AD so we have considered 
previous studies that used the P3b latency measure to compare people with 
AD to typically developing populations. A recent meta-analysis of 40 studies 
which used the P3b latency measure to compare these groups found an 
average effect size of 1 (Howe, Bani-Fatemi, & De Luca, 2014, pg. 68, fig. 1). 
Powering a two-tailed t-test to detect a difference in means with the more 
conservative effect size of 1, a power of 95% and a significance level of 5% 
gave a sample size of 27 in each group (a total sample of n = 54). Therefore, 
assuming that a third of people are unlikely to tolerate the EEG procedure and 
produce usable data (Seidl et al., 1997), we aimed to recruit 36 people in 
each group (a total sample size of n = 72). To maintain an even age 
distribution, we ended up recruiting 43 people with DS and 39 age- and 
gender- matched controls, but only 36 of the participants with DS completed 
all of the electrophysiological measures.  
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2.5.6   
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2.5.6  Sample composition  	
Completed all electrophysiological assessments at the cross-sectional phase:  
36 x people with DS aged 20+ years (3 with DS-AD) 
39 x age- and gender-matched typically developing (TD) controls  
 
Completed repeat neuropsychological assessments at the longitudinal phase: 
35 x people with DS  
 
For the three participants with DS who also had a dementia diagnosis, the 
choice was made to retain them within the DS-group analyses. This decision 
was primarily made because AD pathology is an inevitable part of adult aging 
in DS (Mann, 2006). Therefore, adults with DS can be considered as at 
various stages of this pathological development. However, this PhD cannot 
meaningfully partition these stages of pathological development, and 
therefore the group cannot be meaningfully partitioned. Of course, a binary 
clinical judgement (AD, no AD) was made about the adults with DS. However, 
this binary judgement does not acknowledge those individuals who may be 
impaired by AD pathology but do not meet criteria for an AD diagnosis. 
Nevertheless, where appropriate, the contributions from the adults with DS 
who met clinical criteria for an AD diagnosis were highlighted on the graphical 
displays.  
 
The between-groups (DS, TD) age- and gender-matching can be found in 
appendix Q.  	
2.6 Measures used with both age- and gender- matched control 
participants and participants with Down’s Syndrome 
2.6.1 Hearing  	
As the EEG paradigms involved the presentation of auditory stimuli hearing 
loss was screened for with the Siemens HearCheck Navigator, which has 
been validated as an appropriate tool (Fellizar-Lopez et al., 2011). The 
Siemens HearCheck Navigator sequentially delivers tones at two frequencies 
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(1000Hz, 3000Hz) and a range of decibels (20dB – 75dB). Participants who 
do not indicate hearing tones delivered at 1000Hz and 3000Hz at 55dB were 
excluded from the study and advised to seek a formal hearing test from their 
GP. This situation did not arise in the study.  
 
2.6.2 Handedness 	
The Edinburgh Handedness Inventory (Oldfield, 1971) was used to assess 
participants’ handedness. 
 
2.6.3 Intelligence Quotient 	
The Kaufman Brief Intelligence Test, second ed. (KBIT; Kaufman & Kaufman, 
2004) was used to approximate participants’ (DS and controls) Intelligence 
Quotient (IQ). The KBIT II assesses verbal IQ with tests of verbal knowledge, 
and performance on riddles. The KBIT II assesses nonverbal IQ with 
performance on matrices. The combined performance forms an IQ composite, 
which is standardised by chronological age. KBIT II is used across all the 
studies in the Defeat Dementia in Down’s Syndrome research stream.   
 
2.7 Measures used with control participants only  
2.7.1  Dementia screening 	
The age- and gender-matched typically developing controls were screened for 
dementia with the Addenbrooke’s Cognitive Examination Revised (ACE-R; 
Mioshi, Dawson, Mitchell, Arnold, & Hodges, 2006), and excluded from the 
study at the lower cut-off of 88. The ACE-R assessment and cut-off were 
employed to be able to exclude potential control participants with evidence of 
mild cognitive impairment (MCI) or dementia. The ACE-R was developed from 
the mini-mental state examination, and assesses subdomains which can be 
impaired in MCI and dementia: orientation, attention, memory, verbal fluency, 
language and visuo-spatial. No control participants were excluded from this 
study based on their ACE-R assessment. The ACE-R can be found in 
appendix R.  
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2.8 Measures used with participants with Down’s Syndrome only  
2.8.1 Blood tests 	
Blood samples were taken by a healthcare professional trained in phlebotomy 
at the Herchel Smith Building, Cambridge. Quantitative Fluorescent 
Polymerase Chain Reaction (QFPCR) analyses were performed on the 
extracted DNA to genetically confirm trisomy 21. The blood samples were 
also analysed to confirm APOE status. The blood samples were further 
analysed to identify pathology that could contribute to cognitive decline and 
behaviour change. The factors that may have potentially given a dementia 
presentation in the absence of AD: calcium deficiency, reduced liver function, 
reduced kidney function, hypo/hyperthyroidism and vitamin B12 deficiency. A 
full blood count and creatinine levels were also taken. However, venepuncture 
was very difficult with many of the participants with DS, so only 15 participants 
had their blood taken for karyotyping and APOE status analysis. Due to the 
small number of samples, blood results were not made use of in this study. To 
adhere with ethical protocols, any abnormal blood results were reported to the 
participants’ GP.  
 
2.8.2  Neuropsychological assessments 
  
The study followed the neuropsychological testing schedule set out in the 
amyloid imaging study (11/EE/0348), in the interests of consistency and 
comparability between the projects. The tests were developed, or adapted, to 
be appropriate for people with intellectual disabilities and cognitive decline 
associated with dementia. The full battery of neuropsychological tests is as 
follows:  
 
• The Cambridge Examination for Mental Disorders of Older People with 
Down's Syndrome and Others with Intellectual Disabilities: CAMDEX-
DS (Ball et al., 2006; Roth, Tym, & Mountjoy, 1986), which includes an 
informant interview  and cognitive assessment (CAMCOG-DS).  
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• The Executive Function test battery for people with DS (EFDS) (Ball et 
al., 2008).  
• The Arizona cognitive test battery (Edgin et al., 2010).  
• The Severe Impairment Battery (SIB) (Saxton, McGonigle, & Swihart, 
1993).  
Only tests directly relevant to the aims and hypotheses of this thesis, focusing 
on cognitive decline and executive dysfunction, were analysed and are 
described in greater detail below. The relevant measures are: the CAMDEX-
DS, including CAMCOG-DS, and the battery of EFDS tests, which can be 
found in appendices S-V.  
 
2.8.3  The CAMDEX-DS– (Ball et al., 2006) 
 
The CAMDEX-DS (Ball et al., 2006) was developed to be informative about 
the development of dementia in people with intellectual disability. The tool 
includes a cognitive assessment component (CAMCOG-DS) and an informant 
interview (CAMDEX-DS).  
 
The CAMCOG-DS assesses participants on seven functional domains 
affected by the presence of AD: orientation, language, memory, attention, 
praxis, abstraction, and perception. The total available score from subscales 
is 109. The assessment is designed to avoid floor effects, and is based on 
well-established dementia assessments for the general population (Mini-
mental status examination) and people with severe ID (SIB).  
 
The CAMDEX – DS informant interview (Ball et al., 2006; Roth, Tym, & 
Mountjoy, 1986) was used to indicate cognitive decline and diagnose 
dementia in DS. A dementia diagnosis from the CAMDEX – DS is a clinical 
decision based on parent or carer reports of the participant’s: best level of 
functioning, cognitive and functional decline mental, and physical health (Ball 
et al., 2006). The interviewee is selected on the basis of having had regular 
contact with the participant for at least 6 months prior to the assessment. In 
this study the dementia diagnosis of a participant with DS was made by an 
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experienced psychiatrist reviewing, blind to the age, gender and previous 
diagnostic status of the participant, the researcher’s CAMDEX – DS informant 
interview with the parent or carer. Three participants were diagnosed as 
having dementia at the cross-sectional phase with this method. No 
participants transitioned to a dementia diagnosis, as assessed with the 
CAMDEX – DS, at the longitudinal phase.  
 
2.8.4  The Executive Function test battery for people with DS – (Ball et 
al., 2008) 
 
The Executive Function test battery drew from previous tests of executive 
function originally developed for the general population. The tests were further 
developed or adapted by Ball et al., (2008), to be appropriate for people with 
intellectual disabilities. The total EFDS score is 51. The subtests that make up 
this score are described below.  
 
The cats and dogs task 
The cats and dogs task is a simplified version of the day-night stroop task 
(Gerstadt, Hong, & Diamond, 1994). The task primarily tests response 
inhibition. In the task, participants are first instructed to sequentially identify 
the cats and dogs along a strip of paper. Then the rule changes, so every time 
the participant sees a cat they should say “dog”, and every time they see a 
dog they should say “cat”. Participants are timed in the task. The maximum 
score is 16, from which the number of errors made is subtracted to give the 
participants’ personal score.  
 
The Tower of London task 
The Tower of London Task was standardised by Krikorian, Bartok, & Gay, 
(1994), as an informative test of planning and working memory. As part of the 
EFDS battery development, the task demands were reduced from twelve to 
four puzzles (Ball et al., 2008). In the task, both the researcher and the 
participant have a block. On each block are three pegs, of reducing length, 
and three beads (red, blue and green). The participant is tasked with moving 
one bead at a time so their block looks like the researcher’s. The participant 
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must do this within a set number of moves (two, three, four or five), which 
correspond to difficulty levels. The participant is given two practice 
opportunities at the beginning of the session after which scoring begins. 
Participants have a maximum of three attempts at each level. Full marks 
(three points) are awarded for participants who complete the level on the first 
attempt, two points for completion on the second attempt, and one point for 
completion on the third attempt. If the participant fails on the third attempt and 
does not receive points for the level then the task ended. The maximum score 
on the task is 12 points.  
 
The Weigl Sorting task  
The task was developed by Weigl, (1941), then further developed by Strauss 
and Lewin (1982), to assess extra dimensional set shifting. For the EFDS 
battery, Ball et al. (2008) adopted a positive scoring system. The researcher 
begins by placing the cards on the table and asking the participant to sort 
them so “the ones that belong together are in a pile together”. The participant 
should then sort the cards into piles of shared colour or shape. If the 
participant fails the initial sort then a score of 0 is given for the task. For 
participants who achieve the initial sort, the researcher asks them to sort the 
cards so “they belong together in a different way”. If the participant achieves 
the spontaneous set shift at this level then they are awarded five points. The 
more instructions a participant needs to achieve the spontaneous set shift, the 
fewer points they receive. If the researcher has to explicitly tell the participant 
to re-sort the cards by colour/shape (as appropriate), then the minimum of 
one point is awarded.  
 
The spatial reversal task  
This task was originally developed by McEvoy, Rogers, & Pennington (1993) 
to assess set shifting within the spatial domain. The task also assesses 
response inhibition. The task is premised on the participant finding the coin 
from a forced choice of two boxes. The participant can only lift one box on 
each trial to find the coin. The coin remains under one box until the participant 
has found it there, four consecutive times. At this point the coin moves under 
the other box, and the participant must learn the new rule. The task is made 
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difficult by placing a screen between the participant and the boxes. The 
screen is put up between each trial and the researcher pretends to move the 
boxes around, behind the screen. If this set shift stage is not attempted or if 
the participant fails to learn the first rule after ten attempts, then no points are 
awarded. The maximum score is seven points, accrued at the set shift phase.  
 
The scrambled boxes task  
The testing procedure was from Griffith, Pennington, Wehner, & Rogers, 
(1999), and slightly modified by Ball et al., (2008) to be a test of working 
memory and response inhibition for the EFDS battery. The task requires 
participants to find three coins, from three separate boxes, labelled with 
different shapes. The participant watches the researcher hide the coins in the 
boxes. The participant then points to a box where they think a coin is. The 
researcher then opens the selected box to tip out a coin or indicate that it is 
empty. The researcher then replaces the lid of the box and the search for 
coins continues. In the first round the three boxes are stationary between 
searches. In the second round the three boxes are scrambled between 
searches. If the participant passes the three-box scrambled condition then the 
test moves to a six-box stationary condition. Again the participant watches the 
researcher put coins in three of the six boxes. If this stage is passed then 
participants move to the final rotation, whereby the boxes are scrambled 
between searches. Only the scrambled conditions are scored. Participants 
can receive a maximum of four points for the three-box scrambled condition, 
and seven points for the six-box scrambled condition. Whenever the 
participant searches in a box where there is no coin, one point is subtracted 
from their total score.  
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2.9 Testing schedule  	
2.9.1 Testing schedule table  	
The testing schedules, order and timings, for the participant groups (DS, TD) 
are shown in table 2.2. 
 
Task category  Task  Participant group  Total 
time 
required 
(minutes) 
DS TD 
Day 1. Home (or other convenient location for participant) visit by researcher 
Pre-engagement 
checks:  
 
Seeking consent ü ü 15 
Siemens HearCheck Screener ü ü 5 
Measure head circumference with 
tape measure to determine EEG 
cap size needed 
ü ü 1 
Edinburgh Handedness Inventory  ü ü 5 
Cognitive measures:  
 
Note. some measures 
may be administered 
over two home visits or 
during the Cambridge 
visit  instead to lessen 
demands on participants  
CAMCOG-DS  ü û 30 
KBIT II ü ü 20 
SIB  ü û 15 
EFDS ü û 30 
Oliver Object Memory Test and 
Test for Sentences 
ü û 5 
Selected tests from ACTB 
(including CANTAB) 
ü û 60 
ACE-R û ü 15 
Total testing time per group for day 1 (minutes) :  186 61  
 
Day 2: Cambridge visit by participant to the EEG Lab, Herchel Smith Building  
Diagnostic measure: Venepuncture for a 10ml blood 
sample, taken by a research nurse, 
for subsequent genetic testing to 
confirm DS diagnosis  
ü û 10 
Electrophysiological 
measures: 
 
Fit the EGI’s HydroCel Geodesic 
Sensor Net 130 (EEG cap)  
ü ü 5 
Gently push aside the hair under 
each electrode and deposit a small 
amount of gel, with a plastic 
syringe 
ü ü 30 
Press and click a digi-pen on each 
electrode so their positions are 
digitised onto the Brainstorm 
computer programme  
ü ü 10 
Record resting state EEG data 
onto the NetStation computer 
programme (5 minutes eyes open, 
5 minutes eyes closed) 
ü ü 10 
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Table 2.2. A schematic of the testing procedure for each group. DS = Down’s 
Syndrome, TD = age- and gender- matched typically developing controls. 
Please note that multiple breaks were taken, as appropriate for each 
participant’s fatigue level, which altered the final testing time.     
 
2.9.2 The cross-sectional testing schedule  	
For participants with DS:  
• 2-3 home visits, made by the researcher: 2-3 hours each of 
neuropsychological testing, including breaks. The first session also 
included the consent procedure. The parent or carer also had a 30 
minutes – 1 hour informant interview on one of these visits, or by 
telephone.  
• 1 Cambridge visit, made by the participant and the parent or carer: 2.5 
hours average of electrophysiological testing, including breaks.  
For age- and gender-matched controls:  
• 1 Cambridge visit, made by the participant: 3 hours of testing which 
included the consent procedure, neuropsychological and 
electrophysiological testing.  
Use MATLAB to play tones, paired-
clicks, and record onto NetStation 
time-locked responses: P50 
suppression 
ü ü 20 
Use MATLAB to play tones, within 
the global-local paradigm, and 
record onto NetStation time-locked 
responses: MMN, P300 (P3a, P3b)  
ü ü 40 
Total testing time per group for day 2 (minutes) : 125 115  
 
Day 3: Repeat home (or other convenient location for participant) visit by researcher.  
This visit is conducted approximately 12 months later than “Day 1”  
Pre-engagement  
checks : 
Seeking consent  ü û 15 
Cognitive measures:  CAMCOG -DS ü û 30 
Total testing time per group for day 3 (minutes)  45 0  
    
Total testing time per group for the study (minutes) 
(day 1 + day 2 + day 3):  
356 176  
	 78 
2.9.3 The longitudinal testing schedule 		
For participants with DS:  
• 1 home visit, made by the researcher: 45 minutes of consent procedure 
and neuropsychological testing with the participant, and 30 minutes – 1 
hour of informant interview with the parent, or carer.  
2.10  Map of home visits 
 
All of the locations that the researcher visited for the cross-sectional and 
longitudinal home visits are shown in figure 2.2.  
 
 
Figure 2.2. Map of home visits made by the researcher.  
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2.11 Home visit safety 	
A thorough risk assessment was conducted to assess any safety risks for 
visiting participants with DS. Researchers adhered to the ‘buddy system’, 
whereby a colleague was aware of the visit location and the researcher 
contacted them when they arrived and left. The participants were always 
visited with ‘the person who knows them best’, and in their home environment 
so they were as comfortable and relaxed as possible.  
 
The next section is concerned with electroencephalography (EEG), more 
specifically the global-local paradigm, which gleans the event related 
potentials (ERPs): mismatch negativity (MMN), P300 (P3a and P3b).    
 
2.12  Electroencephalography  	
An electroencephalogram (EEG) is a recording of bio-electrical activity 
generated by cortical neurons. The raw recording is a coarse measure of 
neural activity (Luck, 2005). Event-related potentials (ERPs) are extracted 
from EEG recordings as averaged, time-locked, specific neural responses to 
specific stimuli (Luck, 2005).  ERPs are characterised by latency and 
amplitude features. The latencies of ERPs index the time taken to process 
stimuli whereas their amplitudes reflect cognitive resource allocation for 
stimuli processing (Duncan et al., 2009). 		
The neural origins of EEG signals begin with action potentials. Action 
potentials are the travel of discrete voltage from the soma (cell body) to the 
pre-synaptic terminals of the axon, stimulating the release of 
neurotransmitters into the synaptic cleft (Luck, 2005). The released 
neurotransmitters then bind to receptors on the post-synaptic terminal, which 
stimulates the ion channels to open or close, resulting in a graded change in 
post-synaptic potential (Luck, 2005). Excitatory postsynaptic potentials (PSP) 
promote the transportation of positively charged ions (Na+) into the cell, 
typically at the apical dendrites site, a ‘sink’ (Lopes da Silva, 2004). Inhibitory 
PSPs promote the transportation of negatively charged ions (Cl-) into the cell, 
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typically at the soma, a ‘source’ (Lopes da Silva, 2004). This generates a 
potential difference, or ‘dipole’, between the apical dendrites and soma. The 
currents flow, intracellularly, from the apical dendrites to the soma. The 
extracellular volume currents complete the loop. The loop results in the 
characteristic ‘rise and fall’ fluctuations see on EEG recordings. The figure 
below (figure 2.3) from Lopes da Silva (2004) visualises the neural origins of 
EEG recordings. 
 
 
 
 
Figure 2.3. from Lopes da Silva (2004) which visualises the neural origins of 
EEG.  
 
Only the summation of at least 50000 PSPs is detectable by electrodes at the 
scalp, and therefore recordable as EEG. In order for the dipoles of PSPs to 
summate, rather than cancel one another, they must not only be proximal but 
share orientation and stimulation (excitatory/inhibitory) (Luck, 2005). The 
recordings are typically made from pyramidal cells because of their 
perpendicular alignment (Luck, 2005). However, waveform polarity (positive or 
negative) is determined by the location and orientation of the cortical, synaptic 
activity (Burgess & Collura, 1993). A visualisation of polarity can be found in 
figure 2.4.  
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Figure 2.4. A visualisation of EEG polarity from Burgess and Collura (1993).  
 
Synchronous firing as a time-locked, processing response to specific stimuli is 
termed event related potentials (ERPs) (Peterson, Schroeder, & Arezzo, 
1995). ERPs are extracted as averaged waveforms from EEG recordings 
(Luck, 2005). ERPs have two categories: 1. Exogenous: an early (within 100 
ms) sensory response that is driven by the properties of the stimulus, and 2. 
Endogenous: a later (post 100 ms) cognitive response of evaluating and 
processing the stimulus (Sur & Sinha, 2009). The present study is focused on 
endogenous components: mismatch negativity (MMN) and P300 (P3a, P3b).  
 
MMN is a negative waveform generated from the difference in response to 
standard and ‘mismatched’ tones, in the absence of conscious attention 
(Hinkley et al., 2010).  MMN reflects automatic sensory memory processes 
involved in pre-attentive cognition. A visualisation of how MMN is generated is 
shown in figure 2.5.  
 
P300 is a positive waveform of two components: P3a and P3b. P3a is the 
earlier component, known as the ‘novelty response’ to a distracting, rare 
stimulus (Friedman et al., 2001). Whereas P3b is the later component that 
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requires active, attentive processing to target stimuli (Polich, 2007). A 
visualisation of the two components is available in figure 2.6.  
 
 
Figure 2.5. The generation of an MMN waveform, adapted from Hinkley et al. 
(2010).  
 
 
 
 
 
 
 
 
Figure 2.6. P3a and P3b waveforms, adapted from Polich (2007).  
 
EEG records bio-electrical activity generated at the cellular level, essentially, 
instantaneously at the scalp (Luck, 2005). The technique has exquisite 
temporal accuracy, however the source of the signal is smeared as it spreads 
through the conductive medium of the scalp, limiting spatial resolution. MEG 
records the magnetic fields generated from the electrical currents and 
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provides improved spatial resolution but at the cost of only being able to 
record radial dipoles, whereas EEG can record from both tangential and radial 
dipoles.  
 
2.13 Global Field Power  	
The EEG analyses in this thesis are predominantly focused on Global Field 
Power (GFP). Lehman and Skrandies first described the GFP computation in 
1980, as a spatial standard deviation. The premise of GFP is that more field 
lines indicate that more synchronous neuronal activation is being recorded, 
and therefore more information is gained (Skrandies, 1990). GFP computes 
field activity, at each time point and electrode, as a mean of all the absolute 
potential differences (Lehmann & Skrandies, 1980). The result corresponds to 
the spatial standard deviation (Lehmann & Skrandies, 1980). GFP is plotted 
as a function of time, and the time at which the GFP reaches it’s maximum 
(largest deviation), can indicate the latencies of ERPs (Skrandies, 1990). The 
advantages of GFP include that as a reference- and polarity-independent 
technique, electrophysiological data from all the recording electrodes are 
evaluated to determine the power of deviations (i.e. ERPs), within a given 
time frame (Lehmann & Skrandies, 1980). The results are also less 
ambiguous than typical waveshape analyses (Skrandies, 1990).   
 
2.14 Electroencephalographic assessments   	
All electrophysiological assessments were conducted in the EEG Lab at the 
Herchel Smith Building, Cambridge. A high-density array EEG net of 129-
channels (HydroCel Geodesic Sensor Net by Electrical Geodesics Inc., 
Eugene, Oregon) was used. To ensure good conductance of the electrodes, 
the hair directly underneath the electrodes was gently pushed aside and a 
small amount of conducting gel (Spectra 360) deposited on the exposed 
scalp, with a plastic syringe. Then, the location of each electrode on the scalp 
was digitsed onto the Brainstorm computer programme by sequentially 
clicking a digi-pen to each electrode. Participants were then seated in an 
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electronically shielded room and the EEG net they were wearing plugged into 
the Net Amps 300 amplifier (Electrical Geodesics Inc.) so continuous EEG 
data could be collected and recorded onto the NetStation software package. 
The researcher watched participants during testing via a live video feed. The 
recording parameters were: <100KOhms impedance, 1000Hz sampling rate 
for resting-state EEG collection, 500 Hz sampling rate for ERP collection, and 
referenced to the vertex. The electrophysiological data was recorded for 
resting-state EEG. A paired clicks paradigm was also used to generate a P50 
suppression effect. Finally, the ‘global-local’ task, which is an auditory oddball 
paradigm, was used to generate MMN, P3a and P3b. The resting-state EEG 
data was ten minutes of EEG recording, five minutes eyes open with a fixation 
cross and five minutes eyes closed, from participants sitting, relaxed and 
comfortable, in a dimly-lit room. The ERPs (P50 suppression, MMN, P3a, 
P3b) were elicited by auditory stimuli (tones). The auditory stimuli were 
presented to participants: using Psychtoolbox version 3 (Brainard, 1997) 
running in MATLAB; at a comfortable volume as judged by participants; 
binaurally; through Etymotics ER-3A earphones. During the P50 suppression 
task participants watched, without sound, the first 20 minutes of the season 1, 
‘Spring’ episode of ‘Frozen Planet’. The focus of this thesis is on the ‘global-
local’, auditory oddball paradigm which elicited: MMN, P3a and P3b ERPs.  
 
The global-local paradigm was selected because the multi-level design 
generates three ERPs (MMN, P3a, P3b) within a predictive coding framework, 
which makes an interesting addition to the analyses and conclusions. 
Furthermore, MMN and P3b have been tested in separate AD, DS and aging 
populations previously. These factors will be explored together in the present 
study. MMN has been most successfully linked with frontotemporal dementia 
(Hughes & Rowe, 2013), which is of interest in the present study as frontal-
type symptoms are some of the earliest indicators of AD in DS. P3b is the 
most studied ERP in the AD literature but, to our knowledge, P3a has been 
little studied, which adds an exploratory component to the study.  
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2.15 Global local paradigm  	
The global-local paradigm was originally developed by Bekinschtein et al., 
(2009) to clearly delineate MMN, P300 components within one odd-ball 
paradigm. The paradigm has two levels of deviation: 1. Global – between trial 
variance: when a different group of sounds elicit a P3b component, when 
explicit attention is paid to the difference; 2. Local – within trial variance: when 
different individual sounds elicit MMN and P3a components. The local effect is 
present in the absence of explicit attention. 
 
At the beginning of testing, for the present study, participants were informed 
that they were about to hear groups of sounds. Participants were asked to 
listen carefully to the groups of sounds because at the end of each block they 
would be asked:  “can you tell me what group of sounds you heard a lot?” and 
“can you tell me what group of sounds you heard sometimes?”. Participants’ 
answers were recorded at the end of each block. The purpose of the 
questioning was to maintain participants’ attention on the groups of sounds 
(global effect). At the end of each block, participants were also asked about 
their arousal levels on a scale of 1-10 (1 – Asleep to 10 – Fully awake), and 
attentiveness (1 – Mind wandering/unattentive to 10 – Fully attentive to 
stimuli).  Participants took a break between each block at a length of their 
choosing. A total of 8 experimental blocks were presented, with total testing 
time, including breaks and questioning, taking an average of 40 minutes.  
 
Each participant was played tones at a volume that they indicated as audible 
and comfortable. The tones were mixtures of three sinusoids of either type: A 
(500, 1000, and 2000 Hz), or B (350, 700, and 1400 Hz). These mixtures are 
identical to those used in the original development (Bekinschtein et al., 2009). 
Each tone lasted 50ms and was presented in a five-tone group, with 100ms 
intervals. The tone sequences consisted of either five identical tones (AAAAA 
or BBBBB), or four identical tones then a different tone (AAAAB or BBBBA). 
The tone sequences were presented either entirely monaurally, to the left or 
right ear, or predominantly monoaurally with an interaural, opposite ear, final 
tone.  
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The grouping of the tones into sequences determined their status as: local 
standards, local deviants, global standards, global deviants or interaural 
deviants. The ‘local’ sequences focus on the individual tones. The ‘local 
standard’ is when the five tones in the sequence are identical (AAAAA or 
BBBBB). The ‘local deviant’ is when the fifth tone in the sequence differs in 
type (AAAAB or BBBBA), and/or laterality, ‘interaural deviant’ (AAAAA, 
BBBBB, AAAAB, and BBBBA). The ‘global’ sequences are concerned with 
comparing tones at a group (sequence) level. The ‘global standard’ is the 
repetitive five-tone sequence; the ‘standard’ is tied to the repetition with the 
block rather than the tone type (A or B). The ‘global standard’ is presented 
100 times within a block, making up approximately 71.5% of the testing 
presentations. The ‘global deviant’ is the five-tone sequence, which differs 
from the ‘standard’ in the block. The ‘global deviant’ sequence is 
psedorandomly presented between 19 and 21 times in a block (14.25% of 
presentations) in a monoaural form, and a further 19-21 times (14.25%), in an 
interaural form. The pseudorandomisaton procedure consisted of deviant 
sequences being interspersed with two to five standard sequences, and two 
to three standards preceding the next 80% of deviants. The full list of global 
deviants and global standards is listed in table 2.3, and a schematic of 
presentations is available in figure 2.7.  
 
There were eight experimental blocks, each containing approximately 160 
sequences (groups of sounds). Each block was counterbalanced by the 
dominant tone type (A or B) and laterality of monoaural tone delivery (left or 
right). The ‘global standard’ was established at the beginning of the testing 
phase with 3s of silence followed by 20 presentations of the monoaural 
sequence. The testing phase of the block contained 138-142 sequences. The 
sequences were separated by randomly sampled periods of silence, which 
last between 700ms and 1000ms. The eight experimental blocks were 
structured into ‘X’ and ‘Y’ types, as in table 2.3, allowing for across-block 
orthogonal contrasts. For example, a global standard monoaural sequence of 
AAAAA, in block X, would also be a local standard. Conversely, against a 
global standard monoaural sequence of AAAAB, the AAAAA sequence could 
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be considered a global deviant. Due to the predominance of monoaural 
delivery, lateral, interaural tone delivery was always locally and globally 
deviant. The analyses were focused on contrasts, which included an inter-
aural deviant. The block presentation is also pseudorandomised so that the 
initial presentation is always an X block, and only two blocks of the same type 
(X or Y) can be presented consecutively. The block design is laid out more 
clearly in table 2.3.  
 
  
Laterality Tone type Block type Global 
standard 
Global 
deviant 
Interaural 
deviant 
Left A X AAAAA AAAAB AAAAA 
Left B X BBBBB BBBBA BBBBB 
Left A Y AAAAB AAAAA AAAAB 
Left B Y BBBBA BBBBB BBBBA 
Right A X AAAAA AAAAB AAAAA 
Right B X BBBBB BBBBA BBBBB 
Right A Y AAAAB AAAAA AAAAB 
Right B Y BBBBA BBBBB BBBBA 
  
Table 2.3. The eight experimental blocks presented as auditory stimuli in the 
global-local paradigm. The blocks are counterbalanced for: laterality, tone 
type, and deviance. The italicised letter indicates the interaural deviant.  
The table is adapted from (Chennu, Noreika, et al., 2013).  
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Figure 2.7. A schematic of the experimental design, adapted from Chennu, 
Noreika et al., (2013). One sequence is composed of five tones, visualised as 
notes in the schematic. The black notes in a sequence are the same A or B 
tone; the red notes are the comparatively different A or B tone. For the X 
blocks, the standard sequences were monoaural repetitions of the same tone 
type, with deviation in tone type (A or B) or laterality (left or right). Conversely, 
for Y blocks, the fifth tone of the standard sequences differed in type. This 
differing context (X or Y blocks) allows the same stimuli sequence to elicit a 
different ERP (MMN, P3a, P3b).  
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2.16 Pre-processing  	
The sequence below is of the custom MATLAB scripts, with Statistical 
Parametric Mapping (SPM) utility, used to pre-process the raw EEG data 
gathered with the global-local paradigm. The pre-processing pipeline was 
originally developed by Dr Tristan Bekinschtein and Dr Srivas Chennu, and 
then adapted for the present study by Dr Srivas Chennu. Miss Sally Jennings 
conducted the pre- and post-processing analyses. The purpose of each step 
is described.  
 
During pre-processing, the researcher was blinded to the participant’s identify 
but not group (DS, controls). 
 
Step 1. Data import – the data is imported and converted to a MATLAB-SPM 
appropriate file type so analyses can continue. During this step the data are 
also down-sampled from 500Hz to 250Hz, to make the files a more 
manageable size. The channel locations and head shape from GSN-
HydroCel-128 is also loaded. A low pass filter of 25Hz and high pass filter of 
0.5Hz is also applied. This version of the file is then saved, with an 
appropriate ending to be picked up by the next script. This saving method is 
true of each preprocessing step.  
 
Step 2. Delete channels – channels on the neck, cheeks and forehead, which 
by virtue of their location would hold more noise than signal, were removed 
from further analyses to remove unnecessary noise from the data. The 
channels excluded were:  
 
1,8,14,17,21,25,32,38,43,44,48,49,56,57,63,64,68,69,73,74,81,82,88,89,94,9
5,99,100,107,113,114,119,120,121,125,126,127, and 128.  
 
The following analyses were restricted to the remaining 90 channels. A 
visualization of the channels can be found in figure 2.8.  
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Figure 2.8. The HydroCel Geodesic Sensor Net 128 channel map, taken from 
the Electrical Geodesic manual.  
 
Step 3. Epoch data – the data was sectioned within windows -200 to 700ms, 
relative to the fith tone, to create epochs of interest. The ERPs were 
calculated  50-650ms post stimulus. Epochs were baseline corrected between 
-200 – 0ms preceding the onset of the fith tone. 
 
Step 4. Mark bad trials and channels – bad trials and channels were visually 
identified and marked. The channel variance threshold (T1) was set at 40000; 
The trial variance threshold (T2) was set at 2000. The purpose was to remove 
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only the worst trials as the rest could predominantly be corrected for with 
Independent Component Analysis (ICA). Please find an example of the 
thresholds below, in figure 2.9.  
 
Figure 2.9. The blue dashed line indicates the threshold. Channels and trials 
whose variance exceeds the threshold are marked for removal.  
 
Step 5. Reject artifacts - bad trials and channels, which were highlighted at 
the ‘mark bad’ stage were removed. Rejected channels were interpolated with 
spherical spline interpolation.  
 
Step 6. Compute ICA – the EEGLAB toolbox was employed to run 
Independent Component Analysis (ICA) on the data.  
 
Step 7. Mark ICA – used to bring scalp maps and time course plots of the ICA 
components. The technique was purposed to remove well-defined artifacts 
such as muscle movement, eye blinks and roving eye movements, without 
losing an epoch of data. Please find below, in figure 2.10, an example IC.  
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Figure 2.10. The figure shows a characteristic slow-eye blink IC for removal. 
The nature of the IC is revealed in the isolated ocular location of the activity, 
shown on the scalp map (top left).  
 
Step 8. Reject ICA – to reject independent components, which had been 
marked for removal at the ‘mark ICA’ stage  
 
Step 9. Mark bad trials and channels – to identify any remaining bad 
channels/trials after ICA.  T1 corresponds to channels and was set at 500; T2 
corresponds to trials variance and was set at 250. The same threshold system 
is used as before.  
 
Step 10. Reject artifacts - bad trials and channels that were highlighted at the 
‘mark bad’ stage were removed. Rejected channels were interpolated with 
spherical spline interpolation. 
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Step 11. Re-reference – the data was re-referenced to the mastoid sites 
(’E57’ ‘E100’).  
 
Step 12. Calculate ERPs – condition-wise ERPs were calculated. The 
conditions were: ld = local deviant, ls = local standard, gd = global deviant, gs 
= global standard, ad = inter-aural deviant. The condition list pairs for each 
ERP are set up as: MMN – (ld,ls), (ad,ls); P3a – (ad,ls), (ad,gs); P3b – 
(gd,gs), (ad,gs). 
 
Step 13. Grand average – average ERPs by participant and group (DS, 
controls).   
 
Step 14. Generate images – sensor/source images were generated for SPM 
applicable statistics, as SPM only works with images.  
 
Step 15. SPM batch – to build an SPM general linear model (GLM) on the 
sensor/source images. This was set up in terms of the contrast of interest. For 
example, to set up a between groups (DS, controls) comparison, as seen in 
Chapter 3, the following was used:  
spmbatch({'downs','controls'},'EEG') 
 
Step 16. Plot contrasts – used to plot the contrasts of interest: MMN – (ld,ls), 
(ad,ls); P3a – (ad,ls), (ad,gs); P3b – (gd,gs), (ad,gs).  
 
Step 17. Print cluster – used to load contrasts and identify clusters of interest, 
the script is detailed in the appendix W.  
 
 
Step 18. Plot cluster – used to image the spatio-temporal clusters of interest. 
An example of the controls group MMN is as follows: 
plotcluster('controls',{'ad','ls'},'mmn','EEG','statwin',[50 650],'dir','neg') 
 
The plot cluster function gives the output seen in figure 2.11.  
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Figure 2.11. Age- and gender-matched controls MMN. The black outline 
identifies the significant cluster. Blue indicates negative activity whereas red 
indicates positive. The white electrode is the electrode in which the difference 
between the deviant and standard is maximal, and is mapped out below the 
scalp map. The green line indicates the response to standard tones. The blue 
line indicates the response to deviant tones. The p value is the significance of 
the difference between the tones, and the time in ms indicates the time course 
being mapped out.  
  
 
Step 19. Plot ERPs – used to plot the ERPs. Masking is used: MMN: 100-200, 
earlier P300: 200-400, later P300: 400-650. This is a small volume correction 
which, using the 50-650 range, focuses in the analysis on the a-priori analysis 
windows of interest so they are not masked by the other ERPs and variance. 
The choice of time-windows is 1. Informed by the literature, and 2. Confirmed 
statistically with spatio-temporal cluster analyses, and visually at the ‘plot 
cluster’ stage. The literature justification for the time-windows is described in 
the chapter 3, section 3.3. The spatio-temporal cluster analyses are described 
Time (ms) 
A
m
pl
itu
de
 (µ
V
) 
	 95 
in chapter 3, section 3.5.2. The output from the ‘plot ERP’ stage is shown in 
figure 2.12. This technique is predominantly used in chapter 5.  
 
 
 
 
 
Figure 2.12. P3a for adults with DS who are higher scorers on the scrambled 
boxes task. Each line is the time course of a participant with DS. Red on the 
scalp map indicates positivity, the darker red the more positive the activity.  
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2.17 Post-processing 	
The pre-processing steps, and time-windows, are uniform across the 
chapters. The post-processing analyses, which are pertinent to each of the 
research questions and will be explained in the results chapters: 3, 4, 5 and 6.  
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3 Chapter 3. Exploring differences on selected EEG measures 
between adults with Down’s Syndrome and typically 
developing controls 
 
3.1 Aim  	
To use electroencephalographic measures (MMN, P3a, Pb) to compare adults 
with Down’s Syndrome and typically developing controls, within a predictive 
coding framework.  
 
3.2 Introduction 	
In this thesis, the Down’s syndrome (DS) group is matched in age and gender 
to the typically developing (TD) control group. Consequently, age is inherently 
controlled for in between-group comparisons. The purpose of the initial 
between-groups comparison was to: 1. Confirm the presence of the ERPs, 
and 2. Assess the baseline electroencephalographic (MMN, P3a, P3b) 
differences between the groups, prior to deeper investigations based on: age 
(chapter 4), executive dysfunction (chapter 5) and cognitive decline (chapter 
6). The electroencephalographic measures are elicited under a ‘global-local’ 
paradigm (Bekinschtein et al., 2009), which alters the context of simple tones 
to create a predictive hierarchy (Chennu, Noreika, et al., 2013). Consequently, 
the group comparisons can be considered within a predictive coding 
framework.  
 
Predictive coding uses a hierarchical framework to economically deliver a 
stable, internal representation of the external environment (Jack & Hacker, 
2014). The framework is economical and hierarchical in that top-down 
predictions constrain the processing of bottom-up sensory input, to the 
unexpected: ‘prediction errors’ (Friston, 2005). Within a predictive coding 
framework MMN and P300 (P3a and P3b) might be explained as prediction 
error signals (Friston, 2005; Garrido et al., 2007; Lieder et al., 2013; 
Wacongne et al., 2011; Wacongne, Changeux, & Dehaene, 2012). The 
global-local paradigm embeds auditory regularity at local (tone) and global 
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(tone sequence) levels, the violations of which are termed ‘prediction errors’ 
(Bekinschtein et al., 2009). Violations at the ‘local’ level are detected in the 
absence of attention. The low-level, prediction errors manifest as MMN and 
P3a waveforms (Bekinschtein et al., 2009). Prediction errors at the ‘local’ level 
feed-forward to a temporally-extended ‘global’ level for pattern extraction 
(tone sequences) (Chennu, Noreika, et al., 2013). Violations at the ‘global’ 
level are detected when attention is paid; the resulting signal is a P3b 
waveform (Bekinschtein et al., 2009).  
 
The literature comparing the electrophysiological measures of interest (MMN, 
P3a, P3b) between adults with DS and age- and gender- matched typically 
developing (TD) controls	is limited, and out-dated. Previous research has 
suggested that people with DS show comparatively decreased amplitudes of 
the potentials: MMN (Arisi et al., 2012; César et al., 2010; Lalo et al., 2005), 
and P3b (Blackwood et al., 1988; César, Caovilla, Munhoz, & Ganança, 2010; 
Kakigi, Neshige, Matsuda, & Kuroda, 1994; Lalo, Vercueil, Bougerol, Jouk, & 
Debû, 2005; Medaglini et al., 1997; Seidl et al., 1997; St. Clair & Blackwood, 
2013; Vieregge, Verleger, Schulze-Rava, & Kömpf, 1992; Wetter & Murphy, 
1999), compared to TD adults. Therefore the present study would expect a 
similar pattern.  	
Although P300 comprises two potentials: ‘P3a’ and ‘P3b’ (Polich, 2007), in the 
literature, P3b has been much more extensively studied (Polich & Kok, 1995). 
As a result, explicit investigations of the P3a waveform in adults with DS have 
proved difficult to find. However, when investigating P300 with a P3b focus, 
Kakigi et al. (1994) reported a frontal shift in the DS group that was not 
evident in age-matched controls. The frontal shift could have been the result 
of a P3a dominated response, considering that the P3a component is fronto-
centrally distributed (Polich, 2007). The early behavioural presentation of 
Alzheimer’s disease in DS seems to be weighted towards changes in 
cognitive functions underpinned by the frontal lobes (Ball et al., 2006; Ball, 
Holland, Treppner, Watson, & Huppert, 2008). Therefore, the frontal locus of 
P3a activity means that it could be of clinical relevance in early DS-AD. P3a is 
associated with distractibility and disinhibition, which could enhance the 
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waveform as disinhibited behaviours develop, or diminish the waveform as 
neurons are lost from the frontal cortex, with aging and AD (Fjell & Walhovd, 
2004). Of course, caution must be taken with suggestions that behavioural 
inhibition and inhibition of a sensory response (habituation) can be conflated.  
 
The few previous studies which have compared people with DS and typically 
developing controls have predominantly employed a single canonical 
electrode approach to the analyses of P3b (Blackwood et al., 1988; César, 
Caovilla, Munhoz, & Ganança, 2010; Kakigi, Neshige, Matsuda, & Kuroda, 
1994; Lalo, Vercueil, Bougerol, Jouk, & Debû, 2005; Medaglini et al., 1997; 
Seidl et al., 1997; St. Clair & Blackwood, 2013; Vieregge, Verleger, Schulze-
Rava, & Kömpf, 1992; Wetter & Murphy, 1999). Single canconical electrode 
selection is based on where the event-related potential is typically maximal, 
for example Fz for MMN. However, the morphology of the DS brain is 
fundamentally different to that of the typically developing population with: 
reduced overall cortical volume (Lott, 2010); disproportionately diminished 
frontal lobes (Aylward et al., 1999); reduced neuronal density (Lott, 2010), 
amongst other features. The atypical brain morphology in DS may result in 
atypical electrodes having maximal electrophysiological responses.  
 
This thesis acknowledges the potential confounds of the atypical DS brain by 
employing an across-scalp approach to explore the factors of: age (chapter 
4), cognitive function (chapter 5) and cognitive decline (chapter 6). The 
across-scalp approach is called global field power (GFP). GFP is a reference- 
and polarity-independent technique, which evaluates electrophysiological data 
from all recording electrodes to determine the power of standard deviations in 
signal (i.e. ERPs) for each time point, within a given time frame (Lehmann & 
Skrandies, 1980). However, prior to investigations based on GFP, the time 
frames of interest must first be confirmed as encompassing the ERPs of 
interest. This is one the objectives for the present chapter. The potential time-
windows of interest are proposed from the literature, as described in section 
3.3. Within these proposed time-windows, the ERP presence is confirmed 
with spatio-temporal cluster analyses, following the procedure developed by 
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Chennu, Finoia, et al., (2013). The methodology of this procedure is described 
in section 3.5.2.  
 
3.3 Time-windows  	
Spatio-temporal cluster analyses are used to confirm the presence of the 
ERPs, within the time-windows of interest (Chennu, Noreika, et al., 2013), 
section 3.5.2. Then, in the following chapters (4,5,6), the GFP maxima for the 
ERPs (MMN, P3a, P3b) will be measured as a function of time, within the 
time-windows of interest (Lehmann & Skrandies, 1980).  
 
The chosen time windows are informed by the literature. According to the 
literature, the MMN waveform typically peaks between 100-200ms post-
stimulus (Brønnick, Nordby, Larsen, & Aarsland, 2010; Friston, 2005; Hughes 
& Rowe, 2013; Naatanen, Jacobsen, & Winkler, 2005; Risto Näätänen & 
Kähkönen, 2009; Pekkonen, 2000; Pekkonen, Hirvonen, Jääskeläinen, 
Kaakkola, & Huttunen, 2001; Thönnessen et al., 2008; Wacongne et al., 
2012).  
 
As the name suggests, the P300 (P3a, P3b) waveform typically peaks around 
300ms post-stimulus. However, the time-window can extend to as long as 
1000ms post-stimulus for the processing of complex linguistic stimuli (Duncan 
et al., 2009). The P300 time-window is typically defined between 250-650ms 
post-stimulus, encompassing both earlier (P3a) and later (P3b) components 
of the potential (P300). Indeed, van Dinteren, Arns, Jongsma and Kessels 
(2014) performed a systematic review and meta-analysis of 75 studies which 
investigated P300 across the lifespan, which included an analysis of the 
latency values. Figure 3.1. is adapted from the article. As the figure (3.1.) 
displays, the majority of P300 latency values occur in the 250-400ms time 
frame, as the name (300ms) expects. In the context of the present study, 
P300 latency is typically increased for: 1. Older adults (Duncan et al., 2009; 
Kerr et al., 2010; Polich, 2007; Rossini et al., 2007; Schiff et al., 2008; 
Walhovd et al., 2008); and 2. Adults with DS (Blackwood et al., 1988; César, 
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Caovilla, Munhoz, & Ganança, 2010; Kakigi, Neshige, Matsuda, & Kuroda, 
1994; Lalo, Vercueil, Bougerol, Jouk, & Debû, 2005; Medaglini et al., 1997; 
Seidl et al., 1997; St. Clair & Blackwood, 2013; Vieregge, Verleger, Schulze-
Rava, & Kömpf, 1992; Wetter & Murphy, 1999). Therefore, the latency ranges 
have been parsed to identify potential earlier (200-400ms) and later (400-
650ms) components.  
 
 
 
 
Figure 3.1. P300 latencies, across the lifespan, from 75 cross-sectional 
studies. Each data point represents an individual participant. The graph is 
adapted from van Dinteren et al. (2014), page 8.  
The appropriateness of the proposed time-windows for GFP analyses, in the 
following chapters (4,5,6), is confirmed with the spatio-temporal cluster 
analyses in the present chapter (3), section 3.5.2, 3.6.2.  
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3.4 Hypotheses 	
Adults (DS, TD) are expected to generate significant clusters for the ERPs 
(MMN, P3a, P3b), within the proposed time-windows of interest.  
 
Adults with DS will have significantly smaller MMN and P3b amplitudes, than 
age- and gender-matched TD controls.  
 
Adults with DS will have significantly different P3a amplitudes than age- and 
gender-matched TD controls. The direction of the difference (smaller vs. 
larger) is unknown.  
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3.5 Methods 	
3.5.1 General methods 		
Full details of participant identification; neuropsychological assessments; EEG 
acquisition, paradigms and pre-processing, can be found in chapter 2, 
sections 2.5, 2.8, 2.14, 2.15 and 2.16.  
 
3.5.2 Spatio-temporal cluster analyses  		
The aim of the cluster analyses was to calculate the ERPs (MMN, P3a, P3b) 
with subject-wise averages, for each condition. The cluster analysis procedure 
follows that developed by Chennu, Finoia, et al., (2013). A Monte Carlo 
procedure was used to: 1. Identify temporal clusters, and 2. Estimate the p-
values of statistically significant differences in response between pairs of 
conditions: deviant vs. standard. The response to deviations, in the absence 
of active attention, generated ‘local’ MMN (negative directionality) and P3a 
(positive directionality) responses. The response to deviations, when active 
attentive processes were engaged, generated a ‘global’ P3b (positive 
directionality) response. A randomisation testing procedure was used to 
establish the statistical significance of the different clusters for each ERP. The 
steps for the Monte Carlo randomisation procedure were as follows: 
1. The subject-wise condition averages were mixed and separated into 
two random samples.  
2. Average ERPs were calculated for the random samples. 
3. Steps 1 (randomisation) and 2 (resampling) were repeated 1000 times.  
4. The original, and randomised, ERPs for each time-point were 
compared, to generate t-values and p-values.  
5. The original, and randomised, ERPs were clustered based on 
contiguity and having p values of <.05.  
6. The cluster-level t-values were retained.  
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7. The distribution of cluster-level t-values generated by the 
randomisation procedure was compared to the original ERPs, to 
calculate a non-parametric p-value, which is reported.  
 
The result of the randomisation procedure is a Monte Carlo estimate of the 
statistical significance for the original clusters and ERPs. The method is used 
to control for family wise error and multiple comparisons (Maris, 2004; Maris & 
Oostenveld, 2007). The appropriate script can be found in appendix W.  
 
The results of this analysis are used to confirm the ERPs of interest (MMN, 
P3a, P3b) within the time-windows of interest (100-200ms, 200-400ms, 400-
650ms). The confirmation of the ERPs and time-windows forms the basis of 
the across-scalp GFP analyses in the forthcoming chapters (4,5,6), relative to 
the factors of interest: age, cognitive function, and cognitive decline.  
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3.6 Results 	
3.6.1 Participant demographics  	
36 adults with DS (22-55 years), and 39 TD controls (20-59 years), completed 
the cross-sectional phase of the study. Independent samples t-tests for 
Equality of Means were conducted, with Equality of Variances assumed (p > 
.05) to find that the participant group with Down’s Syndrome (DS) and the 
typically developing (TD) control group did not significantly differ in age (p = 
.15). Equality of Variance was not assumed (p < .05) for group comparisons 
on hearing acuity. The number of tones identified from the Siemens Hear 
Check Screener assessed hearing acuity. An independent samples t-test for 
the Equality of Means found that the number of tones identified did not 
significantly differ between groups (p = .12). A chi-square test of 
independence was performed to examine the relationship between gender 
(male, female) and group (DS, TD) and found no significant relationship: X2 
(1, 75) = 2.24, p = .134. Please see table 3.1 for more details.  
 
 
Group N Number 
of males 
Number 
of 
females 
Mean 
age 
(years) 
SD Mean 
number 
of tones 
heard 
SD 
Down’s Syndrome 36 21 15 36.56 9.38 9.83 1.8 
Controls 39 17 22 40.08 11.34 10.33 .70 
Table 3.1. Participant demographics: sex, age and hearing acuity.  
 
For the age- and gender-matched typically developing controls: the lowest IQ 
score, as assessed by the Kaufman Brief Intelligence Test, second edition 
(KBIT II), was 90; the lowest dementia-screening score, as assessed by the 
Addenbrooke’s Cognitive Examination - Revised (ACE-R), was 88. Therefore, 
the group is considered as appropriate to be ‘typically developing controls’, for 
this study. The test values can be found in table 3.2. The comparable DS 
results can be found in chapter 5, section 5.6.1.1.  A visualization of the 
spread and distribution of the groups’ (DS, TD) KBIT II scores can be found in 
figure 3.2.  
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Variable Minimum Maximum Mean  SD  
Age (years) 20 59 40.08 11.43 
KBIT II IQ composite score 90 136 111.56 11.58 
ACE-R  88 100 95.36 3.68 
Table 3.2. Test values for the age- and gender- matched TD controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Boxplots of the groups’ (DS, TD) IQ composite scores, as 
measured by the KBIT II, and standardized by age.  
 
The participant demographics described in this section apply to each of the 
results chapters.  
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3.6.2 Spatio-temporal cluster analyses  
 
3.6.2.1 MMN 	
Participants showed group-wise (controls, DS) statistically significant clusters: 
the response to deviant tones within 100-200ms (MMN response) significantly 
differed to the standard tone response. The age- and gender- matched 
typically developing (TD) controls showed the difference at p = 5.6e-31 
(p<.001) level, the participants with DS showed the difference at a p = .0004 
level. The interaction between groups (controls, DS) showed a significant 
cluster difference, for an MMN response, at between 98-118ms, with a peak 
at 102ms, p = .00124. In summary, the MMN response was significantly larger 
for control participants than participants with DS. This comparison is 
visualised in figure 3.3.  
 
 
 
Figure 3.3. The image on the left shows the age- and gender- matched 
controls group. The image on the right shows the participants with DS group. 
The bottom half of the images maps the time course, by group. The green line 
shows the response to standard tones and the blue line indicates responses 
to deviant tones, the amplitude difference of which produces an MMN 
response. The horizontal, thick blue line shows the temporal extent of the 
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significant cluster of contiguous time points where the response to deviants 
(within an MMN context) was greater than standards. The significance of the 
difference for controls is p = 5.6e-31, and for participants with DS is p = .0004. 
The vertical, dashed red line indicates the time point in the cluster where the 
ERP was maximal. These time points are mapped out on the scalp maps, in 
the upper half of the image. For controls the time point was 108ms, for 
participants with DS the time point was 128ms. On the scalp map, blue 
indicates electrodes with more negative ERP amplitude in response to deviant 
tones compared to standard tones, and red indicates electrodes with more 
positive ERP amplitude in response to deviant tones compared to standard 
tones. The black line indicates the spatial location of the significant difference 
cluster. The white circle indicates the electrode where the difference is 
maximal.  
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3.6.2.2 Earlier P300  	
Participants showed group-wise (controls, DS) statistically significant clusters: 
the response to deviant tones within 200-400ms (P300 response) significantly 
differed to the standard tone response. The age- and gender- matched TD 
controls showed the difference at p = 5.6e-31 (p<.001) level, the participants 
with DS showed the difference at a p = 1.2e-26 (p<.001) level. The interaction 
between groups (controls, DS) showed a cluster difference, at between 382-
398ms, with a peak at 394ms, p = .01. In summary, adults with DS showed a 
large P3a response in this time period. However, the parietal locus of the P3 
response in controls, combined with the later onset (340ms), presents this 
time period (200-400ms) as dominated by a P3b response, for TD controls. 
This comparison is visualised in figure 3.4. 
  
 
 
 
Figure 3.4. The image on the left shows the age- and gender- matched 
controls group. The image on the right shows the participants with DS group. 
The bottom half of the images maps the time course, by group. The green line 
shows the response to standard tones and the blue line indicates responses 
to deviant tones. The horizontal, thick blue line shows the temporal extent of 
the significant cluster of contiguous time points where the response to 
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deviants was greater than standards. The significance of the difference for 
controls is p = 5.6e-31, and for participants with DS is p = 1.2e-26. The 
vertical, dashed red line indicates the time point in the cluster where the ERP 
was maximal. These time points are mapped out on the scalp maps, in the 
upper half of the image. For controls the time point was 340ms, for 
participants with DS the time point was 236ms. On the scalp map, blue 
indicates electrodes with more negative ERP amplitude in response to deviant 
tones compared to standard tones, and red indicates electrodes with more 
positive ERP amplitude in response to deviant tones compared to standard 
tones. The black line indicates the spatial location of the significant difference 
cluster. The white circle indicates the electrode where the difference is 
maximal.  
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3.6.2.3 Later P300 	
In an attempt to explore whether the participants with DS displayed the later 
P3 component (P3b), the 400-650ms window was analysed for this group. 
The participants with DS did not show a significant cluster in this time-window, 
indicative of a P3b response. This is visualised in figure 3.5. In summary, the 
participant groups showed inverse patterns. The participants with DS showed 
a large P3a response but no significant P3b response, whereas control 
participants showed a significant P3b response but no significant P3a 
response.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. The image shows the participants with DS group. The bottom half 
of the image maps the time course. The green line shows the response to 
standard tones and the blue line indicates responses to deviant tones. The 
vertical, dashed red line indicates the time point in the cluster where the ERP 
was maximal. However, there were no significant clusters in this time-frame. 
Nevertheless, this time point of maximal difference is mapped out on the scalp 
map, in the upper half of the image. For the participants with DS the time point 
was 400ms. On the scalp map, blue indicates electrodes with more negative 
ERP amplitude in response to deviant tones compared to standard tones, and 
red indicates electrodes with more positive ERP amplitude in response to 
deviant tones compared to standard tones. The white circle indicates the 
electrode where the difference is maximal.  
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3.7 Cluster analysis confirmation of time-windows 	
The time-windows chosen from the literature (section 3.3) were explored in 
the present chapter as the time frames in which statistically significant MMN, 
P3a, and P3b clusters were expected for the ERPs.  
 
Following the spatio-temporal cluster analyses the post-stimulus time-
windows were confirmed as follows: MMN – 100-200ms, P300 – 200-400ms. 
The 200-400ms time-window was dominated by a P3b response for the 
control participants and a P3a response for the participants with DS. The later 
P300 time-window (400-650ms) was also explored for adults with DS. 
However, no significant clusters for a P3b response were found between 400-
650ms. Nevertheless, there is a-priori evidence that P3b is affected by typical 
and pathological aging (chapter 1, section 1.12.2). Therefore, in relation to 
these factors, P3b should continue to be explored in the following chapters 
(4,5,6).  
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3.8 Discussion 	
In the present study, participants with DS showed significantly smaller MMN 
responses than age- and gender-matched TD controls. This result is in 
agreement with previous research which has compared the potential (MMN) 
between the groups (DS, controls) (Arisi et al., 2012; César et al., 2010; Lalo 
et al., 2005). Previous studies have eluded to a frontal shift in P300 for 
children (Kaneko et al., 1996b) and adults (Kakigi et al., 1994; Vieregge et al., 
1992) with DS. The present study unpicks this enlarged frontal response to 
find a significantly enhanced P3a for the participants with DS.  
 
For control participants, the P300 response is predominantly parietal in 
nature, which suggests more P3b contributions, to the response, than P3a 
(Polich & Kok, 1995). This finding is juxtaposed against the lacking P3b 
response for participants with DS, in the presence of a large P3a response. 
P300 can be considered as both the capture (P3a) and maintenance (P3b) of 
attention. Within this conceptualisation, we can consider the relative strengths 
and weaknesses of the DS cognitive profile. A cognitive examination of 86 
adults with DS (16-34 years) found that although episodic memory 
performance is generally poor in DS, controlling attention and encoding 
information are especially impaired (de Sola et al., 2015). This cognitive 
profile ties into the electrophysiological finding that attention is captured 
(enlarged P3a), but not necessarily maintained and encoded (no P3b) in DS.  
 
The lacking P3b response in DS could be a product of the attentional 
demands required to elicit the response. Whilst MMN is pre-attentional and 
automatic (Duncan et al., 2009); P3b requires attention and the active 
maintenance of working memory (Polich, 2007). Most people with DS have 
attentional and cognitive deficits. In this study, these attentional deficits are 
reflected in the indistinguishable P3b response from baseline, for participants 
with DS, at a group level. This lacking response is reflected in how the 
participants completed the task. At the end of each block, participants were 
asked to report what group of sounds they heard alot and what group(s) they 
heard sometimes, to maintain attention and develop a P3b response. The 
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majority of participants with DS were unable to report the distinction, and 
instead focused their report on the rare, inter-aural deviant. This rare deviant 
focus is congruent with an enlarged P3a response. In contrast, all the control 
participants perceived and reported the distinction, to show a P3b response. 
Furthermore, a P3a response is generated in the absence of a task, whereas 
P3b generation is task dependent (Polich & Criado, 2006). This distinction 
maps onto the behavioural findings that the overwhelming majority of adults 
with DS were not performing the task (P3a), whereas all the TD controls were 
easily performing the task (P3b).  
 
The deviant, inter-aural stimulus, which leads to a P3a response, is infrequent 
but repeated, as part of a group. Consequently, the involuntary attention 
switch response should eventually be habituated; then contextualised by the 
task, for a P3b dominated response. This effect is seen in the TD control 
participants. However, for the adults with DS, this habituation process does 
not occur, leading to a consistently large P3a response. P3a has a fronto-
central locus (Polich, 2007), and has been suggested as an index of 
distractibility and disinhibition (Fjell & Walhovd, 2004). Inhibitory control is an 
executive function, under-pinned by the frontal lobes. The early behavioural 
presentation of AD in DS is weighted towards changes in cognitive functions 
underpinned by the frontal lobes (Ball et al., 2006; Ball, Holland, Treppner, 
Watson, & Huppert, 2008). Therefore the increased P3a response in DS could 
be interesting from an executive dysfunction perspective, associated with 
early signs of AD. However, we must take care not to conflate the two, as 
behavioural inhibition and the habitual inhibition of a sensory response are 
dissociable mechanisms. The habituation hypothesis, and other potential 
mechanisms, are explored further in chapter 5.  
 
Perception can be viewed as a testable hypothesis (Jack & Hacker, 2014), 
whereby perceptive ‘predictions’ are challenged by ‘prediction errors’.  In 
terms of predictive coding, perceptive processing is constrained to instances 
when the top-down ‘prediction’ is challenged by bottom-up ‘prediction errors’ 
(Friston, 2005). The feedback loops are functionally asymmetric, whereby 
bottom-up ‘prediction errors’ drive the formation of top-down ‘predictions’, 
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which in turn modulate the processing of bottom-up stimuli (Friston, 2005). 
Predictive coding can be used to contextualise ERPs (MMN, P3a, P3b) as 
‘prediction errors’ (Garrido et al., 2007; Leavitt, Molholm, Ritter, Shpaner, & 
Foxe, 2007; Wacongne et al., 2012). Within this framework, MMN and P3a 
are low, ‘local’ level violations of the prediction which occur in the absence of 
attention (Bekinschtein et al., 2009). The uptake of these low, ‘local’ level 
violations into a ‘global’ framework, updates the ‘prediction’ (Chennu, Finoia, 
et al., 2013). The ‘global’ framework requires the active maintenance of 
attention and if violated, results in a P3b waveform (Bekinschtein et al., 2009). 
To place the findings of the present study within a predictive coding 
framework: for participants with DS the low-level, attention independent, 
prediction error that generates MMN and P3a responses, is present. 
However, the higher order, attention dependent, prediction error that 
generates P3b is not discernible from baseline in DS. This suggests a deficit 
in DS for feeding-forward from the attention-independent to the attention-
dependent system, which is temporally extended to allow for pattern 
extraction.  
 
A counter proposal for the predictive coding hypothesis of MMN generation is 
synaptic habituation, in that repeated stimulation reduces amplitudes and 
novel stimulation recovers the reaction (May & Tiitinen, 2010). Indeed, 
adaptation and short-term plasticity are essential features of cortical synapses 
(Calford, 2002) and, more specifically, the functioning of the auditory cortex 
(Brosch & Schreiner, 2000). However, Wacongne et al., (2012) argues that 
synaptic habituation and predictive coding are complimentary rather than 
contradictory hypotheses. Wacongne et al., (2012) presents a model of 
spiking excitatory and inhibitory neurons, which are distinctly attuned for: 
environmental input, prediction and prediction errors, and modulated by 
NMDA receptor synaptic transmission. Wacongne et al., (2012) argues 
strongly for an active, predictive system rather than a passive effect. As such, 
synaptic habituation is proposed as a necessary but not sufficient mechanism 
to generate MMN responses (Wacongne et al., 2012). 
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The present study uses the information gained about ERP time-windows in 
this chapter to inform GFP analyses in the upcoming chapters (4,5,6). The 
primary benefit of using GFP analyses is that the whole brain is considered, 
bypassing issues of differing sites of maximal potential because of the atypical 
brain anatomy in DS (Lott, 2010). 
 
3.9 Summary 	
In summary, participants with DS showed significantly smaller MMN 
responses than age- and gender- matched controls. This finding is consistent 
with the literature. However, a novel finding of the study is that while the 
controls showed a standard P3b response the participants with DS showed a 
very large P3a response.  
 
Having established the waveforms at a group level (the group with DS and the 
TD controls), we can now explore the effects of: age (chapter 4), executive 
dysfunction (chapter 5), and cognitive decline (chapter 6), using whole-brain 
GFP analyses.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
	 117 
4 Chapter 4. Investigating whether EEG evidence supports 
the accelerated aging hypothesis of Down’s Syndrome 
 
4.1 Aim 	
To use electroencephalographic measures as a means of testing the 
accelerated brain aging hypothesis in Down’s Syndrome.  
 
4.2 Introduction  	
People with Down’s Syndrome (DS) are hypothesised to experience 
accelerated aging. This hypothesis is supported across several physiological 
systems: from earlier menopause to premature skin wrinkling (see Zigman, 
2013 for a review). This thesis is concerned with testing the hypothesis that 
people with DS experience accelerated aging to the neurological system, with 
the event-related potentials (ERPs): mismatch negativity (MMN) and P300 
(P3a, P3b). Accelerated aging in DS is, importantly, characterised by early-
onset Alzheimer’s disease (AD) (Zigman, 2013). Age is the primary, and only 
irrefutable, risk factor for AD. Therefore, in the search for meaningful markers 
of pathological aging (AD), we must first acknowledge the contributions of 
typical aging (Humpel, 2011).  
 
Sensory memory and perceptual accuracy decline with typical aging (Demiral 
et al., 2012; Fakhri et al., 2012; Lauzière et al., 2012; Stewart & Wingfield, 
2009). Therefore, as MMN can be used to index sensory memory (Pekkonen 
et al., 1996), the relationship between this ERP and typical aging has been 
tested. Previous studies of electrophysiological aging, with the typically 
developing (TD) population, have generally agreed that MMN amplitudes 
decrease with increasing age (Alain, McDonald, Ostroff, & Schneider, 2004; 
Alain & Woods, 1999; Bertoli, Smurzynski, & Probst, 2002, 2005; Cooper, 
Todd, McGill, & Michie, 2006; Czigler, Csibra, & Csontos, 1992; Horváth, 
Czigler, Birkás, Winkler, & Gervai, 2009; Horváth, Czigler, Winkler, & Teder-
Sälejärvi, 2007; Karayanidis et al., 1995; Kisley, Davalos, Engleman, 
Guinther, & Davis, 2005; Pekkonen et al., 1996; Pekkonen, 2000; Rimmele, 
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Sussman, Keitel, Jacobsen, & Schröger, 2012; Schiff et al., 2008; Tsolaki, 
Kosmidou, Hadjileontiadis, Kompatsiaris, & Tsolaki, 2015; Woods, 1992). 
There has been some opposition to a relationship between MMN amplitude 
and age (Amenedo & Dıáz, 1998), but a recent meta-analysis concluded that, 
on balance, there was a robust relationship (Cheng, Hsu, & Lin, 2013). 
Although there is some suggestion that MMN latencies increase with 
increasing age (Bertoli et al., 2002, 2005; Cooper et al., 2006; Tsolaki et al., 
2015), the amplitude relationship is considered more robust (Schiff et al., 
2008).  
 
Schiff et al. (2008) go on to suggest that later, more cognitive components, 
such as P3b, are potentially more sensitive to age effects than MMN. In 
chapter 3, a consistent P3b effect was found in the earlier time window (200-
400ms), for the TD adults. However, for the DS group, the earlier time window 
was dominated by a P3a response and no consistent P3b effect was found in 
the later time window (400-650ms). Nevertheless, P3b latency is typically 
increased for older adults (Duncan et al., 2009; Kerr, van Albada, Rennie, & 
Robinson, 2010; Polich, 2007; Rossini, Rossi, Babiloni, & Polich, 2007; Schiff 
et al., 2008; Walhovd, Rosquist, & Fjell, 2008). Consequently, the inconsistent 
P3b effect could be the result of age effects, and thus tie into an accelerated 
aging hypothesis of DS. Accordingly, this chapter will also explore age effects 
in the 400-650ms time-window, for the adults with DS.  
 
P300, specifically the P3b component, has been linked with typical adult aging 
from physiological, cognitive and electrophysiological perspectives. 
Physiologically, the parietal cortex, which enable P3b generation, shows 
reduced thickness for older adults (Lemaitre et al., 2012). Cognitively, P3b 
indexes attentive and memory processes, which are often compromised for 
older adults (Quigley et al., 2010; Quigley & Müller, 2014). 
Electrophysiologically, P3b shows decreased amplitudes and increased 
latencies for TD older adults (Duncan et al., 2009; Kerr, van Albada, Rennie, 
& Robinson, 2010; Polich, 2007; Rossini, Rossi, Babiloni, & Polich, 2007; 
Schiff et al., 2008; Tsolaki et al., 2015; Walhovd, Rosquist, & Fjell, 2008).   
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Again, P3b has been the focus of P300-aging research (Duncan et al., 2009; 
Kerr et al., 2010; Polich, 2007; Rossini et al., 2007; Schiff et al., 2008; Tsolaki 
et al., 2015; Walhovd et al., 2008). Nevertheless, P3a and P3b waveforms are 
strongly correlated, and have been demonstrated to correlate with age in the 
same way as one-another: reducing amplitudes and increasing latencies 
(Walhovd & Fjell, 2001). Furthermore, P3a has been presented as having a 
linear relationship with age (Fjell & Walhovd, 2004); a relationship that is 
potentially stronger than that of the P3b component with age (Fjell & Walhovd, 
2004).   
 
The suggestion of decreased MMN, P3a and P3b amplitudes for older adults 
plays into an “under-recruitment” model of typical aging. The “under-
recruitment” model equates poorer performance with reduced activity. Indeed, 
fMRI studies with older adults have suggested that during memory encoding 
(Logan et al., 2002) and retrieval (Cabeza et al., 2004) activity is reduced in 
the prefrontal cortex and medial temporal lobes, respectively.  
 
A topographical study of P300 distribution found that, with age, sources move 
to have a frontal distribution, and the maximum intensities gain a temporal 
locus (Tsolaki et al., 2015). In addition, MMN may present more parietally with 
increasing age (Anderer, Semlitsch, & Saletu, 1996). These topographical 
findings present an argument for whole brain, rather than single canonical 
electrode, analyses when exploring the relationship between the ERPs and 
typical aging. The atypical DS brain morphology (Lott, 2010), presents a 
further argument as to why atypical electrodes may be maximal for the ERPs, 
rendering single canonical electrode analyses inappropriate.  
 
This thesis has chosen to extract the global field power (GFP) maxima, and 
associated latencies. GFP is a reference- and polarity-independent technique, 
which evaluates electrophysiological data from all recording electrodes to 
determine the power of deviations (i.e. ERPs), within a given time frame 
(Lehmann & Skrandies, 1980). The time at which the GFP maxima (largest 
deviation) occurs can indicate the latencies of ERPs (Skrandies, 1990).   
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GFP is extracted from the post-stimulus time frames of interest, for each ERP: 
MMN – 100-200ms, P300 – 200-400ms. In this time-window (200-400ms) the 
P300 response is dominated by a P3a response for adults with DS, and a P3b 
response for the TD controls. In an exploration of the potential effects of age 
on P3b generation, the later time window (400-650ms) will also be 
investigated for adults with DS.  
 
We would expect the electrophysiological hallmarks of typical aging: reducing 
amplitudes, akin to GFP maxima, and increasing latencies, to be exacerbated 
for adults with DS, within an accelerated aging framework.  
 
4.3 Hypotheses 	
1. Older TD adults will show smaller GFP maxima and longer latencies 
(MMN, P3b) than younger adults, in their group. 
 
2. Older adults with DS will show smaller GFP maxima and longer 
latencies (MMN, P3a, P3b) than younger adults, in their group.  
  
3. With age, adults with DS will show a greater decrease in GFP maxima 
(MMN, P3b), and greater increase in latencies, than TD controls.  
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4.4 Methods 	
Full details of participant identification; neuropsychological assessments; EEG 
acquisition; paradigms and pre-processing, can be found in chapter 2, 
sections 2.5, 2.8, 2.14, 2.15 and 2.16.  
 
The data was pre-processed using custom MATLAB scripts, as described in 
chapter 2, section 2.16. The GFP maxima were extracted from post-stimulus 
time frames where the ERPs of interest would be expected: MMN: 100-
200ms, P300: 200-400ms, 400-650ms. Please see appendix X for the custom 
script used to gain the GFP values. Please see chapter 3, sections 3.3, 3.7 for 
more details on the time windows. The GFP maximum and latency values for 
each ERP time-window, and for each participant, were exported to SPSS for 
aging analyses.  
 
In analyses where age is not handled as continuous variable, a ‘younger’ and 
‘older’ adult dichotomy is used, with the split at 40 years old. Research by 
Annus et al (2015) informed the dichotomy. The research used a radioactive 
analogue of thioflavin: selective carbon–11 labelled radioisotope Pittsburgh 
Compound B (11C-PIB). PIB binds to beta-amyloid (Aβ), which allows this 
composite of senile plaques to be visualized in a Positron Emission 
Tomography (PET) scan. Previous research, using this technique, has 
suggested that people with DS begin to exhibit abnormal PIB binding from the 
age of 39 years old (Annus et al., 2015), and consistently in the 40s (Annus et 
al., 2015; Handen et al., 2012; Hartley et al., 2014; Jennings et al., 2015; 
Sabbagh et al., 2011). This sigmoidal relationship between age and abnormal 
binding is visualised in figure 4.1 (from Annus et al., 2015). This qualitative 
shift at the age of 40 informed the dichotomy for the present aging analyses.  
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Figure 4.1. Taken from Annus et al., (2015) page 4, figure A: The sigmoidal 
relationship between age and abnormal PIB binding. The dichotomy begins 
around age 40 (years old).  
 
For a full explanation of the methods used, including: recruitment, data 
acquisition and pre-processing, please see chapter 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 123 
4.5 Results 
 
4.5.1 Participant demographics  	
The participant groups (DS, TD) were matched for age and sex, as 
summarized in table 4.1. For a detailed review of the participant (DS, TD) 
demographics, please see chapter 3, section 3.5.1. Participant demographics.  
 
Group N Number 
of males 
Number 
of 
females 
Mean 
age 
(years) 
SD 
Down’s Syndrome (DS) 36 21 15 36.56 9.38 
Typically Developing (TD) Controls 39 17 22 40.08 11.34 
 
Table 4.1. Participant demographics: sex and age.  
 
4.5.2 Correlations with age – within groups 	
The Shapiro-Wilk Test of Normality indicated that the GFP maxima and 
latencies for all the associated ERPs (MMN, P3a, P3b), for both groups (DS, 
controls), significantly differed to the normal distribution (p < .05). Therefore 
Non-Parametric, Spearman’s Rank-Order correlations were used. Age did not 
significantly correlate with the standardized IQ scores for participants with DS: 
r  = .244, p = .152, or controls: r = .005, p = .978. There were also no 
relationships between age and gender for participants with DS: r  = .022, p = 
.9, or controls: r = .246, p = .132. Therefore, neither IQ nor gender will be 
considered further in this exploration of aging effects. Furthermore, based on 
the aging hypotheses being highly directional, the subsequent analyses are 
one-tailed. To correct for multiple comparisons, the Bonferroni correction is 
applied at p < .02. This level is based on the three ERPs (MMN, P3a, P3b) 
being clustered in families of GFP maximum (µV2) and latency (ms): p < .05/ 3 
= 0.02 (2 d.p.). An exploration of each GFP maxima and latency found that 
either: 1. There were no statistical outliers for the DS or control groups, as no 
participant was >3 standard deviations from the mean, or 2. If there were 
outliers, a sensitivity analysis revealed that the results were unchanged by 
their presence or absence, so they were retained in the analyses. For more 
details on the results of the sensitivity analysis please see appendix Y.   
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For participants with DS, the GFP maximum in the 100-200ms range (MMN) 
negatively correlated with age: r = - .385, p = .010. The latency of the GFP 
maximum (MMN) positively correlated with age: r = .367, p = .014. All other 
correlations between age and ERPs, for DS and controls, failed to reach 
significance (p > .02). Please see tables 4.2 and 4.3 for the correlational  
analyses for each ERP, by group, and Figure 4.2 for visualization.  
 
 
Table 4.2. Spearman’s Rank-Order correlations (one-tailed), by group (DS, 
controls), between age and ERP GFP maxima (MMN, P3a, P3b); all values 
are rounded to 3 s.f.; * indicates correlations which are significant at p < .02 
level.  
 
 
Table 4.3. Spearman’s Rank-Order correlations (one-tailed), by group (DS, 
controls), between age and ERP latencies (MMN, P3a, P3b); all values are 
rounded to 3 s.f.; * indicates correlations which are significant at p < .02 level. 
Group GFP maxima 
time-windows 
(ms) 
 Associated 
ERP 
Mean  
GFP 
Maxima  
(µV2) 
SD Correlation values 
with age 
 r p 
 
DS 
100-200 MMN 5.97 5.39 -.385* .010 
200-400 P300 (a) 9.87 7.99 -.191 .132 
400-650 P300 (b) 3.79 3.55 -.101 .279 
 
 
Controls 
100-200 MMN 11.32 6.83 .261 .054 
200-400 P300 (b) 8.39 7.21 .060 .358 
 
Group GFP maxima 
time-windows 
(ms) 
 Associated 
ERP 
Mean  
Latencies 
of GFP 
Maxima 
(ms) 
SD Correlation values 
with age 
 r p 
 
DS 
100-200 MMN 131.89 18.1 .367* .014 
200-400 P300 (a) 251.67 49.28 .144 .201 
400-650 P300 (b) 476 65.32 .182 .144 
 
 
Controls 
100-200 MMN 125.44 17.3 .013 .469 
200-400 P300 (b) 293.54 57.86 .024 .442 
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Figure 4.2. Scatterplot of participants’ age (DS and age- and gender-matched 
typically developing controls), against GFP Maximum: 100-200ms, MMN 
(µV2). The figure shows a significant effect of age for participants with DS but 
not controls. The MMN for adults with DS-AD sits within the range of 
responses for older adults with DS (no AD).  
 
4.5.3 Correlations with age – between groups  	
Only the ERPs that significantly correlated with age at a within-group level 
(GFP maximum and latency - MMN) will be explored at a between-group 
level.  
 
ANCOVAs were conducted to assess whether there were group (DS, 
controls) by age interactions with GFP maximum for MMN: F(1) = 7.318, p = 
.009, and MMN latency: F(1) = 2.848, p = .096.  
 
The nature of the significant group by age interaction, with GFP maximum for 
MMN, was further explored with an independent samples t-test, using a 
dichotomy of 40 years old. Previous research has suggested that at the age of 
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40 adults with DS begin to show abnormal PIB binding, lending itself to be the 
dichotomous age of ‘younger’ vs. ‘older’ in this study. For the analysis, 
Equality of Variances was assumed (p > .05). Younger participants did not 
significantly differ, between groups (DS, controls), in GFP maximum (MMN): 
t(37) = -1.511, p = .139. However, older participants with DS had a 
significantly smaller GFP maximum for MMN (M = 4.16, SD = 4.31) than older 
controls (12.35, SD = 7.44): t(34) = -3.820, p = .001. Please see Table 4.4 for 
more group details.  
 
Dichotomy Group N Mean GFP maximum 
between 100-200ms, 
MMN (µV2) 
SD SE 
Younger (< 40 
years old) 
DS 21 7.26 5.80 1.27 
C 18 10.12 6.03 1.42 
Older (> 40 years 
old) 
DS 15 4.16 4.31 1.11 
C 21 12.35 7.44 1.62 
 
Table 4.4. Details of the dichotomous groups (younger vs. older), where 
appropriate the values are rounded to 2 d.p 
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4.6 Discussion  	
This chapter aimed to address whether ERPs can be used to investigate the 
accelerated neurological aging hypothesis of DS.  
 
At a within group analysis level the key findings were, for participants with DS: 
the GFP maximum for MMN negatively correlated with age and MMN latency 
positively correlated with age. All other ERP with age correlations, for DS and 
controls, failed to reach significance.  
 
The pattern seen with aging in DS, of reducing GFP maxima for MMN, and 
increasing latencies, is inline with the typical ERP-aging literature (Alain, 
McDonald, Ostroff, & Schneider, 2004; Alain & Woods, 1999; Bertoli, 
Smurzynski, & Probst, 2002, 2005; Cooper, Todd, McGill, & Michie, 2006; 
Czigler, Csibra, & Csontos, 1992; Horváth, Czigler, Birkás, Winkler, & Gervai, 
2009; Horváth, Czigler, Winkler, & Teder-Sälejärvi, 2007; Karayanidis et al., 
1995; Kisley, Davalos, Engleman, Guinther, & Davis, 2005; Pekkonen et al., 
1996; Pekkonen, 2000; Rimmele, Sussman, Keitel, Jacobsen, & Schröger, 
2012; Schiff et al., 2008; Tsolaki, Kosmidou, Hadjileontiadis, Kompatsiaris, & 
Tsolaki, 2015; Woods, 1992). The lacking relationship with age in the control 
group, however, could be a product of youth. When Tsolaki et al. (2015) 
explored typical aging with MMN and P3b, comparisons were made between 
younger adults, aged 25-40 years, and older adults, aged 60+ years old. With 
this dichotomy, Tsolaki et al. (2015) found a significant effect of aging. In 
contrast, the oldest control participant in the present study was 59 years old. 
As a consequence of selecting a control group that is age-matched to the DS 
group, the ‘older’ cohort is potentially still too young to demonstrate 
substantive aging effects, as measured with electrophysiology. This 
interpretation could lend credence to the accelerated aging hypothesis of DS 
because, in stark contrast, their ‘older’ cohort demonstrated aging effects, as 
measured by MMN.  
 
This suggestion of accelerated aging is reinforced at the between group 
analysis level: whilst younger participants (DS and controls) had similar GFP 
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maxima (MMN); older participants with DS had significantly smaller GFP 
maxima (MMN) than older controls. This presents a case that the aging effect 
seen within the DS group is driven by the over 40s. This finding is 
complementary to the amyloid-binding literature, which shows a sigmoidal 
relationship between age and abnormal binding, focused around 40 years 
(Annus et al., 2015; Handen et al., 2012; Hartley et al., 2014; Jennings et al., 
2015; Sabbagh et al., 2011). The relationship between abnormal binding and 
the ERPs is explored further in chapter 6.  
 
Whilst, at the within group level both the GFP maximum and latency for MMN 
significantly correlated with DS age. In contrast, when comparing aging 
between groups (DS, controls), only the GFP maximum for MMN withstood 
correction. If we consider the wider literature, which agrees on a relationship 
between age and MMN amplitude, akin to GFP maximum, but disputes 
whether MMN latency is also effected by age (Pekkonen et al., 1996; 
Pekkonen, 2000; Schiff et al., 2008), this is perhaps less surprising.  
 
There are challenges explaining the	differential age effects on MMN for adults 
with DS and TD controls in terms of the accelerated aging hypothesis. The 
primary issue is the inextricable link between AD and age, which is 
exacerbated by the consistent development of AD pathology for adults with 
DS over the age of 40 (Annus et al., 2015; Handen et al., 2012; Hartley et al., 
2014; Jennings et al., 2015; Sabbagh et al., 2011). Therefore, the observed 
effects of aging on MMN for the DS group could be attributable to the 
development of AD pathology rather than to a process of accelerated aging. 
Unfortunately, the cause of the observed age effects cannot be disentangled 
within the limitations of the present thesis.  
 
Whether of not the participants with DS are demonstrating accelerated aging, 
it is surprising that the well-characterised P3b component did not demonstrate 
aging effects with this group. This could, however, be a product of the differing 
attentional requirements to elicit both ERPs. Whilst, MMN is pre-attentional 
and automatic (Duncan et al., 2009); P3b requires attention and the active 
maintenance of working memory (Polich, 2007). Most people with DS have 
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attentional and cognitive deficits, which could lead to P3b compromise. 
Indeed, chapter 3 showed that the P3b response in DS was indistinguishable, 
from baseline, at a group level. Therefore, P3b was perhaps too variable 
within group to demonstrate a cohesive aging effect. The P300 component is 
further discussed in Chapter 5, which explores these more cognitively driven 
ERPs within a wider context of participants’ executive functioning.  
 
The “under-recruitment” model of aging equates poorer performance with 
reduced activity. This would play into a reduction in ERP amplitude, for older 
adults. In DS, not only do dendritic numbers increase at a slower rate during 
childhood but they also decline at a faster rate in adulthood (Takashima, Iida, 
Mito, & Arima, 1994). Dendrites are essential for synaptic functioning (Kasai 
et al., 2003; Sorra & Harris, 2000), and EEG measures summed post-synaptic 
potentials (Luck, 2005). Therefore, from a physiological perspective, one 
would expect an accelerated alteration to the EEG recordings. In the present 
study, age effects were limited to one ERP component (MMN).  
 
4.7 Summary 	
The study investigated electrophysiological measures (MMN, P300) as a 
means of comparing aging between people with DS and TD individuals, with a 
view to exploring accelerated aging in DS. For adults with DS, the GFP 
maximum for MMN decreased with age and MMN latencies increased, which 
is a typical aging pattern. When comparing aging between the groups (DS, 
controls), it was found that the younger adults (< 40 years old) were similar 
whereas older adults with DS (> 40 years old) had a significantly smaller 
MMN than older controls. The presence of electrophysiological aging in DS, 
against the absence in age-matched controls, presents a tentative argument 
that the cortical processes and structures associated with the generation of 
MMN responses are differentially affected by age in DS.  
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5 Chapter 5. Examining relationships between EEG measures 
and neuropsychological measures of executive function  
 
5.1 Aim 	
To explore whether electroencephalographic measures relate to a range of 
neuropsychological measures, that have been reported to be sensitive to the 
functional decline associated with the early stages of Alzheimer’s disease in 
Down’s Syndrome. 
 
5.2 Objectives  	
1. To investigate potential relationships between summary 
neuropsychological measures and event related potentials (ERPs). 
 
2. To explore whether the ERPs relate to specific neuropsychological 
measures (scrambled boxes, Tower of London), which are potentially 
most sensitive to the functional decline associated with the early stages 
of Alzheimer’s disease in Down’s Syndrome.   
 
5.3 Introduction 	
In a prospective, population based study conducted by Ball et al. (2006) it was 
suggested that early clinical indicators of Alzheimer’s disease (AD), for 
participants with Down’s Syndrome (DS), were better defined by changes in 
personality, behaviour, adaptive functioning and executive dysfunction than by 
declines in episodic memory.  These findings suggest that frontally mediated 
processes should be the focus when investigating early indicators of AD in 
DS. Others researchers also subscribe to the hypothesis that AD manifests 
differently for adults with DS, in the initial stages (Ball et al., 2008; Lott & 
Head, 2001; Nieuwenhuis-Mark, 2009; Strydom et al., 2010). However, there 
is some opposition to the proposal that frontal compromise is the first 
symptom of DS-AD (Blok, Scheirs, & Thijm, 2016; Deb, Hare, & Prior, 2007).   
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To explore the hypothesis that frontally mediated processes are targeted early 
in DS-AD, Ball and colleagues developed a battery of assessments for 
executive function (2006, 2008), appropriate for aging adults with DS 
(Executive Function test battery for people with Down’s Syndrome: EFDS) 
(Willner et al., 2010). An assessment of the battery found that the number of 
informant reported changes in personality and behaviour was related to 
performance on two executive function tasks in the battery: Tower of London 
(ToL) and scrambled boxes (Ball et al., 2008). In a longitudinal study of 55 
adults with DS, informant reported changes in personality and behaviour, at 
the initial assessment, were significant risk factors for developing the clinical 
features of Alzheimer’s disease, at a five year follow-up (Ball et al., 2006). The 
most common changes were reduced concern for others and emotional 
lability (Ball et al., 2006). As the present study is primarily concerned with 
prospective indicators of AD, the analyses are focused on the tests of 
executive function (scrambled boxes and ToL), which could be most sensitive 
to the early signs of AD in people with DS.  
 
The scrambled boxes task was designed to test working memory and 
response inhibition (Griffith et al., 1999). The task requires participants to 
remember where the researcher has hidden three coins and inhibit the 
response to search in the same box. Tower of London (ToL) is a test of 
planning and working memory (Krikorian et al., 1994). The task is premised 
on the participant using a set number of moves to match their ‘tower’ with that 
of the researcher.  
 
However, executive functioning spans beyond working memory, response 
inhibition and planning to include activities such as mind-set shifting and self-
monitoring (Ball et al., 2008), which are assessed as part of the larger EFDS 
battery. Furthermore, there are other factors to consider in task performance, 
such as IQ (as assessed with the KBIT II) and global cognitive function (as 
assessed with CAMCOG). Therefore, this chapter will firstly examine the 
relationship between several summary scores of cognitive and intellectual 
functions, and the ERPs (MMN, P3a, P3b). Then, based on the observations 
by Ball et al (2008), the relationships between specific cognitive tests of 
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interest (scrambled boxes, ToL) and the ERPs (MMN, P3a, P3b) will be 
examined.  
 
The ERP measures used in the present study were gained from the global 
local paradigm: MMN, P3a, P3b. The global local paradigm uses hierarchical 
predictive coding (Chennu, Noreika, et al., 2013). As discussed in Chapter 3, 
the MMN response from low-level, attention independent, prediction errors 
were significantly reduced for participants with DS compared to age- and 
gender-matched controls. Low-level, attention independent, prediction errors 
also generated a P3a response. For the participants with DS, the P3a 
response was significantly enlarged, which could suggest greater distractibility 
(Fjell & Walhovd, 2004). Furthermore the higher order, attention dependent, 
prediction errors that generated a P3b response were dramatically reduced, 
for participants with DS. Based on these findings patterns in chapter 3, one 
may expect similar results for the lower and higher scorers on the executive 
function tasks, in the present chapter. Conversely, although the summary 
neuropsychological measures (CAMCOG-DS, EFDS, KBIT II) have broad 
clinical utility and therefore warrant investigation; by virtue of being global 
measures of cognition, these composite scores are unlikely to map onto 
specific biological processes, such as the ERPs.  
 
5.4 Hypotheses 	
Hypothesis for objective 1: summary measures  
The summary neuropsychological measures (CAMCOG-DS, EFDS, KBIT II) 
have broad clinical utility, but their breadth also means that they are unlikely 
to map onto specific ERPs (MMN, P3a, P3b).  
 
Hypothesis for objective 2: specific measures  
Participants who score lower on the executive function tasks (scrambled 
boxes and ToL) will shower smaller field intensities for MMN and P3b, but a 
larger field intensity for P3a, than higher scoring participants.  
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5.5 Methods 
5.5.1 Exploration of the summary neuropsychological measures   
 
Full details of participant identification; neuropsychological assessments; EEG 
acquisition; paradigms and pre-processing, can be found in chapter 2, 
sections 2.5, 2.8, 2.14, 2.15 and 2.16.  
 
The data was pre-processed using custom MATLAB scripts, as described in 
chapter 2, section 2.16. The GFP maxima were extracted from post-stimulus 
time frames where the ERPs of interest would be expected: MMN: 100-
200ms, P3a: 200-400ms, P3b: 400-650ms. Please see appendix X for the 
custom script used to gain the GFP values. Please see chapter 3, sections 
3.3, 3.7 for more details on the time windows. The GFP maximum and latency 
values for each ERP time-window (MMN, P3a, P3b), and for each participant, 
were then exported to SPSS for correlation analyses with the summary, 
neuropsychological measures: CAMCOG; EFDS Battery; KBIT II.  
 
5.5.2 Exploration of the Tower of London and scrambled boxes tasks   
 
For comparisons between the ERPs (MMN, P3a, P3b) and individual 
executive functioning tasks of interest (ToL, scrambled boxes), custom 
MATLAB scripts with SPM utility were used. The data from the executive 
functioning tasks is ordinal, with a small range. In comparison the EEG data 
from which the ERPs are derived, is continuous with relatively wide windows 
of interest. Dichotomies were used in an attempt to manage the disparity in 
the data types, by creating a clear distinction in task performance. Participants 
were grouped by their performance on the executive function tasks: lower 
(<33%), average (33-66%) and higher (>66%) thirds of scorers. The analyses 
were performed on 16 ‘lower’ scorers and 13 ‘higher’ scorers on the 
scrambled boxes task, and 15 ‘lower’ scorers and 14 ‘higher’ scorers on the 
ToL task. The average scorers (7 for scrambled boxes, 7 for ToL) were 
excluded from the analyses to focus the analyses on the lower and higher 
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scorers, combating the small scoring range, and allowing for clearer answers 
to the relationship between task performance and electrophysiological factors.  
 
The dichotomy protocol for comparing ‘lower’ and ‘higher’ scorers on the 
executive function tasks was as follows:  
1. makegroups('downs',17) – the number ‘17’ corresponds to subscale 
(e.g. ToL) being assessed. 
2. The output is the participant subject numbers for the ‘lower’ and 
‘higher’ scorers on the subscale, which should be copied to the 
loadsubj. file.  
3. spmbatch({'downs_ToL_low','downs_ToL_high'},'EEG') – which 
includes both aspects of the dichotomy for comparison with the 
electrophysiological measures (MMN, P3a, P3b).  
4. runcon('MMN_dichotomy') – runs the ‘low’ and ‘high’ scorers contrast 
for each of the electrophysiological measures, a random field theory 
correction is applied.  
5. grandaverage('downs_ToL_high') – generates average waveforms for 
the group for visualisation at the next step, the grand average should 
also be run for ‘low’ version of the dichotomy.   
6. ploterp('downs_ToL_high',{'ad','ls'},'topowin',[100 200]) – run for each 
level of the dichotomy and each electrophysiological measure, to allow 
the potential differences to be visualised.  
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5.6 Results  
5.6.1 Exploration of the summary neuropsychological measures   
 
Objective: To investigate potential relationships between summary 
neuropsychological measures and event related potentials (ERPs). 
 
Hypothesis: The summary neuropsychological measures (CAMCOG-DS, 
EFDS, KBIT II) are clinically meaningful measures, which warrant 
investigation, but their breadth also means that they are unlikely to map onto 
specific ERPs (MMN, P3a, P3b).  
 
5.6.1.1 Participant demographics  
 
36 adults with DS completed the cross-sectional neuropsychological and EEG 
testing schedule. Of the 36 adults, 3 had a dementia diagnosis, 21 were male 
and 33 were right handed. For more demographic details see chapter 3, 
section 3.5.1. Table 5.1 provides more cognitive detail for the participants. 
 
 
Table 5.1. Scores for the summary neuropsychological measures for the 
cross-sectional phase participants with DS. All the values are rounded to 3.s.f.  
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5.6.1.2 Whole-group correlations between the summary 
neuropsychological measures and age  
 
Spearman’s Rank-Order correlations (two-tailed) between participants’ age 
and the summary neuropsychological measures found no significant 
relationships: CAMCOG: r = .178, p = .298; EFDS: r = .244, p = .152; KBIT: r 
= -.230, p = .177. Therefore, age is considered no further in the following 
analyses of the summary neuropsychological measures.  
 
5.6.1.3 Whole-group correlations between the summary 
neuropsychological measures and the ERPs  
 
The Shapiro-Wilk Test of Normality indicated that the GFP maxima and 
latencies for all the associated ERPs (MMN, P3a, P3b), for the DS group, 
significantly differed to the normal distribution (p < .05). Therefore Non-
Parametric, Spearman’s Rank-Order correlations were used. To correct for 
multiple comparisons, the Bonferroni correction is applied at p < .02. This 
level is based on the three ERPs (MMN, P3a, P3b) being clustered in families 
of GFP maximum (µV2) and latency (ms): p < .05/ 3 = 0.02 (2 d.p.).  The 
investigation is exploratory so the subsequent analyses are two-tailed. All 
correlations between the summary neuropsychological measures (CAMCOG, 
EFDS, KBIT II) and the GFP maxima and latencies (MMN, P3a, P3b) failed to 
reach significance at the p <.02 level. The correlation values for each 
summary neuropsychological measure are displayed in tables 5.2, 5.3, and 
5.4. An exploration of each GFP maxima and latency found that either: 1. 
There were no statistical outliers for the DS or control groups, as no 
participant was >3 standard deviations from the mean, or 2. If there were 
outliers, a sensitivity analysis revealed that the results were unchanged by 
their presence or absence, so they were retained in the analyses. For more 
details on the results of the sensitivity analysis please see appendix Y.  
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Table 5.2. Spearman’s Rank-Order correlations (two-tailed) between 
CAMCOG and the GFP maxima and latencies (MMN, P3a, P3b).  
 
 
Table 5.3. Spearman’s Rank-Order correlations (two-tailed) between EFDS 
and the GFP maxima and latencies (MMN, P3a, P3b).  
 
 
Table 5.4. Spearman’s Rank-Order correlations (two-tailed) between age 
standardised KBIT II and the GFP maxima and latencies (MMN, P3a, P3b).  
 
There is an argument that the age standardization of the KBIT II, leads to a 
high number of adults with DS at floor (Startin et al., 2016). Therefore, the 
analyses were also run with the raw KBIT scores, which can be found in 
appendix Z. As with the standardized scores, the raw KBIT II scores also did 
not correlate with the ERP measures, for the adults with DS. The study also 
has KBIT II measures for the control participants, a group on which the age 
standardization procedure was developed. In light of these findings, the thesis 
continues with the standardized scores.  
Summary 
neuropsych. 
measures 
GFP maxima 
time-windows 
(ms) 
 Associated 
ERP 
GFP Maxima  
(µV2) 
Latencies of GFP 
Maxima (ms) 
 r p r p 
 
CAMCOG 
100-200 MMN -.288 .089 .003 .984 
200-400 P3a -.263 .121 .172 .315 
400-650 P3b -.008 .963 .161 .347 
Summary 
neuropsych. 
measures 
GFP maxima 
time-windows 
(ms) 
 Associated 
ERP 
GFP Maxima (µV2) Latencies of GFP 
Maxima (ms) 
 r p r p 
 
EFDS 
100-200 MMN .191 .264 -.019 .911 
200-400 P3a .048 .780 -.046 .788 
400-650 P3b -.009 .961 .016 .925 
Summary 
neuropsych. 
measures 
GFP maxima 
time-windows 
(ms) 
 Associated 
ERP 
GFP Maxima (µV2) Latencies of GFP 
Maxima (ms) 
 r p r p 
 
KBIT II 
100-200 MMN -.345 .039 .162 .347 
200-400 P3a -.318 .059 -.014 .937 
400-650 P3b -.037 .829 .160 .353 
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5.6.2 Exploration of the Tower of London and scrambled boxes tasks   
 
Objective. To explore whether the ERPs distinguish between high and low 
scorers on specific neuropsychological measures (scrambled boxes, ToL) that 
are potentially sensitive to the functional decline associated with the early 
stages of AD in DS.   
 
Hypothesis. Participants who score lower on the executive function tasks 
(scrambled boxes and ToL) will shower smaller field intensities for MMN and 
P3b, but a larger field intensity for P3a, than higher scoring participants.  
 
5.6.2.1 Demographics of the dichotomized groups 
 
Independent samples t-tests for Equality of Means were conducted, with 
Equality of Variances assumed (p > .05) to find that the ‘lower’ scoring and 
‘higher’ scoring groups on the scrambled boxes task did not significantly differ 
in: age (p = .67), hearing acuity (p = .89), and IQ composite score (p = .43). A 
chi-square test of independence was performed to examine the relationship 
between gender (male, female) and group (lower, higher) to find no significant 
relationship: X2 (1, 29) = 1.51, p = .219. 
 
Independent samples t-tests for Equality of Means were conducted, with 
Equality of Variances assumed (p > .05) to find that the ‘lower’ scoring and 
‘higher’ scoring groups on the ToL task did not significantly differ in: age (p = 
.32), hearing acuity (p = .32), and IQ composite score (p = .46). A chi-square 
test of independence was performed to examine the relationship between 
gender (male, female) and group (lower, higher) to find no significant 
relationship: X2 (1, 29) = 2.78, p = .096. 
 
The demographics of the groups can be found in tables 5.5 and 5.6. 
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Table 5.5. Demographics of the groups dichotomized by scrambled boxes 
score. Sex (male) should be read as: number of females (number of males). 
Mean number of tones heard indicates the performance on the hearing acuity 
test. The IQ composite score is gained from the KBIT II. SD refers to the 
standard deviation of the immediately preceding column.  
 
 
Table 5.6. Demographics of the groups dichotomized by ToL score. Sex 
(male) should be read as: number of females (number of males). Mean 
number of tones heard indicates the performance on the hearing acuity test. 
The IQ composite score is gained from the KBIT II. SD refers to the standard 
deviation of the immediately preceding column. 
 
 
 
 
 
 
 
 
 
 
	 140 
5.6.2.2 Cluster analyses 
 
The relationship between participants’ (DS) performance (‘low’ vs. ‘high’) on 
the executive function tasks (scrambled boxes, ToL task) and field intensity of 
the ERPs (MMN, P3a, P3b) were explored in SPM. Masks were applied to 
refine the analysis windows to post-stimulus time frames where the ERPs of 
interest would be expected: MMN: 100-200ms, P3a: 200-400ms, P3b: 400-
650ms (see chapter 3, section 3.3). The SPM images were family wise error 
(FWE) corrected for multiple comparisons with Random Field Theory (RFT). 
 
The relationship between participants’ (DS) performance (‘low’ vs. ‘high’) on 
the scrambled boxes task and the field intensity of P3a was  
explored in SPM. A mask was applied to refine the analysis window to the 
time-course where a P3a response would be expected: 200-400ms (post-
stimulus). The SPM images were family wise error (FWE) corrected for 
multiple comparisons with Random Field Theory (RFT). The estimated 
Gaussian Full Width at Half Maximum (FWHM) smoothness was: 40.2mm x 
56.1mm x 55.0ms (9.5 x 10.4 x 13.8 voxels). The RESEL count (R) was 63.24 
(2dp):  
 
R = V / ( FWHMX × FWHMY × FWHMZ ) 
R = 86221/(9.5 x 10.4 x 13.8) (voxels)  
R = 63.24 (2dp)  
 
Consequently, the statistic images were assessed for cluster-wise 
significance using a cluster-defining threshold of p <.001 (2.5224e-05). The 
height threshold (F) was 19.37 (2dp), and the extent threshold (k) was 10 
voxels. One cluster was found at this FWE-corrected level (p <.001) of 872  
voxels. The cluster has three levels of local maxima (more than 8mm apart). 
The peak maximum was located 4x 9 x 252 (mm x mm x ms), with an effect 
size of 31.20 (2dp), at a FWE-corrected p <.05, significance level of p < .001. 
The maxima details are listed in table 5.7.  
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Table 5.7. Characterising the cluster in which ‘low’ and ‘high’ scorers on the 
scrambled boxes differ in P3a global field intensity. N = number of voxels from 
which the cluster and local maxima are derived. 1-3 = are the local maxima of 
the cluster, in descending order of strength, 1 is the peak maximum. Location: 
x = ranges from left to right (mm); y = ranges from posterior to anterior (mm); t 
= the latency of the ERP (ms). Z = Z-score. The FWE corrected significance 
level of the maxima is also listed (p <).  
 
The cluster location is detailed in figure 5.1.  
 
 
Figure 5.1. The contrasts are calculated for ‘low’ – ‘high’ scoring groups. The 
contrasts work upon the five experimental conditions: {'ld','ls','gd','gs','ad'}, 
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within the 50-650ms time frame. For the P3a contrast, a 200-400ms mask is 
used and the contrasts, inline with the conditions, are set up as:[0   1   0   0  -1   
0 -1  0  0  1]).  
 
  
The ‘low’ scorers have a significantly larger P3a field intensity than the ‘high’ 
scorers, on the scrambled boxes task. This is demonstrated visually in figure 
5.2. 
 
 
 
 
 
Figure 5.2. Results from scrambled boxes median split dichotomy: left – right, 
higher scoring group – lower scoring group. Each line maps an individual’s 
progression over the time course, with 0 indicating the stimulus. There is 
much higher variability in the lower scoring group. The P3a peak is mapped in 
the scalp maps. Red indicates positive activity, with blue indicates negative 
activity. P3a is a positive, fronto-central waveform, as reflected above. 
 
This method was used for all the ERPs (MMN, P3a, P3b) and both executive 
function tasks of interest (scrambled boxes, ToL) but no more significant 
clusters were found. The results were as demonstrated in figure 5.3.  
Higher Scorers Lower Scorers 
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Figure 5.3. The no significant clusters output. This output was seen for all the 
contrasts between all the ERPs (MMN, P3a, P3b) and executive function 
tasks of interest (scrambled boxes, ToL), except P3a with scrambled boxes.  
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5.7 Discussion  	
The correlational analyses found no relationship between the summary 
neuropsychological measures (CAMCOG, EFDS, KBIT II) and the ERP 
measures (MMN, P3a, P3b). This suggests that the subscales, which 
compose the summary measures either: 1. Do not individually correlate with 
the ERPs; or 2. Any subscale-ERP correlation effects are diluted by the other 
subscale non-relationships, when presented as a summary measure. The 
summary measures are composed of a large number of subscales, which 
would make individual explorations of all the subscales an insurmountable 
multiple comparisons problem. Therefore, this finding supports an argument 
for focusing on the subscales, which are literature-defined as most promising: 
ToL, scrambled boxes (Ball et al., 2008; Willner et al., 2010).  
 
Although the summary measures were not expected to map onto specific 
ERPs, the IQ composite measure (KBIT II) moderately correlated with MMN 
GFP maximum (r = -.345), and may have done so significantly if not for the 
multiple comparisons correction (p =.039). This correlation was with the IQ 
composite score, standardised by age, but the same result was found for a 
correlation with the raw IQ scores: r = -.323, p = .055 (see appendix Z). The 
summary neuropsychological measures were investigated based on having 
broad clinical utility, but by virtue of being broad measures they were viewed 
as unlikely correlates for the specific ERPs. However, in chapter 3 MMN 
significantly differed for the adults with DS and the TD controls. A key 
difference between the groups (DS, TD) is their mean IQ; therefore a potential 
relationship between IQ and MMN is not an unreasonable finding.   
 
In the focused analyses of the executive function tasks (ToL and scrambled 
boxes), which have been considered most sensitive to the early signs of AD  
(Ball et al., 2008), performance on the ToL did not significantly correlate with 
MMN, P3a or P3b responses. The ToL task was developed to assess 
planning and working memory (Krikorian et al., 1994). Perhaps this did not tie 
so readily into the electrophysiological (global-local) task demands, which 
weight more heavily towards learning than planning. However, performance 
	 145 
on the scrambled boxes task related to P3a. The ‘lower’ scorers on the 
scrambled boxes task had a significantly larger P3a field intensity than the 
‘higher’ scorers. This pattern mirrors that of the DS (lower scorers) and 
controls (higher scorers), in chapter 3. This potentially ties into issues with 
habituating, and inhibiting, a strong response to the rare deviant. The 
scrambled boxes task was designed to test working memory and response 
inhibition (Griffith et al., 1999). P3a is a fronto-centrally distributed potential 
(Polich, 2007), which has been suggested as an index of disinhibition (Fjell & 
Walhovd, 2004).  Executive functions are underpinned by the frontal lobes, 
the dysfunction of which is implicated in early indicators (Ball et al., 2008; Ball 
et al., 2010), and relates to potential prognostic indicators (Ball et al., 2006), 
of AD in DS. Therefore, the results suggest that P3a indexes an executive 
dysfunction (disinhibition), and relates to a sensitive task (scrambled boxes), 
implicated in early signs of AD in DS. Of course caution must be taken not to 
conflate behavioural and sensory inhibition.  
 
An alternative mechanism for the enlarged P3a response seen in DS could be 
“over-recruitment”. “Over-recruitment” refers to heightened brain responses, 
which are typically associated with better task performance. However, an 
fMRI study of typically developing older adults found that those with lower 
recall task performance had enhanced right PFC dominance (Cabeza et al., 
2002). There are three prevailing theories to explain this “over-recruitment’: 1. 
The lower scoring older adults are inefficiently using the same systems that 
they have always had, rather than engaging alterative mechanisms (Cabeza 
et al., 2002); 2. The activity is non-selective, the system has less control 
(Logan et al., 2002); 3. The more challenging the task the greater the 
resources, and congruent activity, required to succeed (Grady, 2008). These 
theories are not mutually exclusive, or directly testable within the framework of 
the present study. However, it does provide an interesting extrapolation as to 
why adults with DS who score lower on a neuropsychological measure might 
display a heightened P3a response.  
 
Of course, any “over-recruitment” model, which relates an enlarged P3a 
response to executive dysfunction, plays into an ID as well as AD mechanism. 
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This is an age-old problem of DS-AD research, parsing the ID from the AD 
(Deb et al., 2007). Indeed, Deb et al. (2007) argues that frontal compromise is 
a latter symptom in DS-AD but because gaining an AD diagnosis is so difficult 
in DS, the diagnosis does not occur until this latter stage, thus masquerading 
as an early clinical symptom. However, for the present study, there were no 
electrophysiological-neuropsychological relationships with global IQ 
performance (KBIT II) or global cognitive functioning (CAMCOG), which 
argues against the P3a-scrambled boxes connection being merely a reflection 
of global cognitive function, and suggests that there is something specific 
about the cognitive functions indexed by scrambled boxes task. Furthermore, 
if one subscribes to a model of early frontal compromise for DS-AD, this 
relationship could be potentially informative about early stages of the disease. 
 
P300 reflects both the capture (P3a) and maintenance (P3b) of attention. The 
presence of an enlarged P3a response, in the absence of a significant P3b 
response, is perhaps unsurprising if you consider the cognitive profile of DS. 
Implicit memory formation requires the capture but not necessarily the 
maintenance of attention (Graf & Schacter, 1985), whereas explicit memory 
formation requires the active maintenance of attentive processes (Graf & 
Schacter, 1985). In a study by Vicari, Bellucci, and Carlesimo (2000), 
designed to differentiate the memory types, children with DS had comparable 
implicit memory performance to TD children but impaired explicit memory 
performance. Furthermore, information encoding and attention control, which 
serves explicit memory processes, are significantly impaired in DS (Carlesimo 
et al., 1997; de Sola et al., 2015). Within a predictive coding framework, the 
local capture of attention is automatic (P3a) but a failure to encode, 
contextualize, then retrieve the information at a global level, would lead to a 
failure in response (P3b).  
 
The enlarged P3a response, in the present study, builds on the frontal shift in 
P3 seen in previous DS-EEG work (Kakigi et al., 1994; Vieregge et al., 1992). 
Previous studies have hypothesised that an enlarged frontal P3 (P3a) is a 
product of: 1. Disturbed P3b generation (Kakigi et al., 1994); 2. Habituation, 
and inhibition, deficiencies (Díaz & Zurron, 1995b), and 3. A reflection of 
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accelerated aging in DS (Kakigi et al., 1994). The present study addresses 
each of these hypotheses: 1. P3b generation was disturbed for adults with 
DS, compared to TD controls (chapter 3); 2. The enhanced P3a correlated 
with a cognitive measure of inhibition, which would suggest a relationship 
between the two (chapter 5); 3. The enhanced P3a response did not correlate 
with age, thus did not reflect accelerated aging (chapter 4). The next step is to 
explore the clinical value of an enlarged P3a, in terms of its predictive value 
for cognitive decline (chapter 6).  
 
5.8 Summary  	
In summary, a neuropsychological assessment (scrambled boxes), which 
poses congruent demands to the global-local paradigm (learning, attention), 
most readily mapped onto an electrophysiological product of the paradigm 
(P3a). A large P3a response for lower scorers on the scrambled boxes task 
unpicks the large P3a response seen for the DS group in chapter 3. This 
finding is potentially of clinical interest as the scrambled boxes task is 
considered one of the most sensitive measures to the early stages of AD in 
DS. The next step is to assess whether the electrophysiological measures 
have prognostic value for cognitive decline in DS (chapter 6).   
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6 Chapter 6. A preliminary exploration of EEG measures as 
predictors of cognitive decline  
 
6.1 Aim 	
To investigate the potential value of electroencephalographic (EEG) 
measures as predictors of cognitive decline in adults with Down’s syndrome.   
 
6.2 Objectives  	
1. To explore the relationship between different modes of imaging (PET, 
EEG), in the search for early markers of AD in DS.  
 
2. To explore whether the EEG measures (MMN, P3a, P3b) could predict 
cognitive change, one-year later.  
 
6.3 Introduction  	
6.3.1 Introductory paragraph 
 
The final stage of the thesis is to explore whether the EEG measures (MMN, 
P3a, P3b) have prognostic value for the cognitive decline associated with AD 
in DS. The thesis has built through the chapters. The initial comparison was 
between people with DS and age-matched controls, which found that people 
with DS had a significantly smaller MMN, larger P3a, and inconsistent P3b 
responses. Next, the factor of age was explored to find that MMN was smaller 
in older adults with DS but not the control group, which is suggestive of 
accelerated aging. Finally, the relationship with neuropsychological 
assessments was explored to find that lower performers (with DS) also had a 
larger P3a response. The predictive value of these ERP measures has been 
little studied and this thesis only aims for an exploratory analysis. 
Consequently, the previous findings in the thesis will form a strong basis for 
the hypotheses in the present chapter.  
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An investigation into early indicators of AD is important for facilitating early 
diagnosis and for the evaluation of potential therapeutic interventions. There 
is great interest in developing markers for preclinical stages of AD so that 
therapeutic interventions, when they become available, can be administered 
when there is still functionality to be preserved rather than the more 
challenging task of restoring lost functions (Jackson & Snyder, 2008). 
 
An exploratory investigation into potential early markers of AD was conducted 
with two distinct approaches:  
1. Multi-modal imaging: PET + EEG (objective 1) 
2. Longitudinal follow-up of cognitive data (objective 2)  
 
6.3.2  Introduction to objective 1 	
A subset of adults with DS also participated in an amyloid imaging study 
(ethics reference: 11/EE/0348), at a similar time to their EEG and 
neuropsychological assessments. As part of the amyloid imaging study 
participants underwent structural and functional MRI scans, as well as a PET 
scan. We planned an exploratory analysis of this unique, multi-modal dataset 
because: 1. PET and MRI scans are expensive, and potentially invasive, 
therefore it would be useful if a less invasive, less expensive technique (such 
as EEG) could be telling, at least initially, about beta-amyloid (Aβ) load and 
ease the screening process; and 2. Biomarkers of AD are most likely to be 
informative in combination (Humpel, 2011), which presents an argument for 
investigating a combinatory analysis of these modalities.  
 
The multi-modal analysis is specifically focused on the relationship between 
the EEG and PET scan data. The PET scan images Aβ load with the selective 
carbon–11 labelled radioisotope PIB (11C–PIB). A comparison of these 
modalities has been chosen as Aβ accumulation (PET) and synaptic 
dysfunction (EEG) appear prior to structural brain changes (MRI) (figure 6.1; 
Sperling et al., 2011). Therefore this small, exploratory analysis is focused on 
measures, which are sensitive to changes earliest in the AD time course.   
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Figure 6.1.  “Hypothetical model of dynamic biomarkers of AD” taken from 
Sperling et al. (2011, pg 21). Aβ accumulation and synaptic dysfunction 
appear prior to structural brain changes.  
 
Prior to the present amyloid study, which is detailed in Annus et al. (2015), 
PET imaging with PIB Aβ tracers have been conducted previously with the DS 
population. The first study was conducted by Landt et al. (2011), which was 
pilot, proof of concept work. The study found PET imaging to be safe and 
acceptable for the participants with DS. The ethical considerations of imaging 
work with potentially vulnerable adults was followed up by d’Abrera, Holland, 
Landt, Stocks-Gee and Zaman (2013), to confirm these safe and acceptable 
conclusions. The Landt et al. (2011) study, and the studies which followed 
(Annus et al., 2015; Handen et al., 2012; Hartley et al., 2014; Jennings et al., 
2015; Sabbagh et al., 2011), agreed a strong age effect with Aβ binding in 
DS. The studies found that Aβ binding, as indicated by PIB tracers, was 
generally absent in adults under 35 years old, but consistently present in 
adults over the age of 45 years. This intimate link with age is a relevant and 
potential confound for the present study, and AD research more widely.  
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In terms of investigating the sequence of Aβ binding throughout the DS brain, 
Handen et al. (2012) was the first to note a striatal beginning to the sequence. 
Hartley et al. (2014) proceeded to confirm this striatal predominance. The 
PET work by Annus et al. (2015), which forms the basis of the present 
analyses, confirmed the striatal finding and described the following sequence 
of Aβ binding spread, in a cross-sectional sample of adults with DS:  
1. Striatum 
2. Dorsal prefrontal cortex and anterior cingulate cortex 
3. Ventral prefrontal cortex and areas of the parietal lobe 
4. Lateral temporal cortex and the rest of the parietal lobe 
5. Primary sensory and motor areas 
6. Associative visual cortex, premotor cortex, and the rest of the temporal 
lobe 
7. Occipital lobe 
8. Thalamus and parahippocampal cortex 
9. Amygdala 
It is important to reflect on the pattern of Aβ accumulation, to provide 
biological foundations for the sequence of cognitive compromise in DS-AD.  
 
The comparisons between Aβ binding and cognition were restricted to the 
CAMDEX (including the CAMCOG-DS) in the Annus et al. (2015) study. The 
study found that Aβ deposition was associated with lower CAMCOG scores 
(Annus et al., 2015). The measure was developed by Ball et al., (2006) to be 
a meaningful assessment of cognitive decline associated with dementia for 
people with intellectual disabilities (ID). 1. The CAMDEX-DS informant 
interview takes into account parent/carer’s views on changes in the 
participant’s behaviour(s), which may be clinically meaningful. 2. The 
CAMCOG-DS is a cognitive assessment that is acceptable for people with ID 
and assesses domains, which may be compromised in AD development. The 
longitudinal follow-up portion of the present study is also limited to this robust 
assessment of cognitive decline.  
 
The focus of the present analysis is on the relationship between PIB binding 
(Aβ load) and the EEG measures (MMN, P3a, P3b). As EEG is a cortical 
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measure the analyses will be restricted to PIB binding in the cortex. P3b was 
recently explored as a potential AD diagnosis marker for “at risk” older adults 
(Bennys et al., 2017). The researchers found that P3b latency was 
significantly increased for the 15 adults who were identified, from PET 
imaging, as Aβ positive (Bennys et al., 2017). Furthermore, parietal P3b 
amplitude correctly categorised 69.4% of older adults into the Aβ positive 
group (Bennys et al., 2017). In light of these findings, we would hypothesise a 
potential relationship between P3b and PIB binding, in the present study.  
 
The current literature does not compare the other ERPs (MMN,P3a) with PIB 
binding, so the hypotheses are extrapolated from the findings with this group 
(DS) from the previous chapters. Firstly, MMN has been shown to be 
decreased, and latency increased, for older adults with DS (chapter 4), and as 
age is significantly related to abnormal PIB binding (Annus et al., 2015), a 
similar pattern may be expected in relation to abnormal PIB binding, in the 
present study. Secondly, participants with DS have shown larger P3a 
responses in relation to executive dysfunction (chapter 5). Executive functions 
are served by the frontal-lobes and are compromised early in DS-AD from 
both behavioural (Ball, Holland, Treppner, Watson, & Huppert, 2008), and PIB 
binding (Annus et al., 2015) perspectives. Therefore, we hypothesise that this 
pattern of an increased P3a may persist in relation to abnormal PIB binding.  
 
Given that markers of AD are most likely to be effective in combination 
(Humpel, 2011), it will be interesting to consider the interplay between the 
factors, with an exploratory analysis. Therefore, depending on whether there 
are independent relationships between the factors (PIB binding, EEG and 
longitudinal change in CAMCOG score) a combinatory, predictive model of 
CAMCOG score change will be explored.  
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6.3.3 Introduction to objective 2  
 
Longitudinal research is essential for identifying accurate predictors of AD.  
The present study includes an exploratory, longitudinal component in an 
attempt to ascertain the predictive value of the EEG measures (MMN, P3a, 
P3b) for cognitive decline. The study was designed with two phases. At the 
cross-sectional phase, an initial electroencephalographic (MMN, P3a, P3b) 
assessment and a range of cognitive tests (including CAMDEX-DS) were 
performed. At the longitudinal phase, approximately one year later, the 
cognitive assessment that is considered most sensitive to cognitive decline 
(CAMDEX-DS), was repeated. The CAMDEX-DS includes a cognitive 
assessment component (CAMCOG-DS) and an informant interview 
(CAMDEX-DS) (Ball, Holland, Huppert, Treppner, & Dodd, 2006).  
 
The present study assessed cognitive decline as the difference in CAMCOG 
scores between the cross-sectional and longitudinal phases. The most 
pertinent guidance for the present study, in the current literature, is a 
longitudinal cognitive investigation by Benejam et al. (2014). The study used 
CAMCOG to indicate that adults with DS who transitioned to a dementia 
diagnosis (within three years) declined by an average of -9.6 points at a one-
year follow up (Benejam et al., 2014). Furthermore, the memory, language 
and visual perception subscales were the primary targets of the decline. 
People with DS, who did not develop dementia, had a stable total CAMCOG 
score. However, when creating a dichotomy by age (>/< 40 years), the 
healthy older adults with DS showed decline on the memory subscale 
(Benejam et al., 2014).  
 
The present study is primarily concerned with ascertaining the predictive 
value of MMN, P3a and P3b for cognitive decline. This cognitive decline was 
assessed by a difference in CAMCOG score after one year. Chapter 5 used 
CAMCOG to assess global cognitive functioning, at a group level, and from a 
cross-sectional standpoint. In contrast, the present chapter aims to assess 
cognitive decline, at an individual level, and from a longitudinal standpoint. 
The ERPs were selected on the basis that they might be informative about 
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such decline, either by being: 1. A strong correlate (P3b) for AD (Ally et al., 
2006), or 2. Informative about frontal mechanisms (P3a), and pathology 
(MMN; Hughes & Rowe, 2013), which is an early symptom of DS-AD. 
Nevertheless, again, relationships between the ERPs and cognitive decline 
are not readily discussed in the DS literature. Therefore the hypotheses are 
predominantly based on the study findings from previous chapters, and 
tangible literature sources. 1. P3b is the most robustly associated ERP with 
AD so it is reasonable to assume that there would be a relationship with 
CAMCOG change, in a similar fashion of decreasing amplitudes and 
increasing latencies. 2. The MMN response was clearly decreased, and the 
latency increased, for older adults with DS (chapter 4); considering that age is 
intimately linked to cognitive decline and AD development, a similar 
relationship is expected here. 3. Finally, participants with DS who scored 
lower on a task of executive dysfunction showed larger P3a responses 
(chapter 5); considering that executive dysfunction is one of the earliest 
indicators of cognitive decline associated with dementia (Ball et al., 2008), this 
pattern may be repeated here.  
 
 
6.4 Hypotheses 
 
Hypothesis for objective 1: beta-amyloid 
Participants with more cortical Aβ are expected to show smaller GFP maxima 
for MMN and P3b, and longer latencies. Conversely, a larger GFP maximum 
for P3a is expected. 
 
Hypothesis for objective 2: longitudinal study  
The initial GFP maxima for MMN and P3b are expected to be smaller, and the 
associated latencies longer, for participants who decline on the CAMCOG 
measure. Conversely, a larger initial GFP maximum for P3a is expected.  
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6.5 Methods  
6.5.1 Design 
 
An initial electroencephalographic (EEG) and cognitive assessment followed, 
one year later, by a repeat cognitive (CAMCOG) assessment, was the 
standard study design for all the participants. However, a subset of 
participants also received beta-amyloid imaging at the initial assessment. The 
study design is expanded on, by objective, below. A schematic of the study 
design is detailed in figure 6.2.  
 
Objective 1: 11 participants with DS were enrolled in the amyloid imaging 
follow-up study (ethics reference: 11/EE/0348), as well as the EEG study. 
Consequently, these 11 participants had a Positron Emission Tomography 
(PET) scan within two months of their EEG assessment. The PET scanner 
used was a GE advance (General Electric Medical Systems, Milwaukee, WI, 
USA), the data was acquired in 3D mode at Addenbrooke’s Hospital, 
Cambridge. The PET scan lasted 90 minutes and used intravenously 
administered selective carbon–11 labelled radioisotope PIB (11C–PIB) to 
image the Aβ. Mr Liam Wilson and Dr Tiina Annus, from the Cambridge 
Intellectual and Developmental Disabilities Group, University of Cambridge, 
collected and analysed the PET data. Dr Annus defined the ROIs for PIB 
analysis by manually improving the Brodmann atlas in Colin27 space, 
collapsing across smaller Brodmann regions. The details of the PET scan and 
analysis details can be found in Dr Annus’ paper (Annus et al., 2015). Dr 
Young T. Hong and Dr Tim D. Fryer at the WBIC, University of Cambridge, 
conducted the kinetic modelling and reconstruction of PET data.	As EEG is a 
cortical measure the focus of the comparative PET analyses were on the 
‘Added Brodmann’ values, which reflect a global cortical region of interest 
(ROI).  
 
The amyloid study used the same neuropsychological assessments as the 
EEG study. The amyloid study also involved a 45 minutes MRI scan at 
Addenbrooke’s Hopsital, using a three Tesla Siemens Verio scanner 
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(Siemens AG, Erlangen, Germany). The focus of the analyses remains on 
comparisons between the EEG, neuropsychological and PET data.  
 
Objective 2: 35 participants with DS who completed the initial EEG 
assessment (MMN, P3a, P3b), which includes the 11 with a PET scan, were 
re-approached 10-14 months later (mean 12 months) for a follow-up cognitive 
assessment with the participant (CAMCOG), and informant-interview with the 
parent or carer (CAMDEX). The analyses are focused on the difference 
between participants’ CAMCOG scores at the cross-sectional phase (Time 1) 
and the longitudinal phase (Time 2). The total CAMCOG difference score is 
the score at Time 2 minus the score at Time 1 (T2-T1).  
 
 
 
 
Figure 6.2. A schematic of the study design: left to right is the chronological 
order of the study, the blue sections are cross-sectional, and the green are 
longitudinal. The numbered arrows denote the number of participants who 
transitioned from one phase of the project to the next. The numbered arrows 
from ‘Home Visit 2’ to ‘Cambridge Visit’ indicate that 36 participants 
completed the EEG assessment, of which 15 successfully had blood samples 
taken and 11 had PET (and MRI) scans. 35 of these participants transitioned 
to the ‘Longitudinal Phase’.  
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6.6 Results for objective 1  
 
Objective 1. To explore the relationship between different modes of imaging 
(PET, EEG), in the search for early markers of AD in DS.  
 
Hypothesis for objective 1. Participants with more cortical Aβ are expected to 
show smaller GFP maxima for MMN and P3b, and longer latencies. 
Conversely, a larger GFP maximum for P3a is expected. 
 
6.6.1 Demographics for the amyloid imaging study participants  
 
11 adults with DS participated in the amyloid imaging study and had a PET 
scan at a similar time to their EEG assessment. Of the 11 adults, 3 had a 
dementia diagnosis, 7 were male and 10 were right handed. Table 6.1 
provides more demographic and cognitive detail.  
 
Variable Minimum Maximum Mean  SD  
T1 Age (years) 37 52 45.4  4.94 
T1 KBIT IQ composite score  40 75 59.6 9.64 
T1 total CAMCOG score  65 101 86.6 11 
T2 total CAMCOG score 48 101 83.1 15.3 
T2-T1 total CAMCOG score  -17 3 -3.45 6.31 
 
Table 6.1. Demographics for the participants who took part in the EEG study 
and amyloid imaging study. T1 = time 1 (initial assessment), T2 = time 2 
(follow-up assessment). SD = standard deviation from the mean. The values 
are rounded to 3 significant figures (s.f.).  
 
As EEG is a cortical measure the focus of the comparative PET analyses 
were on the ‘Added Brodmann’ values, which reflect a global cortical region of 
interest (ROI). Aβ is visualized in a PET scan when bound to 11C–PIB, which 
generates PIB binding values. Table 6.2. provides details of participants’ PIB 
binding values, figure 6.3. visualizes the values.  
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Age Gender Added Brodmann 
37 F -0.022230067 
39 M 0.036087267 
43 F 0.159041754 
45 M 0.016788009 
45 M 0.399464693 
47 M -0.008080844 
47 M 0.067498316 
47 F -0.006233943 
51 M 0.422107944 
52 F 0.016097132 
53 M 0.689384281 
 
Table 6.2. The PIB binding scores for the participants, ranked in ascending 
order by participant age.  
 
 
 
 
 
 
Figure 6.3. The PIB binding scores for the participants, ranked in ascending 
order by age. The half black and white dots are participants with DS-AD.  
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6.6.2 Correlations between cortical beta-amyloid load and EEG 
 
The PIB binding values of the 11 participants for the global cortical ROI 
ranged from -.02 to .69 with a mean of .16 (SD = .24). Spearman’s Rank-
Order correlations were used to compare the global cortical ROI PIB binding 
values to the EEG measures (MMN, P3a, P3b). To correct for multiple 
comparisons, the Bonferroni correction was applied at p < .02 (=.05/3). No 
significant correlations were found at this level. The results of the correlations 
are shown in table 6.3. 
 
 
Table 6.3. Spearman’s Rank-Order correlations (two-tailed), between the PIB 
binding values for the global cortical ROI and ERPs (MMN, P3a, P3b); all 
values are rounded to 3 s.f.; the significance level is set at p < .02.  
 
Spearman’s Rank-Order correlations (two-tailed) to compare the global 
cortical ROI PIB binding values to the EEG measures (MMN, P3a, P3b), 
found a correlation coefficient (r-value) between MMN and PIB binding of -
.445. However, this relationship was not significant (p > .02) with the tested 
sample size of 11 adults with DS. However, a correlation coefficient of -.445, 
within a two-tailed test, and Bonferroni corrected significance level of p <.02, 
would be expected from a sample size of 47 (Hulley, Cummings, Browner, 
Grady, & Newman, 2013).  
 
 
 
 
PIB binding values 
for the global 
cortical ROI 
GFP maxima 
time-windows 
(ms) 
 Associated 
ERP 
GFP Maxima (µV2) Latencies of GFP 
Maxima (ms) 
   r p r p 
 100-200 MMN -.445 .170 .396 .265 
200-400 P3a .264 .433 -.303 .365 
400-650 P3b -.382 .247 -.382 .247 
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6.6.3  Correlations between cortical beta-amyloid load and total 
CAMCOG difference scores (T2-T1)  
 
A Spearman’s Rank-Order correlation (two-tailed), between the PIB binding 
values for the global cortical ROI (M = .16, SD = .24) and total CAMCOG 
difference (T2-T1) score (M = -3.45, SD = 6.31), found no significant 
relationship (r = -.229, p = .497). As cortical Aβ load did not correlate with the 
total CAMCOG difference score it is not an appropriate entry into a 
combinatory (with EEG) model of the variable.  
 
6.7 Results for objective 2 	
Objective 2. To explore whether the EEG measures (MMN, P3a, P3b) could 
predict cognitive change, one-year later.  
 
Hypothesis for objective 2. The initial GFP maxima for MMN and P3b are 
expected to be smaller, and the associated latencies longer, for participants 
who decline on the CAMCOG measure. Conversely, a larger initial GFP 
maximum for P3a is expected.  
 
6.7.1 Review of participant data  
 
Initially 35 of the participants with DS were followed up. On reviewing the 
researcher’s notes for all of the CAMCOG tests (T1 and T2), it was found that 
one participant (29 year old male), at T1, had fulfilled criteria for 
“uncooperative behavior”, “silly behavior” and “flat affect”. Additional notes 
from the researcher included: “gave up far too fast, just answering no or I 
don’t know to a lot of the questions.” There were no such notes on their 
follow-up test (T2). The differing states-of-mind of the participant most likely 
explains the vastly improved test-score (+16) between the two time points. 
The study is concerned with cognitive changes rather than changes in mood, 
presenting grounds for excluding the participant. The following analyses are 
focused on the remaining 34 participants.  
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6.7.2 Participant demographics for the follow-up study   
 
34 adults with DS completed initial (cognitive + EEG) and follow-up (cognitive 
only) assessments. Of the 34 adults, 3 had a dementia diagnosis at T1, 20 
were male and 32 were right handed. No participants transitioned to an AD 
diagnosis between T1 and T2. Table 6.4. provides more demographic and 
cognitive detail for the participants. Figure 6.4 is a graph of each participants’ 
cognitive results (CAMCOG total score) at the initial (time 1) and follow-up 
assessments (time 2).  Figure 6.5 depicts the spread and distribution of the 
group’s time 1 and time 2 CAMCOG scores.  
Figure 6.4. Graph of each participant’s total CAMCOG score at time 1 (T1: 
blue circle) and 2 (T2: red square). The vertical line between the points shows 
each participant’s change in total CAMCOG score between time 1 and 2. 
Participants’ are ranked in ascending order by their total CAMCOG score at 
time 1.  
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Figure 6.5. Boxplots of the participants’ with DS total CAMCOG scores at time 
1 and time 2, 10-14 months later.  
 
Variable Minimum Maximum Mean  SD  
T1 Age (years) 22 55 37.6 9.42 
T1 KBIT IQ composite score  40 88 55 12 
T1 total CAMCOG score  58 105 83.9 13 
T2 total CAMCOG score 48 104 82.4 14 
T2-T1 total CAMCOG score  -17 5 -2.06 4.77 
 
Table 6.4. Demographics of the longitudinal phase participants. T1 = time 1 
(initial assessment), T2 = time 2 (follow-up assessment). SD = standard 
deviation from the mean. The values are rounded to 3 s.f.  
6.7.3 Correlation between total CAMCOG difference scores and age  
 
A Spearman’s Rank-Order correlation (two-tailed) between participants’ total 
CAMCOG difference score (T2-T1) and age found no significant relationship: r 
= -.102, p = .561. Therefore, age is considered no further in the following 
analyses of CAMCOG difference scores (T2-T1).  
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6.7.4 Correlations between total CAMCOG difference scores and T1 EEG  
 
The Shapiro-Wilk Test of Normality indicated that the GFP maxima and 
latencies for all the associated ERPs (MMN, P3a, P3b), for the adults with DS, 
significantly differed to the normal distribution (p < .05). Therefore Non-
Parametric, Spearman’s Rank-Order correlations were used. To correct for 
multiple comparisons, the Bonferroni correction was applied at p < .02. This 
level was based on the three ERPs (MMN, P3a, P3b) being clustered in 
families of GFP maxima (µV2) and latency (ms): p < .05/ 3 = .02 (2 d.p.). The 
investigation is exploratory so the subsequent analyses are two-tailed.  
 
The 34 participants’ total CAMCOG difference score ranged from -17 to 5 
points with a mean change of -2.06 points (SD = 4.77 points). For participants 
with DS, the GFP maximum within 100-200ms (MMN) positively correlated 
with participants’ total CAMCOG difference score (T2-T1 performance): r = 
.506, p = .002. The relationship is displayed in figure 6.6. All other correlations 
between the total CAMCOG difference score and the GFP maxima (P3a, P3b) 
and latencies (MMN, P3a, P3b) failed to reach significance at the p <.02 level. 
The correlation values are displayed in table 6.5.  
 
 
 
Total CAMCOG 
difference score 
(T2-T1) 
  
GFP maxima 
time-windows 
(ms) 
 Associated 
ERP 
GFP Maxima (µV2) Latencies of GFP 
Maxima (ms) 
  r p r p 
100-200 MMN .506* .002 -.007 .969 
200-400 P3a .063 .723 -.036 .838 
400-650 P3b -.092 .603 .270 .123 
 
Table 6.5. Spearman’s Rank-Order correlations (two-tailed), between total 
CAMCOG difference scores (T2-T1) and ERPs (MMN, P3a, P3b); all values 
are rounded to 3 s.f.; * indicates correlations which are significant at p < .02 
level; T1 = (time 1) the initial cognitive test visit; T2 = (time 2), the follow-up 
visit 10-14 months after T1.  
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Figure 6.6. The relationship between cognitive difference scores (=T2-T1 total 
CAMCOG score) and mean GFP maxima (MMN). The half black and white 
dots are participants with DS-AD. One adult with DS-AD has shown a rapid 
decline in their total CAMCOG score, which, considering their diagnosis is 
perhaps unsurprising.  
 
6.7.5 Correlations between CAMCOG subscale difference scores and T1 
MMN 
To further explore the relationship between MMN GFP maxima and the total 
CAMCOG difference score, the seven separate subscales: orientation, 
language, memory, attention, praxis, perception, and abstract thinking were 
correlated with the MMN GFP maxima, using Spearman’s Rank-Order. For 
participants with DS, the GFP maximum within 100-200ms (MMN) positively 
correlated with participants’ total CAMCOG difference score (T2-T1 
performance) on the praxis task: r = .447, p = .008. The relationship is 
displayed in figure 6.7. All other correlations between the subscales and MMN 
GFP maxima failed to reach significance (p > .05). The results of the 
correlations are shown in table 6.6. 
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Figure 6.7. The relationship between praxis changes from T1 to T2 (=T2-T1 
praxis CAMCOG score) and Mean GFP maxima (MMN). The half black and 
white dots are participants diagnosed with DS-AD. 
 
CAMCOG subscale difference scores (T2-T1) Correlations with the MMN 
GFP Maxima (100-200ms) 
Subscale M SD r p  
Orientation  -.03 1.29 .088 .622 
Language .06 2.71 .184 .297 
Memory .11 2.91 .268 .125 
Attention -.23 1.11 .084 .636 
Praxis -.57 1.61 .447* .008 
Perception  .43 1.15 -.005 .976 
Abstract Thinking  -1.17 2.38 -.115 .516 
Table 6.6. Spearman’s Rank-Order correlations (two-tailed) between the 
difference scores (T2-T1) on the CAMCOG subscales (orientation, language, 
memory, attention, praxis, perception, and abstract thinking) and participants’ 
MMN GFP Maxima. All the values are rounded to 3 s.f.; *significant at p < .01;  
T1 = (time 1) the initial cognitive test visit; T2 = (time 2), the follow-up visit 10 
14 months after T1; M = mean CAMCOG subscale difference score; SD = 
standard deviation of the mean CAMCOG subscale difference score.  
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6.8 Discussion  	
6.8.1 Key findings 	
An exploratory investigation into potential electrophysiological predictors of 
the cognitive decline associated with AD development (in DS), was conducted 
with two distinct approaches:  
1. Multi-modal imaging: PET + EEG (objective 1) 
2. Longitudinal follow-up of cognitive data (objective 2)  
 
The key findings from the approaches were as follows:  
 
Objective 1. Cortical beta-amyloid load correlated with neither the EEG 
measures (MMN, P3a, P3b), nor cognitive change after one year (T2-T1 
CAMCOG score). As a result, a predictive, combinatory (EEG + PET) model 
of cognitive difference scores was not explored.  
 
Objective 2. Participants’ initial MMN correlated with the difference in total 
cognitive functioning, and praxis, a year later. The difference scores were 
calculated by subtracting participants’ CAMCOG performance at initial testing 
from their performance a year later (T2-T1 CAMCOG scores). All other 
correlations between cognitive difference and the EEG measures (P3a, P3b) 
failed to reach significance.  
 
6.9 General discussion  	
A relationship between Aβ load and cognitive decline may have been 
expected as Annus et al. (2015) found a relationship between CAMCOG 
scores and PIB binding with a similar cohort of DS participants. However, the 
Annus et al. (2015) comparison was made with cross-sectional CAMCOG 
scores rather than longitudinal change. Furthermore, due to the exploratory 
nature of the present study, the sample was limited to 11 participants, which is 
much less than the 49 participants with DS tested in the Annus et al. (2015) 
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study. The present study was also restricted to PIB binding in the cortex 
rather than exploring the whole brain.  
 
A cortical ROI for PIB binding was used, as EEG is a cortical measure. A 
whole cortical ROI was used, rather than fractioning by region because: 1. 
The poor spatial resolution of EEG makes localization difficult. 2. With adult 
aging there can be topographical shifts of ERP sources, for example MMN 
may present more parietally with increasing age (Anderer, Semlitsch, & 
Saletu, 1996). 3. The morphology of the DS brain is fundamentally different to 
that of the typically developing population with: reduced overall cortical 
volume (Lott, 2010); disproportionately diminished frontal lobes (Aylward et 
al., 1999); reduced neuronal density (Lott, 2010), amongst other features. 
Therefore, for an inclusive approach, which attempts to avoid these potential 
confounds, the whole cortex was analysed rather than fractioning by region. 
Moderate and medium effect sizes were shown for the relationships between 
the ERPs and PIB binding (see table 6.2.), although the relationships failed to 
reach significance (p >.02). Furthermore, post-hoc sample size calculations 
revealed that a sample of 47 participants with DS would have been expected 
to find a correlation coefficient of r = -.445 (MMN comparison with PIB), at the 
p < .02 significance level. Therefore, although no significant relationship was 
found between the PIB and EEG data in the present study of 11 participants, 
this finding should be tempered by the exploratory, and inherently 
underpowered, nature of the comparison.  
 
The focus of the present analysis is on cognitive change rather than raw 
cognitive performance because: 1. Lower CAMCOG scores at T1 did not 
predict lower CAMCOC scores at T2 (see figure 6.4.) and 2. Cross-sectional 
CAMCOG performance did not correlate with the ERP measures (see chapter 
5).  
 
The relationship between MMN and total change in CAMCOG score 
suggested that participants with smaller MMN were most likely to show the 
largest declines in CAMCOG score, after one year. Indeed, a visual inspection 
of the data (see figure 6.5) suggested that the 4 participants who dropped 
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more than 7 points over the course of the year drove the correlation between 
MMN and CAMCOG change. Previous work has suggested that adults with 
DS who transition to a dementia diagnosis (within three years) have the 
largest declines in CAMCOG score: an average of -9.6 points at a one-year 
follow up (Benejam et al, 2014). Therefore, if the largest declines in CAMCOG 
score have the strongest relationship with MMN, then this EEG measure may 
be applicable for predicting AD development. This hypothesis could be tested 
in future work with longer follow-up periods, in which time there is an 
increased chance of greater decline rates (>7 points), and transitions to an 
AD diagnosis.  
 
The CAMCOG subscales were investigated to unpick the relationship with the 
total score. The exploratory analysis found a relationship between MMN and 
praxis change. A smaller MMN, at the initial assessment, predicted a decline 
in praxis performance a year later. The praxis subscale is used to assess the 
voluntary motor functions of drawing and performing actions to command 
(Ball, Holland, Huppert, Treppner, & Dodd, 2006). As part of the subscale, 
participants are asked to copy drawings of varying difficulty: circle, square, 
house and clock (Ball et al., 2006). Participants are also asked to demonstrate 
how they would perform actions, such as waving and cutting with scissors 
(Ball et al., 2006). The enaction of these skills requires planning and voluntary 
motor selection, which are functions served by the associative striatum 
(Jankowski, Scheef, Hüppe, & Boecker, 2009). The associative striatum 
encompasses the precommisural putamen and caudate nucleus, of the dorsal 
striatum, which receive projections from the frontal and prefrontal cortices 
(Afifi, 2003; Jarbo & Verstynen, 2015). With the biological underpinnings of 
praxis in mind it is interesting to consider the typical pattern of Aβ 
accumulation as people with DS age: beginning at the striatum then moving to 
the frontal lobes (Annus et al., 2015; Handen et al., 2012; Hartley et al., 
2014). The early vulnerability of areas involved in praxis to Aβ accumulation 
suggests that performance on this subscale might be informative about early 
cognitive compromise in DS-AD.  
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There are complexities and limitations of the study design, which will be briefly 
discussed here and more extensively tackled in chapter 7. Due to the time-
constraints of PhD, the follow-up was limited to one year later, and only 
contained a cognitive component. This feeds into the challenges of dementia 
research more generally: the protracted nature of AD versus the narrow 
sampling window that is feasible within a research context. Furthermore, the 
sample is small, and the number of participants who declined significantly 
over the course of the year, smaller still. However, the results suggest that 
MMN may have potential for predicting cognitive decline in adults with DS, as 
indexed by the CAMCOG assessment. How MMN fairs as a potential 
biomarker against the criteria set out by Humpel (2011) will be addressed in 
the general discussion (chapter 7).  
 
6.10 Summary 	
The overarching aim of this thesis has been to investigate the potential value 
of EEG measures as predictors of cognitive decline.  The chapters have built 
on one another in an effort to achieve this over-arching aim: Firstly, 
establishing a baseline of how adults with DS differ from typically developing 
individuals on the measures used; secondly, exploring the premature aging 
hypothesis in DS; thirdly, looking at the relationship between the 
electrophysiological and neuropsychological, focusing on executive 
dysfunction as one of the first markers of AD in DS; finally, moving from 
markers to predictors, exploring EEG predictors of cognitive decline in DS. 
The general discussion (chapter 7) will use the information gathered in these 
chapters to evaluate EEG as a biomarker of AD, within the context of DS 
research.  
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7 Chapter 7. Discussion  
 
7.1 Thesis aims  	
The overall thesis aims were addressed in each of the findings chapters:  
 
1. To use electroencephalographic measures (MMN, P3a, Pb) to compare 
adults with Down’s Syndrome and typically developing controls, within a 
predictive coding framework (chapter 3).  
 
2. To use electroencephalographic measures as a means of testing the 
accelerated brain aging hypothesis in Down’s Syndrome (chapter 4).  
 
3. To explore whether electroencephalographic measures relate to a 
range of neuropsychological measures, that have been reported to be 
sensitive to the functional decline associated with the early stages of 
Alzheimer’s disease in Down’s Syndrome (chapter 5). 
 
4. To investigate the potential value of electroencephalographic measures 
as predictors of cognitive decline in adults with Down’s syndrome 
(chapter 6).   
 
7.2 Study outline  	
The over-arching aim of the thesis has been to investigate the potential value 
of EEG measures as predictors of cognitive decline. A high-density EEG array 
net was used to acquire EEG data on MMN, P3a and P3b, from 36 adults with 
Down’s Syndrome (DS) and 39 age- and gender-matched typically developing 
(TD) controls. The EEG data was analysed in three ways in an attempt to 
achieve the over-arching aim. Firstly, the extent to which the EEG measures 
differ, but are comparable, between adults with DS and TD adults was 
established. Secondly, the EEG measures were used to explore the 
premature neurological aging hypothesis of DS. Thirdly, the cross-sectional 
relationship between the electrophysiological and neuropsychological 
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measures was established: the focus being on neuropsychological measures 
of executive dysfunction, which is one of the first markers of Alzheimer’s 
disease (AD) in DS. With these findings, finally, the thesis transitioned from 
markers to predictors, by exploring EEG as potential predictors of cognitive 
decline. The main limitations of the study include the potential confounds of 
intellectual disability and age; the generalizability of the research beyond the 
sample; and the practical challenges of performing all of the required 
measures and recruiting adults with DS-AD.  
 
7.3 Abstract of main findings 	
This thesis initially compared adults with DS to TD controls, to find that the 
participants with DS had significantly: smaller MMN, larger P3a, and 
inconsistent P3b responses. Next, the factor of age was explored to find that 
MMN was smaller in older adults with DS but not the control group, which is 
suggestive of accelerated aging. Then, the relationship with 
neuropsychological assessments was explored to find that lower performers 
(with DS) also had a larger P3a response. Finally, the prognostic value for 
cognitive decline was explored to find a relationship between MMN and total 
cognitive change, and praxis changes.  
 
7.3.1 The relationships between the findings  		
• Adults with DS showed a large P3a response in chapter 3. The lower 
scorers on an executive functioning task showed the same enlarged 
P3a response in chapter 5. 
• MMN showed a relationship with advancing age in chapter 4, and 
predicting cognitive decline in chapter 6.  
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7.4 Summaries of the main thesis findings, within the context of the 
literature 
 
7.4.1 Using EEG measures to compare adults with Down’s Syndrome to 
typically developing controls  
 
The thesis began by establishing a baseline of how the ERPs of interest 
(MMN, P3a, P3b) appear for adults with DS, compared to age- and gender-
matched TD controls. The purpose of the initial comparison was to confirm 
that although the ERPs are likely to differ quantitively between groups, they 
do not differ qualitatively. This chapter was a chance to confirm and update 
the limited ERP data for adults with DS, and establish a time-window of 
interest for a novel form of ERP measurement, with this group: global field 
power (GFP).  
 
In line with previous research, participants with DS showed significantly 
smaller MMN (Arisi et al., 2012; César et al., 2010; Lalo et al., 2005), and P3b 
(Blackwood et al., 1988; César, Caovilla, Munhoz, & Ganança, 2010; Kakigi, 
Neshige, Matsuda, & Kuroda, 1994; Lalo, Vercueil, Bougerol, Jouk, & Debû, 
2005; Medaglini et al., 1997; Seidl et al., 1997; St. Clair & Blackwood, 2013; 
Vieregge, Verleger, Schulze-Rava, & Kömpf, 1992; Wetter & Murphy, 1999) 
responses, than TD controls.  
 
This chapter also showed that whilst the controls showed a standard P3b 
response, the adults with DS showed a very large P3a response. This finding 
could be tied into a relationship between the cognitive profile of DS and the 
differing attentional demands of the P300. Attention control and encoding are 
particularly impaired in DS (de Sola et al., 2015), meaning that attention can 
be captured (enlarged P3a), but not necessarily maintained and encoded (no 
P3b).  
 
Having established the waveforms at a group level, the following chapters go 
on to explore the effects of: age (chapter 4), executive dysfunction (chapter 
5), and cognitive decline (chapter 6). 
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7.4.2 The accelerated aging hypothesis of Down’s Syndrome  
 
This chapter used the ERP measures (MMN, P3a, P3b) as a means of 
comparing aging between adults with DS and TD individuals, with a view to 
exploring accelerated neurological aging in DS. As would be expected from 
ERP-aging research with the TD population (Alain, McDonald, Ostroff, & 
Schneider, 2004; Alain & Woods, 1999; Bertoli, Smurzynski, & Probst, 2002, 
2005; Cooper, Todd, McGill, & Michie, 2006; Czigler, Csibra, & Csontos, 
1992; Horváth, Czigler, Birkás, Winkler, & Gervai, 2009; Horváth, Czigler, 
Winkler, & Teder-Sälejärvi, 2007; Karayanidis et al., 1995; Kisley, Davalos, 
Engleman, Guinther, & Davis, 2005; Pekkonen et al., 1996; Pekkonen, 2000; 
Rimmele, Sussman, Keitel, Jacobsen, & Schröger, 2012; Schiff et al., 2008; 
Tsolaki, Kosmidou, Hadjileontiadis, Kompatsiaris, & Tsolaki, 2015; Woods, 
1992), for the adults with DS the MMN decreased with age and the latency 
increased.  
 
However, there was no age effect on the ERPs for controls, which could be a 
product of youth. Previous aging research with TD controls classed older 
adults as 60+ years (Tsolaki et al., 2015). In contrast, the present study 
classed older adults as 40+ years because this is a critical age for adults with 
DS in terms of when abnormal beta-amyloid (Aβ) binding begins (Annus et al., 
2015; Handen et al., 2012; Hartley et al., 2014; Jennings et al., 2015; 
Sabbagh et al., 2011). Indeed, a comparison based on this dichotomy found 
that the younger adults (< 40 years old) were similar across groups (DS, 
controls); whereas older adults with DS (< 40 years old) had a significantly 
smaller MMN than older controls.  
 
The relationship between age and MMN in DS, against an absence for age-
matched TD controls, presents a tentative argument that the cortical 
processes, and structures, which generate MMN show accelerated aging in 
DS.  
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7.4.3 Executive dysfunction in Down’s Syndrome  
 
The summary cognitive measures (CAMCOG, EFDS, KBIT II) are useful 
clinically but, as expected, reflect a wide range of functions that do not readily 
map onto specific electrophysiological processes (MMN, P3a, P3b). However, 
a neuropsychological assessment (scrambled boxes) which is considered to 
be sensitive to the early behavioural changes seen in DS-AD (Ball et al., 
2008), was related to an electrophysiological component (P3a). Indeed, the 
enlarged P3a response seen in the DS-controls comparison was unpicked by 
this neuropsychological-electrophysiological relationship. Adults who scored 
lower on the scrambled boxes task showed significantly larger P3a field 
intensities than higher scorers. These components (scrambled boxes, P3a) 
both tie into inhibitory mechanisms (Fjell & Walhovd, 2004; Griffith et al., 
1999). However, care must be taken not to conflate behavioural (scrambled 
boxes) and sensory (P3a) inhibition.  
 
An alternative mechanism for the enlarged P3a response seen in DS could be 
“over-recruitment”: heightened activity. There are three prevailing theories for 
an over-recruitment model of the enlarged P3a response in lower scoring 
adults with DS: 1. Systems are being used inefficiently, and there is a failure 
to engage new pathways (Cabeza et al., 2002); 2. The systems are being 
engaged in an inefficient and uncontrolled manner (Logan et al., 2002); 3. The 
task is more challenging for lower scoring participants, therefore more 
resources, and congruent activity, are required (Grady, 2008). Although these 
theories cannot be directly tested within the framework of the present study, 
they provide an interesting extrapolation for future work. 
 
Having established a cross-sectional relationship between 
electrophysiological (P3a) and neuropsychological (scrambled boxes) 
measures; the next step was a longitudinal exploration of the 
electrophysiological measures as prognostic indicators for cognitive decline in 
DS.   
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7.4.4 Cognitive decline in Down’s Syndrome  
 
The overarching aim of this thesis has been to investigate the potential value 
of EEG measures as predictors of cognitive decline. Chapter 6 employed two 
approaches in an attempt to achieve this aim: exploring the relationship 
between different modes of imaging (EEG, PET) and, assessing whether EEG 
measures (MMN, P3a, P3b) could predict cognitive change (T2-T1 
CAMCOG), one year later.  
 
The cortical Aβ load, gleaned from the PET scans, correlated with neither the 
EEG measures, nor cognitive change after one year. However, how Aβ 
accumulates in the DS brain is of interest considering that an EEG measure 
(MMN) predicted decline on praxis. For older adults (40+ years) with DS, Aβ 
begins by accumulating in the striatum before moving to the frontal lobes 
(Annus et al., 2015; Handen et al., 2012; Hartley et al., 2014), and these 
fronto-striatal circuits serve the motor function of praxis.  
 
A global cognitive change (T2-T1 CAMCOG total score), after one year, was 
predicted for participants with a smaller MMN at the initial assessment. 
Indeed, an inspection of the data found that participants with the largest drops 
in score (> 7 points) predominantly drove the relationship between MMN and 
CAMCOG change. This observation is of interest considering that a 
longitudinal, cohort study of 44 adults with DS found that those adults (10) 
who developed dementia showed an accelerated rate of change to their 
CAMCOG scores, averaging at  -9.6 points after the first year (Benejam et al., 
2014). In the present thesis, no participants made the transition to dementia. 
This limitation leaves it to future work to assess whether cognitive decline, 
predicted by lower MMN and indexed by CAMCOG change, is indicative of 
AD development in DS.  
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7.5 Evaluation of EEG against biomarker criteria 
 
The definition of a ‘biomarker’ is: “a characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic 
processes, or biological responses to a therapeutic intervention” (Biomarkers 
Definitions Working Group., 2001). This thesis has focused on evaluating 
electroencephalography (EEG) as measure of the typical biological process of 
aging, and as a potential indicator for the pathological development of AD in 
DS. 
 
‘Criteria for establishing a good biomarker for the diagnosis of dementia’ have 
been set out previously by Humpel (2011, p. 27, box 1). However, the criteria 
set out by Humpel (2011) were focused on evaluating blood and cerebral 
spinal fluid biomarkers. Therefore, the present project used a refined and 
categorised version of the criteria so potential electroencephalographic 
markers of AD could be evaluated. Please see table 7.1, for the refined 
criteria and how the present, and future, EEG work can be evaluated against 
it.  
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Table 7.1. Criteria for evaluating EEG as a marker of AD for the present 
project and future investigations. Adapted from ‘criteria for establishing a good 
biomarker for the diagnosis of dementia’ by Humpel (2011, p. 27, box 1).  
From this exploratory study, MMN seems to be the most promising candidate 
for indicating cognitive decline, as measured by the CAMCOG. Indeed, the 
ERP measure is related to both cognitive decline and age (Chapter 4), as 
independent variables, which satisfies much of the “sensitivity” criteria for a 
good biomarker. Furthermore, the inexpensive and non-invasive nature of 
EEG technology satisfies the “feasibility” criteria. The key issue with the 
study’s evaluation of potential EEG markers is the focus on cognitive decline 
rather than a specific sensitivity to the diagnostic development of AD. 
Unsurprisingly, as the cognitive follow-up was only one year after the initial 
assessment, no one transitioned to a dementia diagnosis, which inevitably 
limited the analysis to cognitive decline rather than diagnostic transition. The 
study is a small-scale, preliminary exploration of ERPs as markers for 
cognitive decline. Consequently, although the technology is widely available 
for reproducing the results in other laboratories, the work has yet to be 
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conducted. Therefore it remains for future work to satisfy the “scientifically 
robust” criteria. The findings suggest that EEG markers are potentially 
feasible and sensitive to cognitive decline. Future explorations with larger 
cohorts, followed over longer periods of time, will tell if the markers retain 
feasibility in terms of scientific rigour, sensitivity and specificity to AD.  
 
7.6 Considerations, challenges and limitations 
7.6.1 Potential confounds 
 
The thesis confounds are largely discussed in terms of the common 
comorbidities with AD: ID, age, and epilepsy. An AD diagnosis is inherently 
difficult to make for adults with DS (Deb et al., 2007; Nieuwenhuis-Mark, 
2009; Strydom et al., 2010; Zeilinger et al., 2013), largely due to difficulties in 
parsing the associated ID with the development of dementia symptoms 
(Sheehan et al., 2015). Furthermore, the approaches taken to making a 
dementia diagnosis in DS are numerous, and inconsistent, across studies 
(Nieuwenhuis-Mark, 2009). Nevertheless, Nieuwenhuis-Mark (2009) does 
recommend the semi-structured informant interview: CAMDEX-DS (Ball, 
Holland, Huppert, Treppner, & Dodd, 2006), which was used to diagnose 
dementia in the present study. However, an informant interview is inherently a 
reflection of the parent/carer’s view of the participant’s functioning, which is 
frequently slanted towards changes which are most obvious and have the 
largest impact on the informant’s life (Nieuwenhuis-Mark, 2009). 
 
The ID associated with DS can not only confound a dementia diagnosis 
(Sheehan et al., 2015), but interact with symptomology development. In 
relation to the EEG findings of the present thesis, the stereotypical difficulty 
with maintaining attention in DS is a key, confounding, cognitive deficit. P3b is 
contingent on the active maintenance of attention, which is a difficult activity 
for adults with DS (de Sola et al., 2015; Grieco, Pulsifer, Seligsohn, Skotko, & 
Schwartz, 2015). Given this cognitive deficiency, it is perhaps unsurprising 
that issues with attention maintenance were reflected in difficulties in 
generating a consistent P3b response. P3b is the most consistently used 
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potential for investigating AD in the TD population (Ally, Jones, Cole, & 
Budson, 2006). In the present thesis, the unreliable P3b result may be a 
reflection of how the pre-morbid DS cognitive phenotype interacted with EEG 
development. P3b may thus be an inappropriate measure for investigating the 
development of DS-AD. From a further cognitive standpoint, subjective 
memory complaints are a significant AD symptom, which are also affected by 
attention difficulties (Dubois et al., 2014). These findings present the 
argument for longitudinal investigations of DS-AD: comparisons with 
participants’ own baselines rather than cross-sectional comparisons between 
individuals. This thesis has made an exploratory attempt at this research 
method with a longitudinal, cognitive follow-up after one year, to investigate 
the relationship with participants’ initial EEG findings. 
  
 
There is debate as to whether AD development is related to a critical “age” 
range, or is an inevitable part of the “aging” process (Ritchie & Kildea, 1995). 
Nevertheless, there is an intimate and irrefutable link between age and AD. 
As a consequence, controlling for age effects can also control for AD effects. 
As the EEG data was not normally distributed, the present thesis attempted to 
tackle age effects, when age effects were not the primary outcome measure, 
by assessing whether there was an independent effect on the variable of 
interest, with a series of Spearman’s Rank-Order correlations. For example, 
both age (chapter 4) and cognitive decline score (chapter 6) correlate with 
MMN but they do not correlate with one another (chapter 6). Therefore, the 
assumption is that the effects of the variables on MMN are independent. 
Please see figure 7.1 for a visualisation. The system is by no means perfect, 
but does make logical and meaningful assumptions from the non-parametric 
data.  
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Figure 7.1. Schematic for how cognitive decline and age both correlate with 
MMN, but not one another, therefore we can assume that their relationships 
with the variable (MMN) are independent.  
 
Late-onset epilepsy is a common occurrence for adults with DS-AD (Evenhuis 
et al., 1990; Lai et al., 1989; Mendez & Lim, 2003). This thesis is concerned 
with using EEG measures to research cognitive decline, and EEG measures 
are typically used in epilepsy clinics; therefore, epilepsy is a relevant and 
potential confound to this work. Due to timing and staffing, a neurophysiologist 
did not examine the EEG recordings. However, none of the participants had 
an epilepsy diagnosis. Furthermore, only three participants had a DS-AD 
diagnosis, and this is the group that would be at highest risk for late-onset 
epilepsy.  
 
As only three participants had a DS-AD diagnosis, their data was considered 
in the homogenous, DS group analyses. This decision was made because: 
three is too small a group for independent analyses; the removal of the three 
both detracts from the overall sample size and fails to acknowledge the 
contributions from these participants. Furthermore, considering the difficulties 
of diagnosing AD in DS (Deb et al., 2007; Nieuwenhuis-Mark, 2009; Strydom 
et al., 2010; Zeilinger et al., 2013), combined with the inevitability of AD 
pathology in this group (Ball et al., 2006;  Holland et al., 1998; Mann, 1988, 
2006), all of the participants could be considered to be on a spectrum of 
deterioration. Where participants met criteria for a dementia diagnosis, based 
on the ICD-10 and a psychiatrist’s review of the CAMDEX-DS, they have 
been highlighted in visualisations of the data. The performance of adults with 
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DS-AD do not cluster, instead they were disparate, leading us to believe that 
they were not skewing the findings, but instead add to the power of the study.  
 
7.6.2 Generalisability 
 
As one of the primary concerns of the research was investigating premature 
aging in adults with DS, care was taken to recruit approximately 10 adults per 
decade (20s, 30s, 40s, 50s) in both the DS and TD control groups. The 
groups were also matched for gender. Nevertheless, it is acknowledged that 
these adults are a self-selecting group for research, which may not 
necessarily be representative of the population.  
 
For the adults with DS, the average life expectancy is 57.8 years old for 
women and 61.1 years old for men, in developed countries (Bittles et al., 
2007; Glasson et al., 2003). Consequently, the study is inherently limited to an 
investigation of aging, up to the 50s, and this is for both groups (DS, controls), 
as they were age-matched. For the present study, the effect of age on MMN 
was limited to the adults with DS. The thesis has discussed this finding as a 
reflection of accelerated aging as the adults with DS are reaching this MMN 
reduction first. Previous research with TD controls has found an age effect 
with MMN when older adults were considered to be 60+ years (Tsolaki et al., 
2015). Therefore, more confidence in the premature aging hypothesis could 
be found by adding an older control group.  
 
Another product of the reduced life-expectancy in DS (Bittles et al., 2007; 
Glasson et al., 2003), is preferential sampling. The recruitment of adults in 
their 50s was particularly difficult, especially because there are high rates of 
AD pathology in this age-range (Mann, 2006). Adults with co-morbid DS-AD 
were less likely to be recruited because they are considered a more 
vulnerable group, and are more likely to be supported by carers rather than 
parents. The care homes that were prepared to engage with and support 
research were included in the study whereas those that were not remain an 
unknown quantity. Every effort was made to engage with care homes, and the 
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large demands on carers’ time that research requires, from reimbursing the 
care home for the carers’ time to organising taxis to pick up and drop off 
participants, from local homes. Nevertheless, it was particularly difficult to 
engage adults with DS-AD, potentially because of the misconceptions around 
“research”. Furthermore, none of the participants transitioned to a dementia 
diagnosis over the course of the longitudinal study. As a result, the thesis is 
limited to an investigation of cognitive decline rather than predicting AD 
development.  
 
For the controls, every effort was made to generate a representative sample 
by using ‘Join dementia research’ (JDR), which is a national database. The 
JDR control participant search criteria quickly gained female participants 
within 15 miles of Cambridge. However, males were particularly difficult to 
recruit, resulting in the search radius increasing to 50 miles of Cambridge. 
The large search radius had the advantage of capturing participants outside of 
the ‘Cambridge bubble’, in an attempt to generate a potentially more 
representative IQ range.  
 
7.6.3 Practical challenges 
 
AD is a protracted disease from which a PhD research project necessitates 
studying a narrow sampling window. Consequently, although the thesis has 
included a longitudinal component, the follow-up is only after one year, which 
limits the focus of the thesis to cognitive change rather than AD development.  
 
The modality of stimuli delivery when eliciting ERPs was an important 
consideration in the context of DS because problems with vision and to a 
lesser extent hearing are frequently reported in this population (Lott, 2010). 
Consequently, the ERPs were elicited in the auditory domain as auditory 
compliance is easier to maintain than visual (Bekinschtein et al., 2009). To 
identify potential hearing problems, participants’ hearing was screened at the 
home visit and the tones were played during testing at a level that was 
considered comfortable for each participant.  
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For the global-local paradigm, striking the balance between what was 
achievable for adults with ID, yet still engaging enough for TD controls, was a 
challenge. The global effect (P3b) is premised on participants actively 
engaging with the task, which typically requires participants to count groups of 
sounds (Bekinschtein et al., 2009). Nevertheless, the global effect has been 
observed in some minimally conscious adults, meaning that the verbal recall 
of group numbers is not necessary to generate the effect (Bekinschtein et al., 
2009). In the present study, participants were asked to describe the groups of 
sounds, rather than the more demanding task of both identifying the groups, 
and counting them. The TD controls were able to focus on the task and 
generated a robust P3b effect. However, most adults with DS struggled to 
maintain their attention on the task and move beyond the verbal recall of rare, 
deviant sounds. Consequently, the adults with DS showed a large, attention 
capture, P3a response but failed to show attention maintenance with a 
consistent P3b response. This finding suggests that although the paradigm is 
very effective for generating attention independent responses in DS (MMN, 
P3a), it may not be appropriate for generating an attention contingent 
response (P3b).  
 
The perceived difficulty of the task can influence the nature of the P300 
response (Polich, 2007). For easier tasks there are more parietal, P3b 
influences in the response; whereas harder tasks elicit more frontal, P3a 
responses (Polich, 2007). In this way, the perceived difficulty of the task can 
present issues in generating a consistent P300 effect. This difficulty distinction 
was reflected in the findings: a P3a dominated response for adults with DS, 
and a P3b response for the control participants (chapter 3). As the groups 
were so heterogeneous in ability it was very difficult to match both within- and 
between- groups in terms of difficulty, whilst still maintaining a comparable 
paradigm. The present study chose to use the same paradigm for all 
participants, in the interests of parity at a stimulus level. Future work could 
attempt to distinguish the effects of perceived difficulty by using a paradigm in 
which perceptual difficulty is gradually, and sequentially, increased. A study of 
this type would accommodate individuals’ ability levels, whilst still providing 
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some directly comparable data in which the same stimuli are tested with both 
groups.  
 
From a practical standpoint, it was extremely difficult to gain blood samples 
from the adults with DS, which meant that consequent blood analyses, such 
as ApoE status, could not meaningfully be performed. A research nurse who 
was trained in phlebotomy took the blood samples for the present study. 
However, future work may consider recruiting a phlebotomist who specialises 
in difficult cases.  
 
During the EEG analyses the researcher was blind to the participant’s identity, 
however the group to which they belonged (DS, controls) was discernible. A 
participant’s group was recognisable based on their identification number: 
controls < 40. Furthermore, the DS EEG data was significantly noisier than 
the control data. Therefore, even if the identification numbers had been 
randomised, it would still have been obvious during pre-processing (step 4) 
which group an individual belonged to. Nevertheless, this lack of blinding 
leaves the study potentially vulnerable to unknowing bias by the researcher. 
In contrast, the follow up study was undertaken blind to each participant’s 
initial EEG result. 
 
7.7 Future directions  	
7.7.1 Developing the research  
 
Based on the limitations and challenges of the present work, the key 
improvement to the study would be the addition, or expansion, of the following 
groups: older controls, DS-AD, generalised ID, and abnormal Aβ binding.  
 
For a more comprehensive review of aging, a larger age range of participants 
is required. Recruiting older adults with DS is challenging due to life-
expectancy restrictions, which has recently been reported at between 50 
(Coppus, 2013) and 60 years old (Glasson et al., 2003). However, a cohort of 
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older adults (60+ years) from the typically developing population would 
provide more certainty to the claims that aging in DS is premature, as 
measured by ERPs, and that control participants will eventually demonstrate a 
similar progression.  
 
Due to recruitment difficulties, the present thesis only included three adults 
with DS who also have a diagnosis of AD. Consequently, in order to 
meaningfully include these adults in the analysis, their data has been 
collapsed into the DS group and their presence highlighted, as appropriate, on 
the graphs. The ultimate aim of the research is to assess whether the ERPs 
are useful predictors of AD development. As nobody developed AD over the 
course of the present study, the present study is limited to an exploration of 
cognitive decline (as measured by CAMCOG), which may, or may not, be 
indicative of AD development. AD is a protracted illness, and the present 
study only takes a small snapshot of adults with DS progression on that 
trajectory. As always with AD research, the only way to truly track the 
progression towards the disease is to take a larger sampling window. The 
present study includes a one-year follow-up with some promising results; 
repeated cognitive follow-ups at five-year intervals would be an excellent 
addition.  
 
 
As always with DS-AD research there is the issue of disentangling the 
cognitive compromise due to the ID, from the development of AD. For this 
reason, longitudinal work is of particular importance with this group in order to 
focus on individual change rather than cross-sectional performance. As 
chapter 3 displayed, the ERPs (MMN, P3a, P3b) are quantitatively different 
between adults with DS and TD controls. It was beyond the time constraints of 
the present study, but the addition of a group of IQ matched adults with ID, 
but without a DS diagnosis, would be of interest when trying to parse ID from 
AD symptoms, and their effect on electrophysiology.  
 
A combination of biomarkers will likely provide the most accurate 
representation of whether adults will develop AD (Humpel, 2011). As a result, 
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it would be of interest to analyse across a larger multi-modal imaging set 
(EEG, PET, MRI – structural, functional). The present thesis made an attempt 
at multi-modal analysis but with only 11 participants the investigation was 
limited.  
 
To truly expand the work, studies need to be able to acknowledge that AD 
does not develop ‘cleanly’. For example, epilepsy is closely linked with DS-AD 
(Evenhuis et al., 1990; Lai et al., 1989), EEG is typically used for epilepsy 
research, and so this could be an interesting extension.   
 
7.7.2 Future analyses for the acquired data   	
One potential future analysis avenue for the MMN data acquired in this study 
is dynamic causal modelling (DCM). DCM can be used to create a plausible, 
dynamic representation of EEG responses (David, Harrison, & Friston, 2005; 
Friston, 2003). Specifically, DCM can be used to explain ERPs as a network 
of interacting cortical sources (David et al., 2005). Indeed, Garrido, Kilner, 
Kiebel, and Friston (2007) used DCM to explain MMN as an interaction of 
forward, backward and lateral connections between the primary auditory 
cortex, superior temporal gyrus and inferior temporal gyrus. The study was 
concerned with testing hierarchical predictive coding, and whether MMN was 
driven by forward connections, backward connections, or both (Garrido et al., 
2007). DCM tests specific models, driven by the literature, rather than being a 
wide-spread exploratory technique (Garrido et al., 2007). For this reason, 
although DCM can also be applied to resting state data it is often more 
powerful when tied to a specific, well-defined response. The long history of 
MMN research, combined with its consistently reliable production (Näätänen, 
Tervaniemi, Sussman, Paavilainen, & Winkler, 2001), makes it an ideal 
paradigm with which to test DCM. Having used DCM, on an MMN paradigm, 
to explore hierarchical predictive coding in TD adults (Garrido et al., 2007), 
the model could now be extended to adults with DS. This extension would 
potentially be informative about the mechanisms, which underlie MMN 
generation in DS. 
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7.7.3 Future EEG paradigms to consider 	
This section discusses EEG paradigms that future work could use to explore 
the interaction between DS, typical and pathological (AD) aging.  	
7.7.3.1 Resting state EEG 
 
The acquisition of resting-state EEG data requires only limited cooperation 
from participants and is therefore an appropriate tool irrespective of 
participants’ cognitive abilities. EEG data gathered under a resting-state, 
passive paradigm can be analysed in several ways. The analyses described 
here are an indicative, rather than exhaustive, list of the potential methods for 
interpreting resting-state EEG data.  
 
EEG spectral analyses have been used previously to indicate a slowing and 
reduction of faster frequencies (alpha, beta) and increase of slower 
frequencies (theta, delta) in people with AD compared to age-matched 
controls (Bennys, Rondouin, Vergnes, & Touchon, 2001). Coherence 
analyses are performed on EEG data to approximate the functional 
connectivity between different areas of the cortex (Jeong, 2004). Coherence 
analyses calculated on EEG data from people with AD have indicated 
decreased coherence of alpha and beta bands, suggesting reduced functional 
connectivity (Dunkin, Leuchter, Newton, & Cook, 1994). Furthermore EEG 
data has excellent temporal resolution, making it an ideal basis for 
investigating physiological complexity in the brain (Catarino, Churches, 
Andrade, Baron-Cohen, & Ring, 2011). As a promising candidate, the next 
section will elaborate on physiological complexity.  
 
Physiological complexity in the brain describes the interactive nature of the 
system, for example by feedback loops, over multiple time- and spatial-scales 
(Goldberger, Peng, & Lipsitz, 2002). Multi-scale entropy (MSE) is a coarse-
graining procedure which quantifies the complexity of physiological signals by 
comparing sample entropies across multiple time-scales (Costa, Goldberger, 
& Peng, 2002). MSE analyses can be performed upon 60 second artefact-free 
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epochs of resting state EEG data (Mizuno et al., 2010). A study conducted by 
Takahashi et al. (2009) investigated EEG complexity and aging with MSE to 
show that older adults (mean age 64.5 years old) had reduced EEG signal 
complexity compared to younger adults (mean age 29.2 years old). 
Furthermore, previous studies have successfully used MSE to disambiguate 
people with AD (but not DS) from age-matched controls (Escudero, Abásolo, 
Hornero, Espino, & López, 2006; Jeong, 2004; Mizuno et al., 2010; Park, Kim, 
Kim, & Kim, 2007). The studies predominantly found that EEG data gathered 
from people with AD were less complex over multiple timescales than age-
matched controls, which suggests a significant reduction in non-linear 
dynamics (Escudero et al., 2006; Jeong, 2004; Park et al., 2007). The ease of 
data acquisition, combined with the promising results from aging and AD 
groups, suggest that it would be feasible to evaluate MSE as a potential index 
of aging and AD, in DS.   
 
7.7.3.2 Electrophysiological measures of ‘gating’ for investigating DS-AD: 
P50 suppression and acoustic startle prepulse inhibition  	
The filtering of redundant sensory information by the central nervous system 
is called ‘gating’ (Adler et al., 1982). ‘Gating’ can be either: 1. ‘Sensory’, which 
refers to a suppressed response from cortical neurons; or 2. ‘Sensorimotor’, 
which refers to a suppressed muscular response (Brenner, Edwards, Carroll, 
Kieffaber, & Hetrick, 2004). ‘Sensory gating’ is typically assessed by the 
attenuated magnitude of an ERP response to the second in a pair of repeated 
clicks, under the P50 Suppression paradigm. ‘Sensorimotor gating’ is typically 
assessed by the attenuated magnitude of an electromyography (EMG) 
response to a startling auditory stimulus, which follows a weak tone, under the 
prepulse inhibition (PPI) paradigm. The P50 Suppresion and PPI paradigms 
will now be further discussed with reference to their potential utility for 
investigating aging and early indicators of AD, in DS.   
P50 is an early, positive evoked potential elicited 40-70ms after an auditory 
stimulus (Thomas et al., 2010). The auditory stimulus usually used to evoke 
P50 is a 50ms ‘click’, played in a passive ‘dual-click paradigm’ with a silent 
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movie distracter task. The ‘dual-click paradigm’ is when the same ‘click’ is 
presented twice, with an inter-stimulus interval of 500ms and inter-trial interval 
of 8-10s, resulting in P50 suppression (Adler et al., 1982). P50 suppression is 
the diminished response (reduced P50 amplitude) to the second ‘click’ of the 
pair compared to the first because of the ‘sensory gating mechanism’(Thomas 
et al., 2010). The ‘sensory gating mechanism’ is the inhibition of irrelevant 
(repeated) information which results in reduced neural activity to that stimulus 
so cognitive processing is focused on potentially more useful (novel) 
information (Bender et al., 2014). P50 reduces in amplitude with age whereas 
P50 suppression is relatively robust to aging effects but is diminished in AD 
(Thomas et al., 2010). P50 suppression could be reduced in AD compared to 
age-matched controls because the echoic memory trace of the first stimulus 
decays too rapidly to be sufficiently available to instil a suppression effect by 
the time it’s pair is played (Bender et al., 2014). This hypothesis reflects the 
memory deficits which characterise typical AD; however the 
neuropsychological correlates of P50 suppression are of more interest for AD-
DS symptomatology. The neuropsychological correlates of P50 suppression 
are predominantly executive functions (including working memory requiring 
inhibition and attention) which are underpinned by the frontal lobes (Thomas 
et al., 2010). This is of particular interest in the context of AD-DS because, as 
previously discussed, the earliest clinical indicators are best defined by 
changes in personality, behaviour and executive dysfunction (Ball et al., 
2006). Furthermore, reduced sensory gating for people with AD correlating 
with worse performance on neuropsychological tests of working memory 
requiring inhibition (Thomas et al., 2010) is of particular interest as Ball, 
Holland, Watson and Huppert (2010) found behavioural disinhibition to be one 
of the earliest and most frequently reported signs of AD in DS.  
‘Sensorimotor gating’ is when the motor response to sensory stimulation is 
involuntarily reduced (Ueki, Goto, Sato, Iso, & Morita, 2006). Acoustic startle 
prepulse inhibition (PPI) is an experimental manipulation used to measure 
‘sensorimotor gating’. The PPI paradigm plays a weak auditory stimulus 
(prepulse) approximately 120ms before a startling auditory stimulus (pulse) to 
inhibit the reflexive startle response of an eye blink (Ueki et al., 2006). The 
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reduced eye blink response is measured by applying two electrodes to the 
skin which overlays the orbicularis oculi muscle (Blumenthal et al., 2005). The 
electrodes then conduct the eye blink EMG signal to the recording equipment, 
which can be the same equipment used in EEG and ERP experiments 
(Blumenthal et al., 2005). Physiologically, the inhibition of the startle response 
occurs in the pons but is regulated by the limbic cortico-striato-pallido-pontine 
circuitry (Swerdlow et al., 2001). The cortico-striato-pallido-pontine circuitry 
includes a fronto-striatal loop. PPI as an electrophysiological reflection of 
fronto-striatal loop functioning is of interest considering recent PET imaging 
studies have indicated striatal dominant PiB binding in people with DS without 
AD (Annus et al., 2015; Handen et al., 2012; Hartley et al., 2014).  
The PPI paradigm has been used with typically developing individuals, 
demonstrating that it is greatest for middle-aged individuals but the startle eye 
blink reflex is significantly decreased in amplitude and increased in latency for 
older adults (Ellwanger, Geyer, & Braff, 2003). Previous experiments have 
failed to find that PPI disambiguates AD from typical aging (Hejl, Glenthøj, 
Mackeprang, Hemmingsen, & Waldemar, 2004; Ueki et al., 2006). However, 
PPI could be informative about early indicators of DS-AD if: 1. People with DS 
are preferentially accumulating Aβ in the striatum; 2. Aβ in the striatum 
disrupts fronto-striatal loops; 3. The disruption of fronto-striatal loops 
compromises frontal lobe functioning; 4. Changes to cognitive functions 
underpinned by the frontal lobes characterise the early stages of DS-AD, as 
the Ball et al. (2006, 2008) studies suggest.  
 
7.7.4 Future drug trials  
 
The true value of EEG work in DS-AD research is what it can tell you 
mechanistically, and using this information to guide future treatment trials. For 
example, MMN is mediated by glutaminergic mechanisms (Javitt,    
Steinschneider, Schroeder, & Arezzo, 1996), and this information can be used 
in terms of current and future drug trials.  
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Memantine is non-competitive N-methyl-D-aspartate (NMDA) receptor 
antagonist, which was originally developed by Eli Lilly in 1968 to combat 
diabetes. The Food and Drug Administration (FDA) approved memantine 
administration for moderate to severe AD in 2003. This NMDA-receptor 
antagonist is the only one of its class for AD treatment, the remainder are 
cholinesterase inhibitors (Cummings et al., 2013). Glutamate binds to NMDA 
receptors on the cell, to allow calcium to flow into the cell, and facilitate cell 
signalling, learning and memory. However, an excess of glutamate from cell 
death results in the cell being overwhelmed with calcium, which is damaging. 
A non-competitive NMDA-receptor antagonist (memantine) mediates this 
excessive influx but maintains the typical process (Lipton, 2005).  
 
MMN is modulated by the glutaminergic system, which relies on NMDA-
receptor pathways (Korostenskaja, Nikulin, Kičić, Nikulina, & Kähkönen, 
2007). Memantine, which acts as a NMDA-receptor antagonist, has been 
tested with healthy adults to assess the effect on MMN (Korostenskaja et al., 
2007). The study found that memantine enhanced MMN amplitude, but had 
no effect on latency (Korostenskaja et al., 2007). Furthermore, the study 
suggested that the frontal cortex was differential affected by drug 
administration during MMN generation (Korostenskaja et al., 2007). These are 
interesting observations considering that, in the present study, MMN is 
reduced for adults with DS: 1. Compared to controls, 2. Who are older (40+); 
and 3. Who have shown greater cognitive decline. Therefore, based on the 
strong association between MMN and NMDA receptors (Korostenskaja et al., 
2007), memantine administration would likely enhance MMN for adults with 
DS.   
 
Memantine has been used previously in mouse-models of DS. In a Ts65Dn 
mouse model, acute memantine administration rescued cognitive deficits to 
do with fear conditioning (Costa, Scott-McKean, & Stasko, 2008). Prolonged 
administration (6 months) of memantine in Ts65Dn mice, provided functional 
but not physiological rescue of learning and memory processes (Lockrow, 
Boger, Bimonte-Nelson, & Granholm, 2011). The success of memantine 
administration in mouse models of DS has led researchers to test the drug 
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with humans. Memantine was tested for 52 weeks in a randomised, double-
blind, placebo-controlled clinical trial for adults with DS, over the age of 40 
years (MEADOWS), but to no effect (Hanney et al., 2012). However, this 
clinical trial was primarily run to assess the restorative effects of memantine 
on DS-AD pathology. Furthermore the focus was on cognitive outcomes, 
which can: 1. Be confounded by ID, and 2. Take more than one year to 
recover (Boada et al., 2012; Costa, 2011). Therefore, it may be valuable to 
assess the effects of memantine on adults with DS, without a diagnosis of AD, 
in a preventative rather than reactive motion; then quantify the effects with an 
objective, physiological measure, such as MMN. 
 
From a cognitive stand-point, the heavy frontal component to the memantine 
modulated MMN response (Korostenskaja et al., 2007) could be of interest 
considering the early frontal, functional compromise in DS-AD (Ball et al., 
2008). MMN amplitude recovery could be used as an interim assessment 
before longer-term cognitive follow-ups, as sustained cognitive recovery is 
typically a protracted process (Boada et al., 2012; Costa, 2011). As a longer-
term aim, the effects of memantine administration on MMN and cognitive 
recovery could be tracked at 5-year intervals, with a high-risk group (DS 40+ 
no AD), to see if AD development is modified. This is obviously a time-
consuming and expensive undertaking, however there is a shortage of drug 
trial research to mediate DS-AD, despite this group being at huge risk 
(Hanney et al., 2012; Prasher, 2004).  
 
7.7.5 Recommendations 	
Of the EEG measures explored in this thesis, MMN showed the most robust 
relationship with age and cognitive decline. Therefore, MMN should be the 
primary measure of interest in future investigations using this study design. 
The present thesis included a longitudinal component: a one-year cognitive 
follow-up. Due to the protracted nature of DS-AD, combined with the ID 
confound on performance, baseline measures are essential for investigations 
of cognitive decline with this group. Therefore future work should continue to 
employ longitudinal designs. In the context of the long time course and 
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unclear timing of the onset of the pathology, repeated measures over longer 
time scales – starting years before the development of clinical symptoms, 
would be important. 
 
An additional focus for future work might be the resting-state EEG data. The 
reasons for focusing on the resting-state data are threefold: 1. Considering 
ERP elicited with either auditory or visual stimuli, the acuity of these senses 
decline in older age, whereas resting-state data is stimulus-free; 2. As the 
attention-contingent ERP response (P3b) was so unsuccessful, focusing 
research efforts on task-free EEG paradigms seems prudent; 3. Successful 
biomarkers of AD are likely to be multi-modal (Humpel, 2011) and resting 
state EEG data most readily maps onto fMRI data, for example, in terms of 
exploring connectivity.  
 
In conclusion, EEG is non-invasive, inexpensive, rapid to administer, and 
easy and safe to use repeatedly in the same individual, so future work would 
need not choose between resting state and MMN measures. Furthermore, 
biomarkers of AD are still at the fledgling stages of development so it would 
be prudent to be inclusive rather than exclusive at this stage. The key 
recommendation arising from this thesis would be to focus on employing 
passive (resting, MMN) EEG paradigms within longitudinal study designs.  	
7.8 Final conclusions 	
In conclusion, this thesis aimed to investigate the potential value of EEG 
measures for: 1. Evaluating the premature, neurological aging hypothesis of 
DS, and 2. Predicting cognitive decline. To achieve these aims, the thesis 
began by comparing EEG measures between adults with DS and TD controls: 
to evaluate the waveforms, and investigate premature aging. The thesis then 
focused on the DS group: to establish relationships between 
electrophysiology, executive dysfunction and cognitive decline. The findings 
from this thesis lay groundwork for future studies, which might elucidate 
disease mechanisms, and thus suggest drug targets, in premature aging and 
cognitive decline in DS. 
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Appendix F. Consultee information sheet preface (followed by 
appendix D) 
	
CONSULTEE	INFORMATION	SHEET	
Brain	Activity	in	Down’s	Syndrome	
	
Dear	…………………….	
	
We	 feel	 your	 relative/friend	 is	 unable	 to	 decide	 for	 himself/herself	 whether	 to	
participate	in	this	research.		
	
To	help	decide	if	he/she	should	join	the	study,	we’d	like	to	ask	your	opinion	whether	
or	not	they	would	want	to	be	involved.	We’d	ask	you	to	consider	what	you	know	of	
their	wishes	and	feelings,	and	to	consider	their	 interests.	Please	let	us	know	of	any	
advance	decisions	they	may	have	made	about	participating	in	research.	These	should	
take	precedence.		
	
If	you	decide	your	relative/friend	would	have	no	objection	to	taking	part	we	will	ask	
you	to	read	and	sign	the	consultee	declaration	enclosed.	We’ll	then	give	you	a	copy	
to	keep.	We	will	keep	you	fully	informed	during	the	study	so	you	can	let	us	know	if	
you	have	any	concerns	or	you	think	your	relative/friend	should	be	withdrawn.		
	
If	you	decide	that	your	friend/relative	would	not	wish	to	take	part	 it	will	not	affect	
the	standard	of	care	they	receive	in	any	way.		
	
If	 you	 are	 unsure	 about	 taking	 the	 role	 of	 consultee	 you	 may	 seek	 independent	
advice.		
	
We	will	understand	if	you	do	not	want	to	take	on	this	responsibility.		
	
We	set	out	below	the	information	sheet	that	will	go	to	your	relative/	friend.		
	
	 	
Cambridge	Intellectual	and	Developmental	
Disabilities	Research	Group	
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Appendix G. Cross-sectional study information sheet for the carers of 
the participants with DS  
 
CARER	INFORMATION	SHEET	
	
Brain	Activity	in	Down’s	Syndrome	
	
We	would	 like	 to	 invite	 the	 person	 you	 support	 to	 take	 part	 in	 a	 research	 study.	
Please	take	time	to	read	this	sheet	carefully	for	information.		
	
Who	are	we?	
We	 are	 a	 group	 of	 researchers	 and	 doctors	 from	 the	 Cambridge	 Intellectual	 and	
Developmental	 Disabilities	 Research	 Group	 at	 the	 University	 of	 Cambridge.	 This	
project	is	led	by	Sally	Jennings	who	is	undertaking	it	as	part	of	her	PhD	training.	It	is	
supervised	by	Dr	Howard	Ring	and	Prof	Tony	Holland,	both	academic	psychiatrists	at	
the	University	of	Cambridge.	
	
What	is	this	research	about?	
People	with	Down’s	Syndrome	are	at	increased	risk	of	developing	Alzheimer’s	
disease,	and	do	so	at	younger	ages,	compared	to	the	general	population.	
Electroencephalography	(EEG)	is	a	technology	which	records	brain	activity	through	
electrodes	placed	to	the	scalp.	EEG	is	a	promising	candidate	for	screening	‘at	risk’	
populations	because	it	is	entirely	safe,	relatively	cheap	and	undemanding	for	
participants.	The	aim	of	this	study	is	to	investigate	whether	EEG	has	the	potential	to	
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both	measure	the	effects	of	aging	on	the	brain	and	indicate	early	stages	of	
Alzheimer’s	disease,	in	Down’s	Syndrome.		
	
Why	have	we	contacted	you?	
We	 have	 invited	 the	 individual	 you	 support	 to	 participate	 in	 this	 research	 because	
he/she	has	Down’s	Syndrome	and	is	20+	years	old.	If	he/she	decides	to	take	part,	your	
support	will	be	vital	since	we	request	that	a	parent	or	carer	is	present	at	all	visits.	This	is	
to	make	sure	that	participants	are	comfortable	and	well-looked	after	at	all	time.	In	our	
experience,	this	 is	best	achieved	by	working	alongside	those	who	know	a	participant’s	
individual	needs	best.	We	will	also	need	to	ask	you	some	questions	about	the	individual	
you	 care	 for,	 concerning	 their	 behaviour,	 as	well	 as	 some	 things	 about	 their	medical	
history.		
	
What	are	the	possible	benefits	of	taking	part?	
There	are	no	direct	benefits	to	the	person	you	support	for	taking	part	in	this	project.	
However,	 their	 participation	 in	 this	 research	 will	 help	 us	 to	 gain	 a	 better	
understanding	 of	 aging	 and	 the	 development	 of	 Alzheimer’s	 disease	 in	 Down’s	
syndrome.		
	
What	will	happen	if	he/she	decides	to	take	part?	
We	will	come	to	visit	you	and	the	person	you	support	 to	talk	about	what	they	will	be	
asked	to	do	if	they	decide	to	take	part.	We	will	bring	some	photographs	of	equipment	
which	we	use	to	record	their	brain	activity	and	other	things	they	will	see	to	help	explain	
what	it	will	be	like	to	participate	and	ensure	that	he/she	understands	what	will	happen.	
Following	this,	if	he/she	decides	to	take	part,	we	will	ask	him/her	to	sign	a	form	saying	
that	he/she	understands	what	the	study	entails	and	would	like	to	take	part.	This	form	is	
not	binding	and	they	are	free	to	leave	the	study	at	any	time.	
	
The	study	takes	place	over	two	days.	On	the	first	day,	we	will	come	and	visit	you	and	the	
person	you	support	at	home,	or	another	location	which	is	convenient	for	you.		We	will	
begin	by	playing	sounds	and	asking	him/her	to	raise	his/her	hand	upon	hearing	them.	
This	 screen	 for	 hearing	 loss	 will	 take	 about	 5	 minutes.	 We	 will	 then	 ask	 him/her	 to	
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complete	 a	 handedness	 questionnaire,	which	will	 also	 take	 about	 5	minutes.	We	will	
also	ask	you	some	questions	about	his/her	daily	functioning	and	medical	history.	
	
For	 people	 who	 have	 not	 recently	 participated	 in	 other	 studies	 conducted	 by	 the	
research	group,	we	will	ask	him/her	to	complete	some	memory	puzzles	and	games.	This	
could	take	a	maximum	of	2	hours	40	minutes.	However,	there	will	be	lots	of	breaks	and	
they	can	finish	the	memory	puzzles	and	games	at	the	Cambridge	visit.		
	
On	another	day	convenient	for	you	both,	we	will	ask	you	to	accompany	the	person	
you	support	 to	the	Herchel	Smith	Building,	Cambridge.	Here,	people	who	have	not	
previously	participated	in	studies	conducted	by	the	research	group	will	have	a	blood	
sample	taken	by	a	healthcare	professional,	which	will	take	about	10	minutes.	We	will	
then	record	his/her	brain	activity	by	 fitting	a	wetted	EEG	cap	on	his/her	head.	The	
EEG	 cap	 is	 entirely	 safe	 and	 not	 painful.	 However,	 as	 the	 cap	will	 be	wet	we	will	
place	a	towel	around	their	shoulders	to	prevent	any	dampness	to	their	shoulders.	It	
will	take	about	30	minutes	to	ensure	that	the	cap	is	fitted	properly	and	to	record	the	
locations	 of	 all	 the	 electrodes	 on	 their	 head.	 We	 will	 then	 record	 10	 minutes	 of	
him/her	 at	 rest	 and	 80	 minutes	 of	 him/her	 listening	 to	 various	 sounds,	 through	
earphones,	whilst	watching	a	silent	movie.	Sometimes	they	will	be	asked	to	respond	
to	 the	 sounds	using	 the	 response	pad	provided.	We	would	ask	you	 to	 sit	with	 the	
researcher	in	the	adjoining	room.	There	will	be	lots	of	breaks	which	you	can	spend	
together.		
	
Does	he/she	have	to	take	part?	
No,	it	is	up	to	the	person	with	Down’s	Syndrome	whether	you	take	part	in	this	study.	
They	can	stop	and	leave	the	study	at	anytime.		Leaving	the	study	will	not	affect	the	
care	he/she	receives.	
	
Are	there	any	risks	of	taking	part?	
There	are	no	foreseeable	safety	issues	as	EEG	is	an	entirely	non-invasive	procedure.	
Furthermore,	you	and	the	researcher	will	be	able	to	see	and	hear	the	participant	
throughout	testing	via	a	webcam.		
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Will	he/she	be	paid	to	take	part?	
	
We	 can	 pay	 for	 travel	 to	 and	 from	 Cambridge	 for	 both	 people	 with	 Down’s	
Syndrome	and	their	accompanying	parent/carer.	We	will	also	pay	for	food	and	drink	
while	 in	 Cambridge.	 If	 an	 overnight	 stay	 is	 necessary	 because	 the	 distance	 to	
Cambridge	is	too	great	for	a	return	journey	to	be	feasible	within	the	same	day,	we	
will	cover	the	costs	of	this	accommodation.	We	will	also	reimburse	the	person	with	
Down’s	Syndrome	£20	for	their	time.		
	
What	if	you	find	that	there	is	a	problem?	
We	will	ask	him/her	to	sign	a	form	consenting	to	us	contacting	his/her	GP.	Provided	
that	he/she	agrees,	we	will	write	to	their	GP	to:	1.	Let	his/her	GP	know	that	he/she	is	
taking	part	in	this	study.	2.	Ask	whether	he/she	has,	and	if	so	more	details	of:	a	
genetic	diagnosis	of	Down’s	Syndrome;	a	clinical	diagnosis	of	dementia;	clinically	
diagnosed	hearing	impairment(s);	active,	or	history	of,	epilepsy;	active,	or	history	of,	
psychiatric	or	neurological	disorder(s);	currently	being	prescribed	any	medication(s).	
3.	Contact	his/her	GP	in	the	unlikely	event	that	we	find	something	of	medical	
relevance.			
	
What	if	something	goes	wrong?	
This	 study	 is	 approved	 by	 an	 NHS	 Research	 Ethics	 Committee	 and	 has	 insurance	
cover	 in	 case	 the	person	you	 support	was	harmed.	 This	would	mean	 that	 you	 can	
receive	compensation	 if	anything	went	wrong.	 It	would	not	matter	whether	 it	was	
anyone’s	fault.	This	would	be	under	the	University’s	Clinical	Trials	policy.		
	
If	you,	or	the	person	you	support,	wish	to	complain	about	the	way	you,	or	they,	have	
been	treated	in	this	study,	you	should	be	able	to	complain	directly	to	the	Chief	
Investigator	of	this	study,	Ms	Sally	Jennings	(01223	746147),	Dr	Howard	Ring	(01223	
746121)	or	Prof	Tony	Holland	(01223	746121).	If	you	remain	unhappy	and	wish	to	
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complain	formally,	you	can	do	this	by	contacting	the	Patient	Advice	and	Liaison	
Service	(PALS)	at	the	National	Health	Service		(01223	216756).	
	
What	will	happen	to	the	results	of	the	research	study?	
All	 information	 about	 the	 person	 you	 support	 will	 be	 kept	 private.	 	 All	 the	 data	
collected	 in	 this	 study	 will	 be	 stored	 securely	 by	 the	 research	 team	 for	 up	 to	 10	
years.	The	results	of	the	study	will	be	published	in	scientific	journals.	No	one	will	be	
able	to	tell	that	he/she	took	part	in	the	study.		
	
Who	has	reviewed	the	study?	
This	 study	was	 reviewed	by	 the	 research	 team	 the	University	of	Cambridge.	 It	 has	
also	been	reviewed	by	a	group	of	people	who	awarded	Sally	Jennings	a	grant	to	carry	
out	 the	study.	We	have	the	approval	of	 the	NHS	Research	Ethics	Committee	 to	do	
this	study.		
	
What	to	do	if	I,	or	the	person	I	support,	would	like	to	know	more?	
	Sally	 Jennings	 is	 the	 PhD	 researcher	 on	 the	 project.	 She	 is	 very	
happy	to	talk	to	you	about	the	study	and	answer	any	questions	you	
may	have.	You	can	contact	Sally	by:	
Phone:	01223	746	147	or,	
Email:	srj32@medschl.cam.ac.uk	.		
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Appendix H. Cross-sectional study information sheet for the control 
participants  
 
	
CONTROL	PARTICIPANT	INFORMATION	SHEET	
	
Brain	Activity	in	Down’s	Syndrome	
	
We	would	like	to	invite	you	to	take	part	in	a	research	study.	Before	you	decide	you	
need	 to	understand	why	 the	 research	 is	being	done	and	what	 it	would	 involve	 for	
you.	Please	take	time	to	read	this	sheet	carefully.	You	should	talk	to	others	about	the	
study	if	you	wish.	
	
Who	are	we?	
We	 are	 a	 group	 of	 researchers	 and	 doctors	 from	 the	 Cambridge	 Intellectual	 and	
Developmental	 Disabilities	 Research	 Group	 at	 the	 University	 of	 Cambridge.	 This	
project	is	led	by	Sally	Jennings	who	is	undertaking	it	as	part	of	her	PhD	training.	It	is	
supervised	by	Dr	Howard	Ring	and	Prof	Tony	Holland,	both	academic	psychiatrists	at	
the	University	of	Cambridge.	
	
What	is	this	research	about?	
People	with	Down’s	Syndrome	are	at	increased	risk	of	developing	Alzheimer’s	
disease,	and	do	so	at	younger	ages,	compared	to	the	general	population.	
Electroencephalography	(EEG)	is	a	technology	which	records	brain	activity	through	
electrodes	placed	to	the	scalp.	EEG	is	a	promising	candidate	for	screening	‘at	risk’	
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populations	because	it	is	entirely	safe,	relatively	cheap	and	undemanding	for	
participants.	The	aim	of	this	study	is	to	investigate	whether	EEG	has	the	potential	to	
both	measure	the	effects	of	aging	on	the	brain	and	indicate	early	stages	of	
Alzheimer’s	disease,	in	Down’s	Syndrome.		
	
Why	have	I	been	chosen?	
We	 have	 invited	 you	 to	 take	 part	 because	 you	 are	 healthy;	 do	 not	 have	 Down’s	
syndrome	and	are	over	20	years	old.		
	
What	are	the	possible	benefits	of	taking	part?	
There	are	no	direct	benefits	to	you	by	taking	part	in	this	project.	Your	participation	in	
this	 research	 will	 help	 us	 to	 gain	 a	 better	 understanding	 of	 the	 development	 of	
Alzheimer’s	disease	in	Down’s	syndrome.		
	
What	will	happen	if	I	take	part?	
We	 will	 ask	 you	 to	 visit	 us	 at	 the	 Herchel	 Smith	 Building	 (part	 of	 Addenbrookes	
Hospital)	 at	 a	 time	 that	 suits	 you.	We	will	 ask	 you	 to	 sign	 a	 form	 saying	 that	 you	
understand	what	will	happen	and	that	you	would	like	to	take	part.		This	form	is	not	
binding	and	you	are	free	to	leave	the	study	at	any	time.	
	
We	will	begin	by	playing	sounds	and	asking	you	to	raise	your	hand	when	you	hear	
them.	This	screen	for	hearing	loss	will	take	about	5	minutes.	We	will	then	ask	you	to	
complete	a	handedness	questionnaire,	which	will	also	take	about	5	minutes.	You	will	
also	 complete	 two	 short	 tests	 of	 memory	 and	 problem	 solving,	 which	 will	 take	
around	35	minutes	to	carry	out.			
	
We	will	then	record	you	brain	activity	by	fitting	a	wetted	EEG	cap	on	your	head.	The	
EEG	 cap	 is	 entirely	 safe	 and	 not	 painful.	 However,	 as	 the	 cap	will	 be	wet	we	will	
place	a	towel	around	your	shoulders	to	prevent	any	dampness	to	your	shoulders.	It	
will	take	about	30	minutes	to	ensure	that	the	cap	is	fitted	properly	and	to	record	the	
locations	of	all	the	electrodes	on	your	head.	We	will	then	record	10	minutes	of	you	
at	 rest	 and	 80	minutes	 of	 you	 listening	 to	 various	 sounds	whilst	watching	 a	 silent	
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movie.	 Sometimes	 you	will	 be	asked	 to	 respond	 to	 the	 sounds	using	 the	 response	
pad	provided.		
	
The	whole	study	will	take	about	3	hours	to	complete.		
	
Are	there	any	risks	of	taking	part?	
There	are	no	foreseeable	safety	issues	as	EEG	is	an	entirely	non-invasive	procedure.	
Furthermore,	the	researcher	will	be	able	to	see	and	hear	you	throughout	testing	via	
a	web	cam.	
	
Do	I	have	to	take	part?	
No,	it	is	up	to	you	whether	you	take	part	in	this	study.	If	you	would	like	to	take	part	
you	 will	 be	 asked	 to	 sign	 a	 consent	 form.	 	 You	 can	 stop	 and	 leave	 the	 study	 at	
anytime.		Leaving	the	study	will	not	affect	the	care	you	receive.	
	
Will	I	be	paid	to	take	part?	
	
We	will	pay	for	your	travel	expenses	to	and	from	the	Herchel	Smith	Building	for	the	
research.		We	will	also	reimburse	you	£20	for	your	time.		
	
What	if	you	find	that	there	is	a	problem?	
We	will	ask	you	to	sign	a	form	consenting	to	us	contacting	your	GP.	Provided	that	
you	agree,	we	will	write	to	your	GP	to:	1.	Let	your	GP	know	that	you	are	taking	part	
in	this	study.	2.	Ask	whether	you	have,	and	if	so	more	details	of:	clinically	diagnosed	
hearing	impairment(s);	active,	or	history	of,	epilepsy;	active,	or	history	of,	psychiatric	
or	neurological	disorder(s);	currently	being	prescribed	any	medication(s).	3.	Contact	
your	GP	in	the	unlikely	event	that	we	find	something	of	medical	relevance.			
	
What	if	something	goes	wrong?	
This	 study	 is	 approved	 by	 an	 NHS	 Research	 Ethics	 Committee	 and	 has	 insurance	
cover	in	case	you	were	harmed.	This	would	mean	that	you	can	receive	compensation	
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if	 anything	 went	 wrong.	 It	 would	 not	 matter	 whether	 it	 was	 anyone’s	 fault.	 This	
would	be	under	the	University’s	Clinical	Trials	policy.		
	
If	you	wish	to	complain	about	the	way	you	have	been	treated	in	this	study,	you	
should	be	able	to	complain	directly	to	the	Chief	Investigator	of	this	study,	Ms	Sally	
Jennings	(01223	746147),	Dr	Howard	Ring	(01223	746121)	or	Prof	Tony	Holland	
(01223	746121).	If	you	remain	unhappy	and	wish	to	complain	formally,	you	can	do	
this	by	contacting	the	Patient	Advice	and	Liaison	Service	(PALS)	at	the	National	
Health	Service		(01223	216756).	
	
What	will	happen	to	the	results	of	the	research	study?	
All	information	about	you	will	be	kept	private.		All	the	data	collected	in	this	study	will	
be	stored	securely	by	the	research	team	for	up	to	10	years.	The	results	of	the	study	
will	be	published	in	scientific	journals.	No	one	will	be	able	to	tell	you	took	part	in	the	
study.		
	
Who	has	reviewed	the	study?	
This	 study	was	 reviewed	by	 the	 research	 team	 the	University	of	Cambridge.	 It	 has	
also	been	reviewed	by	a	group	of	people	who	awarded	Sally	Jennings	a	grant	to	carry	
out	the	study.	We	have	the	approval	of	an	NHS	Research	Ethics	Committee	to	do	this	
study.		
	
What	to	do	if	I	would	like	to	know	more?	
Sally	Jennings	is	the	PhD	researcher	on	the	project.	She	is	very	happy	to	talk	to	you	
about	the	study	and	answer	any	questions	you	may	have.	You	can	contact	Sally	by	
phone	on	01223	746	147	or	email	on	srj32@medschl.cam.ac.uk	.		
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Appendix I. Longitudinal study information sheet for the participants 
with DS  
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Appendix J. Longitudinal information sheet for the carers of the 
participating adults with DS 
CARER	INFORMATION	SHEET	
	
Brain	Activity	in	Down’s	Syndrome	
	
	
We	would	 like	 to	 invite	 the	 person	 you	 support	 to	 take	 part	 in	 a	 research	 study.	
Please	take	time	to	read	this	sheet	carefully	for	information.		
	
Who	are	we?	
We	 are	 a	 group	 of	 researchers	 and	 doctors	 from	 the	 Cambridge	 Intellectual	 and	
Developmental	 Disabilities	 Research	 Group	 at	 the	 University	 of	 Cambridge.	 This	
project	is	led	by	Sally	Jennings	who	is	undertaking	it	as	part	of	her	PhD	training.	It	is	
supervised	by	Dr	Howard	Ring	and	Prof	Tony	Holland,	both	academic	psychiatrists	at	
the	University	of	Cambridge.	
	
What	is	this	research	about?	
People	with	Down’s	Syndrome	are	at	increased	risk	of	developing	Alzheimer’s	
disease,	and	do	so	at	younger	ages,	compared	to	the	general	population.	
Electroencephalography	(EEG)	is	a	technology	which	records	brain	activity	through	
electrodes	placed	to	the	scalp.	EEG	is	a	promising	candidate	for	screening	‘at	risk’	
populations	because	it	is	entirely	safe,	relatively	cheap	and	undemanding	for	
participants.	The	aim	of	this	study	is	to	investigate	whether	EEG	has	the	potential	to	
both	measure	the	effects	of	aging	on	the	brain	and	indicate	early	stages	of	
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Alzheimer’s	disease,	in	Down’s	Syndrome.	The	person	you	support	participated	in	
the	EEG	part	of	the	study	last	year.	This	year	we	would	like	to	do	a	follow-up	
cognitive	assessment	to	explore	to	what	extent	EEG	can	predict	future	cognition.		
	
Why	have	we	contacted	you?	
We	 have	 invited	 the	 individual	 you	 support	 to	 participate	 in	 this	 research	 because	
he/she	participated	in	the	first	part	of	the	study	last	year.	If	he/she	decides	to	take	part,	
your	support	will	be	vital	since	we	request	that	a	parent	or	carer	is	present	at	all	visits.	
This	is	to	make	sure	that	participants	are	comfortable	and	well-looked	after	at	all	times.	
In	 our	 experience,	 this	 is	 best	 achieved	 by	 working	 alongside	 those	 who	 know	 a	
participant’s	individual	needs	best.	We	will	also	need	to	ask	you	some	questions	about	
the	 individual	 you	 care	 for,	 concerning	 their	 behaviour,	 as	well	 as	 some	 things	 about	
their	medical	history.		
	
What	are	the	possible	benefits	of	taking	part?	
There	are	no	direct	benefits	to	the	person	you	support	for	taking	part	in	this	project.	
However,	 their	 participation	 in	 this	 research	 will	 help	 us	 to	 gain	 a	 better	
understanding	 of	 aging	 and	 the	 development	 of	 Alzheimer’s	 disease	 in	 Down’s	
syndrome.		
	
What	will	happen	if	he/she	decides	to	take	part?	
We	will	come	to	visit	you	and	the	person	you	support	 to	talk	about	what	they	will	be	
asked	to	do	if	they	decide	to	take	part.	We	will	explain	what	it	will	be	like	to	participate	
and	ensure	that	he/she	understands	what	will	happen.	Following	this,	if	he/she	decides	
to	take	part,	we	will	ask	him/her	to	sign	a	form	saying	that	he/she	understands	what	the	
study	entails	and	would	like	to	take	part.	This	form	is	not	binding	and	they	are	free	to	
leave	the	study	at	any	time.	
	
We	will	then	ask	him/her	to	complete	some	memory	puzzles	and	games.	This	could	take	
a	maximum	of	2	hours	40	minutes.	However,	there	will	be	lots	of	breaks	and	they	can	
finish	the	memory	puzzles	and	games	another	day.		
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Does	he/she	have	to	take	part?	
No,	 it	 is	up	to	the	person	with	Down’s	Syndrome	whether	he/she	takes	part	 in	this	
study.	 They	 can	 stop	 and	 leave	 the	 study	 at	 anytime.	 	 Leaving	 the	 study	 will	 not	
affect	the	care	he/she	receives.	
	
Are	there	any	risks	of	taking	part?	
There	are	no	foreseeable	safety	issues	as	we	will	just	be	playing	memory	puzzles	and	
games	in	a	location	of	your	choosing.		
	
What	if	you	find	that	there	is	a	problem?	
We	will	ask	him/her	to	sign	a	form	consenting	to	us	contacting	his/her	GP.	Provided	
that	he/she	agrees,	we	will	write	to	their	GP	to:	1.	Let	his/her	GP	know	that	he/she	is	
taking	part	in	this	study.	2.	Contact	his/her	GP	in	the	unlikely	event	that	we	find	
something	of	medical	relevance.			
	
What	if	something	goes	wrong?	
This	 study	 is	 approved	 by	 an	 NHS	 Research	 Ethics	 Committee	 and	 has	 insurance	
cover	 in	 case	 the	person	you	 support	was	harmed.	 This	would	mean	 that	 you	 can	
receive	compensation	 if	anything	went	wrong.	 It	would	not	matter	whether	 it	was	
anyone’s	fault.	This	would	be	under	the	University’s	Clinical	Trials	policy.		
	
If	you,	or	the	person	you	support,	wish	to	complain	about	the	way	you,	or	they,	have	
been	treated	in	this	study,	you	should	be	able	to	complain	directly	to	the	Chief	
Investigator	of	this	study,	Ms	Sally	Jennings	(01223	746147),	Dr	Howard	Ring	(01223	
746121)	or	Prof	Tony	Holland	(01223	746121).	If	you	remain	unhappy	and	wish	to	
complain	formally,	you	can	do	this	by	contacting	the	Patient	Advice	and	Liaison	
Service	(PALS)	at	the	National	Health	Service		(01223	216756).	
	
What	will	happen	to	the	results	of	the	research	study?	
All	 information	 about	 the	 person	 you	 support	 will	 be	 kept	 private.	 	 All	 the	 data	
collected	 in	 this	 study	 will	 be	 stored	 securely	 by	 the	 research	 team	 for	 up	 to	 10	
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years.	The	results	of	the	study	will	be	published	in	scientific	journals.	No	one	will	be	
able	to	tell	that	he/she	took	part	in	the	study.		
	
Who	has	reviewed	the	study?	
This	 study	was	 reviewed	by	 the	 research	 team	 the	University	of	Cambridge.	 It	 has	
also	been	reviewed	by	a	group	of	people	who	awarded	Sally	Jennings	a	grant	to	carry	
out	 the	study.	We	have	the	approval	of	 the	NHS	Research	Ethics	Committee	 to	do	
this	study.		
	
What	to	do	if	I,	or	the	person	I	support,	would	like	to	know	more?	
	Sally	 Jennings	 is	 the	 PhD	 researcher	 on	 the	 project.	 She	 is	 very	
happy	to	talk	to	you	about	the	study	and	answer	any	questions	you	
may	have.	You	can	contact	Sally	by:	
Phone:	01223	746	147	or,	
Email:	srj32@medschl.cam.ac.uk	.		
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Appendix K. Information sheet for the carer’s participation as 
CAMDEX informants  
	
CARER	INFORMATION	SHEET	FOR	PARTICIPATION	
	
Brain	Activity	in	Down’s	Syndrome	
	
Who	are	we?	
We	 are	 a	 group	 of	 researchers	 and	 doctors	 from	 the	 Cambridge	 Intellectual	 and	
Developmental	 Disabilities	 Research	 Group	 at	 the	 University	 of	 Cambridge.	 This	
project	is	led	by	Sally	Jennings	who	is	undertaking	it	as	part	of	her	PhD	training.	It	is	
supervised	by	Dr	Howard	Ring	and	Prof	Tony	Holland,	both	academic	psychiatrists	at	
the	University	of	Cambridge.	
	
What	is	this	research	about?	
People	with	Down’s	Syndrome	are	at	increased	risk	of	developing	Alzheimer’s	
disease,	and	do	so	at	younger	ages,	compared	to	the	general	population.	
Electroencephalography	(EEG)	is	a	technology	which	records	brain	activity	through	
electrodes	placed	to	the	scalp.	EEG	is	a	promising	candidate	for	screening	‘at	risk’	
populations	because	it	is	entirely	safe,	relatively	cheap	and	undemanding	for	
participants.	The	aim	of	this	study	is	to	investigate	whether	EEG	has	the	potential	to	
both	measure	the	effects	of	aging	on	the	brain	and	indicate	early	stages	of	
Alzheimer’s	disease,	in	Down’s	Syndrome.	The	person	you	support	participated	in	
the	EEG	part	of	the	study	last	year.	This	year	we	would	like	to	do	a	follow-up	
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cognitive	assessment	to	explore	to	what	extent	EEG	can	predict	future	cognition.		As	
part	of	the	follow-up	cognitive	assessment,	we	would	also	like	to	ask	you	some	
questions	about	his/her	abilities.		
	
Why	have	we	contacted	you?	
The	person	you	 support	 is	participating	 in	 the	 research	 study	and,	 as	 the	person	 that	
knows	them	best,	we	would	like	to	ask	you	some	questions	about	his/her	abilities.	Each	
question	has	 two	parts:	 first	you	will	be	asked	 if	he/she	has	a	problem	 in	a	particular	
area	 of	 function;	 then	 you	 will	 be	 asked	 whether	 this	 is	 a	 deterioration	 or	 whether	
he/she	has	always	had	a	difficulty	 in	 this	area.	You	will	 also	be	asked	some	questions	
about	his/her	medical	history.		
	
What	are	the	possible	benefits	of	taking	part?	
There	 are	 no	 direct	 benefits	 for	 taking	 part	 in	 this	 project.	 However,	 your	
participation	in	this	research	will	help	us	to	gain	a	better	understanding	of	aging	and	
the	development	of	Alzheimer’s	disease	in	Down’s	syndrome.		
	
What	will	happen	if	I	to	take	part?	
We	will	come	to	visit	you	to	talk	about	what	taking	part	involves.	Following	this,	if	you	
decide	to	participate,	we	will	ask	you	to	sign	a	 form	saying	that	you	understand	what	
the	study	entails	and	would	like	to	take	part.	This	form	is	not	binding	and	you	are	free	to	
leave	the	study	at	any	time.	
	
We	will	then	ask	you	some	questions	about	the	abilities	of	the	person	you	support.	Each	
question	has	 two	parts:	 first	you	will	be	asked	 if	he/she	has	a	problem	 in	a	particular	
area	 of	 function;	 then	 you	 will	 be	 asked	 whether	 this	 is	 a	 deterioration	 or	 whether	
he/she	has	always	had	a	difficulty	 in	 this	area.	You	will	 also	be	asked	some	questions	
about	his/her	medical	history.	This	will	take	between	30	minutes	and	1	hour.		
	
Do	I	have	to	take	part?	
No,	you	can	stop	and	leave	the	study	at	anytime.	You	do	not	have	to	explain	why.		
	
	 255 
Are	there	any	risks	of	taking	part?	
There	are	no	foreseeable	safety	issues	as	you	will	just	be	asked	questions.			
	
What	if	you	find	that	there	is	a	problem?	
We	will	ask	you	to	sign	a	form	consenting	for	us	to	share	your	answers	with	the	GP	
of	the	person	you	support,	in	the	event	that	they	are	of	medical	relevance.			
	
What	if	something	goes	wrong?	
This	 study	 is	 approved	 by	 an	 NHS	 Research	 Ethics	 Committee	 and	 has	 insurance	
cover.	This	would	mean	that	you	can	receive	compensation	if	anything	went	wrong.	
It	 would	 not	 matter	 whether	 it	 was	 anyone’s	 fault.	 This	 would	 be	 under	 the	
University’s	Clinical	Trials	policy.		
	
If	you	wish	to	complain	about	the	way	have	been	treated	in	this	study,	you	should	be	
able	to	complain	directly	to	the	Chief	Investigator	of	this	study,	Ms	Sally	Jennings	
(01223	746147),	Dr	Howard	Ring	(01223	746121)	or	Prof	Tony	Holland	(01223	
746121).	If	you	remain	unhappy	and	wish	to	complain	formally,	you	can	do	this	by	
contacting	the	Patient	Advice	and	Liaison	Service	(PALS)	at	the	National	Health	
Service		(01223	216756).	
	
What	will	happen	to	the	results	of	the	research	study?	
All	information	will	be	kept	private.		Your	relationship	with	the	person	you	support,	
but	 not	 your	 name,	will	 appear	with	 your	 data.	 This	 is	 to	 provide	 context	 to	 your	
answers.	All	the	data	collected	in	this	study	will	be	stored	securely	by	the	research	
team	 for	 up	 to	 10	 years.	 The	 results	 of	 the	 study	 will	 be	 published	 in	 scientific	
journals.	No	one	will	be	able	to	tell	that	you	took	part	in	the	study.		
	
Who	has	reviewed	the	study?	
This	 study	was	 reviewed	by	 the	 research	 team	 the	University	of	Cambridge.	 It	 has	
also	been	reviewed	by	a	group	of	people	who	awarded	Sally	Jennings	a	grant	to	carry	
out	 the	study.	We	have	the	approval	of	 the	NHS	Research	Ethics	Committee	 to	do	
this	study.		
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What	to	do	if	I,	or	the	person	I	support,	would	like	to	know	more?	
	Sally	 Jennings	 is	 the	 PhD	 researcher	 on	 the	 project.	 She	 is	 very	
happy	to	talk	to	you	about	the	study	and	answer	any	questions	you	
may	have.	You	can	contact	Sally	by:	
Phone:	01223	746	147	or,	
Email:	srj32@medschl.cam.ac.uk	.		
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Appendix L. Cross-sectional study consent form for the participants 
with DS  
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Appendix M. Consultee declaration form, for the participants with DS  
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Appendix N. Consent form for the control participants  
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Appendix O. Longitudinal study consent form for the participants with 
DS 
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Appendix P. Consent form for the carer’s participation as CAMDEX 
informants  
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Appendix Q: age- and gender- matching  
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Appendix R. ACE-R 
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Appendix S. CAMDEX-DS: Informant interview 
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Appendix T. CAMCOG-DS 
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Appendix U. Tower of London  	 Tower	of	London	Task		Procedure	adapted	from	Kirkorian,	Bartok	&	Gay,	1994,	J	Clin	Exptl	Neuropsychology,	16,	6,	840-850.		Sit	opposit	the	participant	and	place	the	two	boards	with	the	longest	peg	on	the	participant’s	left	and	the	numbers	1,	2,	3	pointing	towards	you;	one	in	front	of	them,	with	the	beads	in	the	start	position,	and	one	in	front	of	you,	with	the	beads	in	the	practice	trial	position	(Practice	1).		Say	“I	want	you	to	move	the	beads	on	your	pegs	to	make	them	the	same	as	
the	beads	on	my	pegs.”When	they	have	done	it	say,	“that’s	good.	That’s	the	
idea.	Each	time	we’ll	start	with	your	beads	like	this	(arrange	the	beads	into	the	start	position).	I’ll	change	mine	and	you	have	to	make	yours	the	same	as	
mine.	I	also	want	you	to	do	it	in	a	certain	number	of	moves.	A	move	means	
taking	a	bead	from	a	peg	and	putting	it	on	another	peg.	There	are	two	rules.	
You	can	only	pick	up	one	bead	at	a	time	so	you	can’t	do	this	(pick	up	two	beads	in	one	hand)	or	this	(pick	up	on	bead	in	each	hand).	You	can’t	put	the	
beads	down	on	the	table.	If	you	get	stuck	we	can	go	back	to	the	beginning.	
Shall	we	have	a	practice?”Arrange	your	board	to	the	first	practice	problem	again.	Say,	“Now,	try	and	make	yours	look	like	this	in	two	moves.”		Provide	feedback	if	the	participant	tries	to	make	an	illegal	move	and	about	the	number	of	moves	allowed.	Say,	“Remember	the	rule.	You	can’t.......	.	Let’s	start	
again.	Have	another	go.	Remember	that	you	have	to	do	it	in	(X)	moves.”	Provide	one	more	practice	trial	with	feedback	as	above.	After	practice,	go	through	the	problems	in	the	order	presented	on	the	sheet	and	continue	to	provide	feedback	if	the	participant	tries	to	make	an	illegal	move	and	about	the	number	of	moves	allowed	for	the	problem.	Say,	“Remember	the	rule.	
You	can’t.......	.	Let’s	start	again.	Have	another	go.	Try	again.	Remember	that	
you	have	to	do	it	in	(X)	moves.”		Discontinue	after	three	consecutive	failed	problems	(i.e.	9	consecutive	failed	trials).			Scoring	The	pegs	are	labelled	1,	2,	3	(small	to	large)	and	the	beads	are	called	R,	G,	B.	Write	down	the	moves	the	participant	makes	on	the	score	sheet.	The	problem	is	solved	if	the	end	position	is	achieved	in	the	required	number	of	legal	moves.			A	trial	ends	if	the	participant	realises	that	the	trial	will	not	succeed	or	if	an	illegal	move	is	made.	The	beads	are	then	reset	to	the	start	position	for	the	next	trial.	Do	not	provide	feedback	after	each	incorrect	move,	wait	until	the	end	of	the	trial.		A	participant	is	allowed	to	modify	a	move	if	they	are	still	holding	a	bead.	
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Three	trials	will	are	allowed	for	each	problem.	Three	points	are	scored	if	the	problem	is	solved	on	the	first	trial,	two	if	on	the	second	trial,	and	on	point	if	on	the	third.			 		Tower	of	London	Task	–	Record	Sheet		
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Appendix V. Scrambled Boxes 	 Scrambled	Boxes	
Equipment:	Small	boxes	with	shapes	on.	Three	coins.		
	
Stationary	condition	
Say	to	the	participant,	"I	am	going	to	put	a	coin	under	each	of	these	boxes".	Then	hide	the	coins.	After	a	short	delay,	say,	"I	would	like	you	to	choose	one	of	
the	boxes	and	look	under	it	to	see	if	you	can	find	a	coin."			
After	the	participant	has	found	a	coin,	remove	it	and	say,	"Now	lets	put	that	box	
back	and	try	to	find	another	coin."			After	replacing	the	empty	box	in	its	original	position,	say,	"This	time	I	would	like	you	to	choose	a	box	you	haven’t	
looked	in	before.	Try	not	to	choose	an	empty	one."			If	participant	successfully	chooses	a	full	box	then	say	“Well	done!		Now	try	
again	and	see	if	you	can	find	another	coin.	Try	to	choose	a	box	you	haven’t	
looked	under	before”			If	participant	chooses	the	empty	box	then	say	“Oh	dear	it’s	empty.		Never	mind,	
let’s	have	another	go.	Try	to	choose	a	box	you	haven’t	looked	in	before”					Repeat	as	above	until	participant	has	found	all	the	coins	or	has	made	FOUR	of	errors.	If	participant	successfully	finds	all	coins	then	say	“Well	done,	you’ve	found	all	
the	coins	now.		Let’s	try	the	same	thing	again	but	this	time,	to	make	it	a	bit	
more	difficult,	I’m	going	to	move	the	boxes	around.”	
	
Scrambled	condition		Say,	"I	am	going	to	put	a	coin	under	each	of	the	boxes	again".		Then	hide	the	
coins	.		After	a	short	delay,	say,	"Now	I'm	going	to	mix	them	up.	I	would	like	you	to	
choose	one	of	the	boxes	and	look	under	it	to	see	if	you	can	find	a	coin.	While	
giving	this	instruction	mix	up	the	location	of	the	boxes	while	the	participant	
watches.		
When	the	participant	finds	a	coin,	say	"Now	let’s	put	that	box	back	and	try	
to	find	another	coin."				
Replace	empty	box	and	after	a	short	delay,	say	to	them,	"I'm	going	to	mix	the	
boxes	up	again	and	I	would	like	you	to	choose	a	box	you	haven’t	looked	in	
before.	Try	not	to	choose	an	empty	one."	While	giving	this	instruction	mix	up	
the	location	of	the	boxes	again	while	the	participant	watches.		If	participant	successfully	chooses	a	full	box	then	say,	“Well	done!		Now	try	
again	and	see	if	you	can	find	another	coin.	Try	to	choose	a	box	you	haven’t	
looked	under	before.”	Again,	while	giving	this	instruction	mix	up	the	location	of	
the	boxes	while	the	participant	watches.	If	participant	chooses	the	empty	box	then	say	“Oh	dear	it’s	empty.		Never	mind,	
let’s	have	another	go.	Try	to	choose	a	box	you	haven’t	looked	in	before”	
Again,	while	giving	this	instruction	mix	up	the	location	of	the	boxes	while	the	
participant	watches.				
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	Continue	until	participant	has	found	all	the	coins	or	made	FOUR	of	errors.	If	the	participant	completes	both	the	stationary	and	scrambled	stages	with	three	boxes,	then	repeat	the	process	with	SIX	boxes.	In	this	case,	testing	continues	until	all	the	coins	have	been	retrieved	or	until	SEVEN	errors	have	been	made.		
	
 
 
 
 
	
SCORE	THE	SCRAMBLED	STAGE
Score	=	4	-	errors	
Score	=	7	-	errors	
Total	score:											/11
	 316 
Appendix W. Script: print cluster  
function printcluster(conname,modality,varargin) 
  
loadpaths 
  
param = finputcheck(varargin, { ... 
    'dir', 'string', {'pos','neg','both'}, 'both'; ... 
    'alpha', 'real', [], 0.05; ... 
    'statwin', 'real', [], [-200 700]; ... 
    }); 
  
%sampling period of data 
samptime = 4; 
  
if isnumeric(modality) 
    %source 
    modality_or_val = sprintf('%d',modality); 
elseif ischar(modality) 
    %sensor 
    modality_or_val = modality; 
end 
     
%% load contrast and identify clusters  
load(sprintf('%s%s_stat_%s.mat',filepath,conname,modality_or_val),'st
at'); 
  
if ischar(modality) && ~isempty(stat.clusters) 
    timeline = stat.statwin(1):samptime:stat.statwin(2); 
    statwinidx = 
intersect(find(timeline>=stat.statwin(1)),find(timeline<=stat.statwin
(2))); 
     
    %select clusters within specified time window 
    selectclusters = timeline(statwinidx(1) + 
cell2mat({stat.clusters.tstart}) - 1) >= param.statwin(1) & ... 
        timeline(statwinidx(1) + cell2mat({stat.clusters.tstop}) - 1) 
<= param.statwin(2); 
    stat.clusters = stat.clusters(selectclusters); 
 
    %select clusters in specified direction (positive/negative) 
    selectclusters = false(1,length(stat.clusters)); 
    for c = 1:length(stat.clusters) 
        plottimeidx = statwinidx(1) + stat.clusters(c).tmax -1; 
        clustpeak = diffcond(:,:,plottimeidx); 
        clustsum = sum(clustpeak(stat.mask(:,:,stat.clusters(c).tmax) 
== stat.clusters(c).clusternum)); 
        if (strcmp(param.dir,'both') || strcmp(param.dir,'pos')) && 
clustsum > 0 
            selectclusters(c) = true; 
        elseif (strcmp(param.dir,'both') || strcmp(param.dir,'neg')) 
&& clustsum < 0 
            selectclusters(c) = true; 
        end 
    end 
    stat.clusters = stat.clusters(selectclusters); 
 
 
     
end 
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if ~isempty(stat.clusters) 
    [~,maxclustidx] = max(cell2mat({stat.clusters.clustersize})); 
else 
    warning('No clusters found!'); 
    maxclustidx = []; 
end 
  
if ~isempty(maxclustidx) 
    if stat.clusters(maxclustidx).clusterpval < param.alpha 
        if stat.clusters(maxclustidx).clusterpval >= 0.00001 
            fprintf('Cluster %d: %d-%dms, peak %dms, p = %.5f.\n',... 
                stat.clusters(maxclustidx).clusternum,... 
                timeline(statwinidx(1) + 
stat.clusters(maxclustidx).tstart - 1),... 
                timeline(statwinidx(1) + 
stat.clusters(maxclustidx).tstop - 1),... 
                timeline(statwinidx(1) + 
stat.clusters(maxclustidx).tmax - 1),... 
                stat.clusters(maxclustidx).clusterpval); 
        else 
            fprintf('Cluster %d: %d-%dms, peak %dms, p = %.1e.\n',... 
                stat.clusters(maxclustidx).clusternum,... 
                timeline(statwinidx(1) + 
stat.clusters(maxclustidx).tstart - 1),... 
                timeline(statwinidx(1) + 
stat.clusters(maxclustidx).tstop - 1),... 
                timeline(statwinidx(1) + 
stat.clusters(maxclustidx).tmax - 1),... 
                stat.clusters(maxclustidx).clusterpval); 
        end 
    else 
        warning('No significant clusters found!'); 
    end 
end 	
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Appendix X. Script: extract global field power values 
function outdata = runstats(listname,condlist,covariateidx,varargin) 
  
loadpaths 
loadsubj 
  
subjlist = eval(listname); 
  
param = finputcheck(varargin, { ... 
'channame', 'cell', ''  ; ...  
'measure','string',{'mean','latency'},'max'; ... 
    'timewin', 'real', [], []; ... 
    }); 
  
if ischar(param) 
    error(param); 
end 
  
if ischar(listname) 
    listname = repmat({listname},size(condlist)); 
end 
  
filesuffix = '_cond'; 
  
for c = 1:length(condlist) 
        filecondname{c} = sprintf('%s',condlist{c}); 
end 
  
for s = 1:size(subjlist,1); 
    subjname = lower(subjlist{s,1}); 
    file2load = sprintf('%s%s%s.mat',filepath,subjname,filesuffix); 
    fprintf('Loading %s.\n',file2load); 
    D = spm_eeg_load(file2load); 
     
    if s == 1 
        timevals = D.time*1000; 
        timewinidx = [find(min(abs(timevals-param.timewin(1))) == 
abs(timevals-param.timewin(1))) ... 
            find(min(abs(timevals-param.timewin(2))) == abs(timevals-
param.timewin(2)))]; 
        for c = 1:length(param.channame) 
            chanidx(c) = 
find(strcmp(param.channame{c},D.chanlabels)); 
        end 
  end 
         
gfpdata = zeros(size(subjlist,1),length(timevals),length(condlist)); 
 
    for c = 1:length(condlist) 
        filecondidx = find(strcmp(filecondname{c},D.conditions)); 
        [~,gfpdata(s,:,c)] = 
evalc('eeg_gfp(D(setdiff(1:D.nchannels,D.badchannels),:,filecondidx)'
')'''); 
    end 
  
  
gfpdata = gfpdata(:,:,1) - gfpdata(:,:,2); 
elseif strcmp(param.measure,'mean') 
    statdata = max(gfpdata(:,timewinidx(1):timewinidx(2)),[],2); 
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elseif strcmp(param.measure,'latency') 
    [~,statdata] = max(gfpdata(:,timewinidx(1):timewinidx(2)),[],2); 
    statdata = timevals(statdata+timewinidx(1)-1)'; 
end 
 end 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 320 
Appendix Y. Sensitivity analysis  
 
The table below details the number of outliers for each GFP maxima and 
latency, by group.  									
The following sections detail the results of the analyses when the outliers 
have been removed, to find no significant changes.		
Chapter 4: age  
 
Spearman’s Rank-Order correlations (one-tailed) between age and the GFP 
maxima and latencies (MMN, P3a, P3b), without the outliers, revealed no 
significant results, which is the same as the analyses in which they are 
included. The test statistics are as follows. For the controls, age correlated 
with neither GFP maxima for MMN (r = .233, p = .083) or P3b GFP maxima (r 
= -.086, p = .310). For the adults with DS, age correlated with neither GFP 
maxima for P3a (r = -.124, p = .239) or P3b (r = -.094, p = .295). Age also did 
not correlate with P3a latency (r = .172, p = .173), for adults with DS.  
 
 
Chapter 5: executive function  
 
Spearman’s Rank-Order correlations (two-tailed) between the summary 
cognitive measures (CAMCOG, EFDS, KBIT II – raw, standardized) and the 
GFP maxima and latencies (P3a, P3b), without the outliers revealed no 
significant results, which is the same as the analyses in which they are 
included. For the adults with DS, P3a GFP maxima correlated with none of 
the following summary measures: CAMCOG (r = -.214, p = .28); EFDS (r = 
.037, p = .813); KBIT II standardized (r = -.272, p = .114); KBIT II raw scores 
(r = -.266, p = .122). P3a latency also did not correlated with any of the 
GFP maxima 
time-windows 
(ms) 
 Associated 
ERP 
Number of outliers 
for the GFP 
Maxima, by group 
Number of outliers 
for the latencies, by 
group 
 DS C DS C 
100-200 MMN 0 2 0 0 
200-400 P300 (a,b) 1 3 4 0 
400-650 P3b 1 N/A 0 N/A 
	 321 
summary measures: CAMCOG (r = .147, p = .423); EFDS (r = .041, p = .825); 
KBIT II standardized (r = -.055, p = .767); KBIT II raw scores (r = -.083, p = 
.650). P3b GFP maxima also did not correlated with any of the summary 
measures: CAMCOG (r = -.052, p = .766); EFDS (r = -.024, p = .889); KBIT II 
standardized (r = -.008, p = .963); KBIT II raw scores (r = .020, p = .909).  
 
Chapter 6: cognitive decline  
 
Spearman’s Rank-Order correlations (two-tailed) between the global cortical 
ROI PIB binding values and the GFP maxima and latencies (P3a, P3b), 
without the outliers, revealed no significant results, which is the same as the 
analyses in which they are included. For the adults with DS, cortical PIB 
binding correlated with neither GFP maxima for P3a (r = .264, p = .433) or 
P3b (r = .382, p = .247). Cortical PIB bindings also did not correlate with P3a 
latency (r = -.119, p = .761), for adults with DS. 
 
Spearman’s Rank-Order correlations (two-tailed) between the total CAMCOG 
difference (T2-T1) scores and the GFP maxima and latencies (P3a, P3b), 
without the outliers, revealed no significant results, which is the same as the 
analyses in which they are included. For the adults with DS, CAMCOG 
change correlated with neither GFP maxima for P3a (r = -.020, p = .910) or 
P3b (r = -.015, p = .933). CAMCOG change also did not correlate with P3a 
latency (r = -.030, p = .873), for adults with DS. 
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Appendix Z. Correlations between the raw KBIT-II composite scores 
and the ERPs 
 
The range of raw KBIT-II composite scores for the adults with DS was 80 to 
179, M = 115.8. SD = 22.3. The correlations between the raw scores and the 
ERPs were not significant. The test statistics can be found in the table below.  
 
 
Spearman’s Rank-Order correlations (two-tailed) between the raw KBIT-II 
composite scores and the GFP maxima and latencies (MMN, P3a, P3b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Raw KBIT-
II scores 
GFP 
maxima 
time-
windows 
(ms) 
Associated 
ERP 
Corelation with GFP 
Maxima 
Correlation with 
GFP maxima 
latencies 
 r p r p 
Composite 100-200 MMN -.323 .055 .114 .510 
200-400 P3a -.304 .071 -.053 .759 
400-650 P3b -.008 .964 .136 .428 
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Appendix AA. Waveform visualisations  	
The figures below depict the distribution of the EEG waveforms over the time-
course. Each line maps an individual’s response to stimuli, with 0 indicating 
the onset of a deviant stimulus. The scalp maps are focused on the negative, 
MMN response (100-200ms). However, the whole time-course, which 
includes the P300 responses (200-400ms), is mapped.  
 
 
 
Mapping the EEG waveforms for participants’ with DS responses to deviant 
stimuli.   
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Mapping the EEG waveforms for TD control participants’ responses to deviant 
stimuli.   
 
